INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(527, 'COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021', 'COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates and laid the groundwork for further doses to be secured through contributions from donorsThese agreements mean that all COVAX s 190 participating and eligible economies will be able to access doses to protect vulnerable groups in the first half of 2021 At least 1 3 billion donor funded doses will be made available to 92 economies eligible for the Gavi COVAX AMC targeting up to 20 population coverage by the end of the year Funding raised in 2020 and early pledges toward 2021 targets alongside these agreements offer clearest pathway yet to ending the acute phase of the pandemic globally by the end of 2021 Geneva Oslo 18 December 2020 COVAX the global initiative to ensure rapid and equitable access to COVID 19 vaccines for all countries regardless of income level today announced that it had arrangements in place to access nearly two billion doses of COVID 19 vaccine candidates on behalf of 190 participating economies For the vast majority of these deals COVAX has guaranteed access to a portion of the first wave of production followed by volume scales as further supply becomes available The arrangements announced today will enable all participating economies to have access to doses in the first half of 2021 with first deliveries anticipated to begin in the first quarter of 2021 contingent upon regulatory approvals and countries readiness for delivery Given these are arrangements for 2 billion doses of vaccine candidates which are still under development COVAX will continue developing its portfolio this will be critical to achieve its goal of securing access to 2 billion doses of safe and effective approved vaccines that are suitable for all participants contexts and available by the end of 2021 However today s announcements offer the clearest pathway yet to end the acute phase of the pandemic by protecting the most vulnerable populations around the world This includes delivering at least 1 3 billion donor funded doses of approved vaccines in 2021 to the 92 low and middle income economies eligible for the COVAX AMC The new deals announced today include the signing of an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca Oxford candidate and a memorandum of understanding MoU with Johnson Johnson for 500 million doses of the Janssen candidate which is currently being investigated as a single dose vaccine These deals are in addition to existing agreements COVAX has with the Serum Institute of India SII for 200 million doses with options for up to 900 million doses more of either the AstraZeneca Oxford or Novavax candidates as well as a statement of intent for 200 million doses of the Sanofi GSK vaccine candidate In addition to this COVAX also has through R D partnership agreements first right of refusal in 2021 to access potentially more than one billion doses based on current estimates from the manufacturing processes under development that will be produced subject to technical success and regulatory approval by candidates in the COVAX R D Portfolio This commitment is evidence that the world learned an important lesson from the 2009 H1N1 pandemic Our research and development efforts have begun to pay off We now have safe and effective vaccines that can protect against COVID 19 and a clear pathway to securing 2 billion doses for the populations at greatest risk all around the world said Dr Richard Hatchett CEO of the Coalition for Epidemic Preparedness Innovations CEPI Securing the right of first refusal of successful vaccine production as part of R D arrangements has helped guarantee equitable access to vaccines a founding principle of CEPI The challenge of delivering the vaccines that have demonstrated success of completing the development of other promising vaccine candidates to further increase supply and of ending the acute phase of the pandemic lies ahead of us Alongside boosting its pathway to two billion doses of approved vaccines through direct agreements with manufacturers the COVAX Facility has also opened another potential source of vaccines Published today the Principles for Dose Sharing provide a framework for higher income economies to make additional volumes secured via bilateral deals available through the Facility primarily to AMC participants on an equitable basis These principles outline that such doses must be safe and effective available as early as possible and should be available in substantive volumes as early as possible in 2021 to enable rapid and flexible deployment by the Facility supporting the overall goal of equitable access First deliveries in Q1 2021Today s announcements on deals and dose sharing mean COVAX can plan for the first deliveries of vaccines in the first quarter of 2021 with the first tranche of doses enough to protect health and social care workers delivered in the first half of 2021 to all participating economies who have requested doses in this timeframe This would be followed by further delivery of doses to all participants in the second half of the year targeting supply of doses equalling up to 20 of participants populations or a lower amount if requested by the participant by the end of the year Additional doses to reach higher coverage levels will then be available in 2022 All deliveries are contingent upon several factors such as regulatory approvals and country readiness The arrival of vaccines is giving all of us a glimpse of the light at the end of the tunnel said Dr Tedros Adhanom Ghebreyesus Director General of the World Health Organisation WHO But we will only truly end the pandemic if we end it everywhere at the same time which means it s essential to vaccinate some people in all countries rather than all people in some countries And we must remember that vaccines will complement but not replace the many other tools we have in our toolbox to stop transmission and save lives We must continue to use all of them The COVAX Facility currently has 190 participating economies This includes 98 higher income economies and 92 low and middle income economies eligible to have their participation in the Facility supported via the financing mechanism known as the Gavi COVAX AMC Of the 92 economies eligible to be supported by the COVAX AMC 86 have now submitted detailed vaccine requests offering the clearest picture yet on actual global demand for COVID 19 vaccines In addition to gathering detailed information on participating economies vaccine requests COVAX through Gavi UNICEF WHO the World Bank and other partners has been working closely with all countries in the Facility particularly AMC eligible participants to help plan and prepare for the widespread roll out of vaccines Conditions that determine country readiness include regulatory preparedness as well as the availability of infrastructure appropriate legal frameworks training and capacity among other factors Securing access to doses of a new vaccine for both higher income and lower income countries at roughly the same time and during a pandemic is a feat the world has never achieved before let alone at such unprecedented speed and scale said Dr Seth Berkley CEO of Gavi the Vaccine Alliance which leads on procurement and delivery for COVAX COVAX has now built a platform that offers the world the prospect for the first time of being able to defeat the pandemic on a global basis but the work is not done it s critical that both governments and industry continue to support our efforts to achieve this goal Early pledges towards 2021 fundraising targetsTo achieve this ambitious goal COVAX currently estimates it needs to raise an additional US 6 8 billion in 2021 US 800 million for research and development at least US 4 6 billion for the COVAX AMC and US 1 4 billion for delivery support Support for the COVAX AMC will be critical to ensuring ability to pay is not a barrier to access Thanks to the generous support of sovereign private sector and philanthropic donors the AMC has met its urgent 2020 fundraising target of US 2 billion but at least US 4 6 billion more is needed in 2021 to procure doses of successful candidates as they come through the portfolio The last two weeks have seen a number of pledges made to Gavi for the COVAX AMC bringing the overall amount raised to US 2 4 billion Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation IFFIm to be paid from 2021 to 2030 This funding will support the Gavi COVAX AMC and comes on top of earlier commitments of NOK 164 1 million in direct funding and 6 25 million in funding transferred from the PCV AMC to support the Gavi COVAX AMC Canada pledged CAD 75 million in funding to support the delivery of COVID 19 vaccines in lower income economies as part of the Gavi COVAX AMC This includes a CAD 5 million investment in the development of a mechanism to equitably reallocate vaccine doses through the COVAX Facility either by donation or exchange Kuwait has confirmed a pledge of US 10 million to the Gavi COVAX AMC Denmark has announced subject to parliamentary approval a commitment of DKK 50 million to Gavi COVAX AMC New Zealand has pledged NZ 10 million to the Gavi COVAX AMC in addition to NZ 7 million pledged earlier this year for the AMC Netherlands has signed and paid a commitment of EUR 5 million to the Gavi COVAX AMCSingapore has pledged US 5 million to the Gavi COVAX AMCThe King Salman Humanitarian Aid and Relief Center KSrelief Gamers Without Borders have confirmed a pledge of US 1 3 million to the Gavi COVAX AMCEstonia has signed a commitment of EUR 70 000 to the Gavi COVAX AMCIn addition to these pledges Team Europe confirmed financial support of EUR 500 million through EUR 400 million European Investment Bank loan and EUR100 million grant to Gavi in support of equitable access through COVAX The goal of COVAX is to deliver two billion doses of safe effective vaccines that have passed regulatory approval and or WHO prequalification by the end of 2021 These vaccines will be offered equally to all participating countries proportional to their populations initially prioritising healthcare workers then expanding to cover vulnerable groups such as the elderly and those with pre existing conditions Further doses will then be made available based on country need vulnerability and COVID 19 threat The COVAX Facility will also maintain a buffer of doses for emergency and humanitarian use Quotes from partnersKarina Gould Minister of International Development Government of Canada said We know that as long as one country is at risk we are all at risk The COVAX Facility is the key to ending this pandemic and will only work if we all come together Now is the time to make our commitment to equitable access a reality so that everyone everywhere has access to a life saving vaccine Dr Kwaku Agyeman Manu Minister of Health for Ghana said The nearly 2 billion COVID 19 vaccine doses announced today by COVAX is a welcome first step but our journey is not yet over As we ve learned with routine immunisation vaccines don t save lives vaccination does This means we need the health infrastructure in place from supply chain and logistics to well trained health workers to ensure the effective and streamlined distribution of vaccines For this we call on governments manufacturers and the private sector to make urgent and necessary investments in COVAX so that no one is left behind because ultimately no one is safe until everyone is safe Dag Inge Ulstein Norway s Minister of International Development and Co chair of the ACT A Facilitation Council said The good news is that many countries foundations and some private companies have already provided support to this important collective effort The bad news is that more is needed We need to look beyond the health sector and the international development sector if we are to find the political and financial resources required to combat the pandemic and its many different impacts Wendy Morton Minister for Global Health at the Foreign Commonwealth and Development Office of the UK which also hosted the Global Vaccine Summit in June said The UK has played the leading role in championing global access to coronavirus vaccines including by being the largest donor to the COVAX Advance Market Commitment No one is safe until we are all safe Along with our international partners the UK is working hard to ensure vaccines get to everyone who needs them Dr John Nkengasong Director of the Africa Centres for Disease Control and Prevention Africa CDC said Since the beginning of the COVID 19 pandemic Africa CDC has established several trusted partnerships across the globe The COVAX partnership is one of such very critical alliances that will allow Africa to secure early access to COVID 19 vaccine needed to start vaccinating our populations across the continent Henrietta Fore Executive Director of UNICEF said This is an unprecedented undertaking addressing a global pandemic while ensuring we do not leave the world s poorest behind UNICEF is bringing the full weight of our experience as the world s largest single procurer of vaccines to help secure and deliver COVID 19 vaccines and help countries prepare to receive and administer them Dr Ngozi Okonjo Iweala co chair of the COVAX Coordination Meeting and Gavi Board Chair said Nine months ago it was hard to imagine that we would have more than one promising vaccine candidate and be in a position to make them available to both high income countries and lower income countries simultaneously The global community has rallied and we now have a platform COVAX that will do this It s time to stop questioning it and give it the support it needs to bring the pandemic to an end as swiftly as possible Jane Halton co chair of the COVAX Coordination Meeting and Chair of CEPI said Science will give us the tools to fight this pandemic but equitable access will allow us to beat it Today marks a significant moment towards our goal of fair and equitable access to COVID 19 vaccines for those most at risk around the world We now have a clear pathway to our goal of delivering 2 billion doses of vaccine in 2021 enabled by COVAX R D investments and deals with manufacturers which can bring an end to the acute phase of the pandemic globally In addition governments can now demonstrate their continued commitment to this goal by contributing doses to COVAX of vaccines secured through bilateral deals Equitable access to vaccines is in all of our interests and we re now a significant step closer to making this a reality Mesfin Teklu Tessema civil society representative of the COVAX Coordination Meeting and Senior Director Head of Health Unit International Rescue Committee said The COVAX Facility is our best hope to ending this pandemic as quickly as possible with equity as its grounding force This announcement today is an important milestone and proof that doses are forthcoming to those most in need everywhere Adar Poonawalla CEO of the Serum Institute of India SII said We are delighted to announce that we have signed for a 100mn doses of Novavax and another 100mn doses of AstraZeneca Oxford vaccines with COVAX with an option of extending it by 900mn doses The advance purchase commitments under COVAX initiative is encouraging as it will further bolster our fight and ensure equitable access at the most affordable price from Serum Institute of India Pascal Soriot Chief Executive Officer AstraZeneca said Today s Agreement is a significant milestone for global access to the AZD1222 vaccine Our collaboration with COVAX is testament to AstraZeneca s commitment to broad equitable access at no profit during the pandemic period We now look forward to progressing our work with COVAX partners to ensure that as many people as possible around the world can access a safe effective vaccine wherever they live Paul Stoffels M D Vice Chairman of the Executive Committee and Chief Scientific Officer Johnson Johnson said Since we initiated development of our COVID 19 vaccine candidate Johnson Johnson has remained committed to ensuring access to vaccines on a not for profit basis for emergency pandemic use Equitable global access inclusive of lower income countries is critical to helping end the COVID 19 pandemic Thomas B Cueni Director General International Federation of Pharmaceutical Manufacturers IFPMA said The reason why we can mark today as a milestone for COVAX securing 2 billion doses of promising vaccines is because the vaccine makers have pulled out all the stops and have delivered beyond all expectations So let s indeed mark this important milestone in ensuring fair and equitable access to vaccines which we have committed to from the outset of the pandemic But let us also remember that we would not be where we are if science and the innovation ecosystem that allows the biopharmaceutical to develop and manufacture life saving treatments had not risen to the challenge so that there are different types of vaccines that will be manufactured in historic quantities Looking to 2021 it is essential that all COVAX partners and governments focus on getting things done and secure the funds need Notes to editorsThe full list of deals that have so far been secured by COVAX on behalf of the Facility is as follows 170 million doses of the AstraZeneca Oxford candidate via an advance purchase agreement between Gavi and AstraZeneca and enabled by a partnership agreement with CEPI to fund scale out of manufacturing200 million doses and options for up to 900 million more of the AstraZeneca Oxford or Novavax candidates via an agreement between Gavi the Serum Institute of India and the Bill and Melinda Gates Foundation500 million doses of the Janssen candidate via a memorandum of understanding with Johnson Johnson200 million doses of the Sanofi GSK vaccine candidate via a statement of intent between Gavi Sanofi and GSKFirst right of refusal for a potential combined total of over 1 billion doses in 2021 based on current estimates from the manufacturing processes under development of promising vaccine candidates via R D partnership agreements with CEPI that will be produced subject to technical success and regulatory approval by candidates in the COVAX R D Portfolio As part of the COVAX R D portfolio CEPI has invested in 10 vaccine candidates 9 of these candidates are still in development and 7 are in clinical trials AstraZeneca University of Oxford Phase 3 Clover Biopharmaceuticals China Phase 1 CureVac Germany Phase 2B 3 Inovio USA Phase 2 Institut Pasteur Merck Themis France USA Austria Phase 1 Moderna USA Phase 3 Novavax USA Phase 3 SK bioscience South Korea Preclinical University of Hong Kong Hong Kong Preclinical University of Queensland CSL Australia Phase 1 programme discontinued CEPI is also evaluating additional candidates for support including next generation vaccine candidates to provide additional options for the future The latest list of participants in the COVAX Facility both self financing and AMC eligible is available here and the latest pledging table of donor contributions to the COVAX AMC is available here The official list of WHO certified Stringent Regulatory Authorities is available here About COVAXCOVAX the vaccines pillar of the Access to COVID 19 Tools ACT Accelerator is co led by CEPI Gavi and WHO working in partnership with developed and developing country vaccine manufacturers UNICEF the World Bank and others It is the only global initiative that is working with governments and manufacturers to ensure COVID 19 vaccines are available worldwide to both higher income and lower income countries CEPI is leading on the COVAX vaccine research and development portfolio investing in R D across a variety of promising candidates with the goal to support development of three safe and effective vaccines which can be made available to countries participating in the COVAX Facility As part of this work CEPI has secured first right of refusal to potentially over one billion doses for the COVAX Facility to a number of candidates and made strategic investments in vaccine manufacturing which includes reserving capacity to manufacture doses of COVAX vaccines at a network of facilities and securing glass vials to hold 2 billion doses of vaccine CEPI is also investing in the next generation of vaccine candidates which will give the world additional options to control COVID 19 in the future Gavi is leading on procurement and delivery for COVAX coordinating the design and implementation of the COVAX Facility and the COVAX AMC and working with Alliance partners UNICEF and WHO along with governments on country readiness and delivery The COVAX Facility is the global pooled procurement mechanism for COVID 19 vaccines through which COVAX will ensure fair and equitable access to vaccines for all 190 participating economies using an allocation framework formulated by WHO The COVAX Facility will do this by pooling buying power from participating economies and providing volume guarantees across a range of promising vaccine candidates The Gavi COVAX AMC is the financing mechanism that will support the participation of 92 low and middle income countries in the Facility enabling access to donor funded doses of safe and effective vaccines UNICEF and the Pan American Health Organisation PAHO will be acting as procurement coordinators for the COVAX Facility helping deliver vaccines to all participants WHO has multiple roles within the COVAX among other things it supports countries as they prepare to receive and administer vaccines and does so in partnership with UNICEF It provides normative guidance on vaccine policy regulation safety R D allocation and country readiness and delivery Its Strategic Advisory Group of Experts SAGE on Immunization develops evidence based immunization policy recommendations Its Emergency Use Listing EUL prequalification programmes ensure harmonized review and authorization across member states It provides global coordination and member state support on vaccine safety monitoring It developed the target product profiles for COVID 19 vaccines and provides R D technical coordination Along with COVAX partners it is developing a no fault compensation scheme for indemnification and liability issues COVAX is part of the Act accelerator which WHO launched with partners in 2020 About Gavi the Vaccine AllianceGavi the Vaccine Alliance is a public private partnership that helps vaccinate half the world s children against some of the world s deadliest diseases Since its inception in 2000 Gavi has helped to immunise a whole generation over 822 million children and prevented more than 14 million deaths helping to halve child mortality in 73 developing countries Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola cholera meningitis and yellow fever vaccines After two decades of progress Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind employing innovative finance and the latest technology from drones to biometrics to save millions more lives prevent outbreaks before they can spread and help countries on the road to self sufficiency Learn more at www gavi org and connect with us on Facebook Twitter and Instagram The Vaccine Alliance brings together developing country and donor governments the World Health Organization UNICEF the World Bank the vaccine industry technical agencies civil society the Bill Melinda Gates Foundation and other private sector partners View the full list of donor governments and other leading organizations that fund Gavi s work here About CEPICEPI is an innovative partnership between public private philanthropic and civil organisations launched at Davos in 2017 to develop vaccines to stop future epidemics CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID 19 CEPI has initiated ten partnerships to develop vaccines against the novel coronavirus The programmes are leveraging rapid response platforms already supported by CEPI as well as new partnerships Before the emergence of COVID 19 CEPI s priority diseases included Ebola virus Lassa virus Middle East Respiratory Syndrome coronavirus Nipah virus Rift Valley Fever and Chikungunya virus CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens Disease X About WHOThe World Health Organization provides global leadership in public health within the United Nations system Founded in 1948 WHO works with 194 Member States across six regions and from more than 150 offices to promote health keep the world safe and serve the vulnerable Our goal for 2019 2023 is to ensure that a billion more people have universal health coverage to protect a billion more people from health emergencies and provide a further billion people with better health and wellbeing For updates on COVID 19 and public health advice to protect yourself from coronavirus visit www who int and follow WHO on Twitter Facebook Instagram LinkedIn TikTok Pinterest Snapchat YouTube About ACT AcceleratorThe Access to COVID 19 Tools ACT Accelerator is a new ground breaking global collaboration to accelerate the development production and equitable access to COVID 19 tests treatments and vaccines It was set up in response to a call from G20 leaders in March and launched by the WHO European Commission France and The Bill Melinda Gates Foundation in April 2020 The ACT Accelerator is not a decision making body or a new organisation but works to speed up collaborative efforts among existing organisations to end the pandemic It is a framework for collaboration that has been designed to bring key players around the table with the goal of ending the pandemic as quickly as possible through the accelerated development equitable allocation and scaled up delivery of tests treatments and vaccines thereby protecting health systems and restoring societies and economies in the near term It draws on the experience of leading global health organisations which are tackling the world s toughest health challenges and who by working together are able to unlock new and more ambitious results against COVID 19 Its members share a commitment to ensure all people have access to all the tools needed to defeat COVID 19 and to work with unprecedented levels of partnership to achieve it The ACT Accelerator has four areas of work diagnostics therapeutics vaccines and the health system connector Cross cutting all of these is the workstream on Access Allocation', 'https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021', 22, 'pending', '2020-12-20 12:17:03', NULL),
(528, 'New study highlights cost-effectiveness of bans on pesticides as a suicide prevention strategy', 'National bans on highly hazardous pesticides can be a cost effective and affordable intervention for reducing suicide deaths in countries with a high burden of suicides attributable to pesticides according to a new study published in The Lancet Global Health today', 'https://www.who.int/news/item/17-12-2020-new-study-highlights-cost-effectiveness-of-bans-on-pesticides-as-a-suicide-prevention-strategy', 22, 'pending', '2020-12-20 12:17:03', NULL),
(529, 'New PSA campaign from WHO and YouTube is a playbook for a safe holiday season', 'The World Health Organization and YouTube have partnered on an inviting and humorous public service announcement PSA to help battle COVID 19 fatigue as we head into the holiday season After nine months of physical distancing lockdowns and other preventative measures the video reminds viewers to stay vigilant and continue to take precautions to prevent the spread of the virus as people in many parts of the world head into the holiday season Voiced by actor and comedian Jon Glaser Parks and Rec Bob s Burgers Girls the short animated video reinforces the WHO s recommendations that viewers should stay home when possible wear a mask if they need to go out wash their hands and stay away from others when in public The PSA also gives advice for how to tackle some of the common holiday activities that could lead to further spread of COVID 19 including travel think twice large gatherings turn around and head home and visiting with high risk relatives try a video call The PSA is available on YouTube starting today and will be promoted through early January as a pre roll ad in features on the YouTube homepage and in posts from YouTube s social media handles', 'https://www.who.int/news/item/17-12-2020-new-psa-campaign-from-who-and-youtube-is-a-playbook-for-a-safe-holiday-season', 22, 'pending', '2020-12-20 12:17:03', NULL),
(530, 'A parasitic infection that can turn fatal with administration of corticosteroids', 'Healthcare workers in tropical and sub tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas need to maintain a high level of awareness about the use of corticosteroids including when this class of anti inflammatories is given to patients suspected of infection with SARS CoV 2', 'https://www.who.int/news/item/17-12-2020-a-parasitic-infection-that-can-turn-fatal-with-administration-of-corticosteroids', 22, 'pending', '2020-12-20 12:17:03', NULL),
(531, 'Launch of the Tripartite Joint Risk Assessment Operational Tool', 'The Operational Tool on Joint Risk Assessment JRA OT has been developed by the Tripartite organisations FAO OIE and WHO and technical experts to provide guidance on how to set up a joint risk assessment process at national level While it describes step by step how to conduct each component of the process it also provides model documents and templates to support its implementation by staff from national ministries responsible for management of zoonotic diseases', 'https://www.who.int/news/item/17-12-2020-launch-of-the-tripartite-joint-risk-assessment-operational-tool', 22, 'pending', '2020-12-20 12:17:03', NULL),
(532, 'Joint Risk Assessment Operational Tool in the time of COVID-19', 'Despite the successful use of the JRA OT in country pilots the COVID 19 pandemic has complicated the ability to provide facilitation support for in country engagement But ironically the zoonotic nature of COVID 19 has made JRA OT more relevant and needed than ever The JRA OT tripartite secretariat mobilized to identify opportunities for virtual facilitation and hybrid models i e combining on site participation and remote online support for conducting JRA in country This process led to the development of a freely available JRA OT online facilitators training pre recorded video presentations and the use of communication platforms like Whatsapp Zoom and Jamboard for working group activities', 'https://www.who.int/news/item/17-12-2020-joint-risk-assessment-operational-tool-in-the-time-of-covid-19', 22, 'pending', '2020-12-20 12:17:04', NULL),
(533, 'WHO launches Baseline report for Decade of Healthy Ageing', '17 December 2020 At least 14 of all people aged 60 years and over more than 142 million people are currently unable to meet all their basic daily needs according to the Baseline report for the Decade of Healthy Ageing released by the World Health Organization today The Baseline report brings together data available for measuring healthy ageing defined by WHO as the process of developing and maintaining the functional ability that enables well being in older age Optimizing functional ability is the goal of the Decade of Healthy Ageing which begins in 2021 and addresses five interrelated abilities that all older people should enjoy the ability to meet basic needs to continue to learn and make decisions to be mobile to build and maintain relationships and to contribute to society The Baseline report presents the experience of countries which have been successful in starting healthy ageing initiatives in each of these areas such as Ireland Mexico and Viet Nam It also stresses that older adults must be engaged throughout The report is intended for people working in government academia civil society and the private sector who make decisions that impact people s ability to live well in older age Humans now live longer than at any time in history But adding more years to life can be a mixed blessing if it is not accompanied by adding more life to years said Dr Tedros Adhanom Ghebreyesus WHO Director General The Baseline Report for the Decade of Healthy Ageing has the potential to transform the way policy makers and multiple service providers engage with older adults We have to work together to foster the abilities and well being of our older generations who continue to give us so much The report also discusses what is needed to promote collaboration and better measure progress towards healthy ageing Evidence and case studies from around the world give practical examples of what can be done in countries and communities with older people points out Dr Anshu Banerjee Director of the Department of Maternal Newborn Child and Adolescent Health and Ageing at WHO According to the report only one quarter of countries around the world are compiling comparable data which can be used to monitor global progress towards healthy ageing Some countries that are collecting and using data to improve policies and programmes for and with older persons are presented in the report These countries are Chile China Finland Ghana India Qatar Singapore and Thailand A number of indicators to be reported on by countries as a demonstration of commitment towards healthy ageing were agreed on by WHO Member States as part of the Global Strategy on Ageing and Health 2016 2020 and endorsed in 2020 within the context of the Decade for Healthy Ageing 2021 2030 Examples are the establishment of a national committee or forum on ageing comprehensive assessments of the health and social care needs of older people and a policy on strengthening long term care The Baseline report notes improvements in all 10 indicators between 2018 when initial data collection took place and 2020 The most progress had been made in establishing national policies relating to healthy ageing and the least in introducing and enforcing legislation against age based discrimination This report will serve as a useful reference against which we can promote learning across countries and measure progress towards healthy ageing during the next decade said Dr Ritu Sadana the lead author of the report and Head of WHO s Ageing and Health Unit We will continue working with governments other UN organizations civil society and world experts to improve evidence and information on all aspects of healthy ageing and support impact in countries More comparable data will enable us to determine clearly the level of progress being made and identify areas where additional attention is needed The context for the Report is the commitment of WHO and the wider UN system to implement efforts to improve the lives of older people through the newly designated UN Decade of Healthy Ageing 2021 2030 WHO will compile progress reports in 2023 2026 and 2029', 'https://www.who.int/news/item/17-12-2020-who-launches-baseline-report-for-decade-of-healthy-ageing', 22, 'pending', '2020-12-20 12:17:04', NULL),
(534, 'Responding to a yellow fever outbreak in Nigeria amidst a global pandemic', 'You can access the original press release by clicking here', 'https://www.who.int/news/item/14-12-2020-responding-to-a-yellow-fever-outbreak-in-nigeria-amidst-a-global-pandemic', 22, 'pending', '2020-12-20 12:17:04', NULL),
(535, 'Neglected tropical diseases: WHO and Sanofi renew decades-long collaboration to sustain elimination efforts', 'The World Health Organization WHO and Sanofi one of the world s leading pharmaceutical companies have signed a new agreement for donations of medicines to sustain specific efforts to eliminate neglected tropical diseases NTDs', 'https://www.who.int/news/item/15-12-2020-neglected-tropical-diseases-who-and-sanofi-renew-decades-long-collaboration-to-sustain-elimination-efforts', 22, 'pending', '2020-12-20 12:17:04', NULL),
(536, 'Monitoring childbirth in a new era for maternal health', 'WHO and HRP launch the Labour Care Guide to improve every woman s experience of childbirth and to help ensure the health and well being of women and their babies The philosophy of labour and delivery care and the recommended World Health Organization WHO approach have developed significantly in the last decades The recognition that every birth is unique is now a cornerstone of the 2018 WHO recommendations on intrapartum care for a positive childbirth experience Over one third of maternal deaths half of stillbirths and a quarter of neonatal deaths result from complications during labour and childbirth The majority of these deaths occur in low resource settings and are preventable through timely interventions Knowing when to wait and when to take life saving action is critical What is the new Labour Care Guide The WHO Labour Care Guide is a new tool which puts the WHO recommendations on intrapartum care into practice It helps skilled health personnel to provide woman centred safe and effective care and to optimize the outcome and experience of childbirth for every woman and baby Launched alongside the WHO Labour Care Guide User s Manual the tool promotes a person centred approach to monitoring a woman s and her baby s health and well being from active first stage of labour to end of second stage of labour This creates a positive feedback and decision making loop as health personnel are encouraged to regularly assess the well being of the woman and her baby record their observationscheck for signs that breach thresholds for health and well being as labour progressesplan what care may be required in consultation with the woman The Guide and Manual recognize that every birth is unique from a woman s personal experience of care to the speed at which her labour progresses The new WHO Labour Care Guide strengthens the relationship between women and their healthcare providers during labour and childbirth improving both individual experience and clinical outcome It is a practical tool for a new era of maternal health where women s values and preferences are at the centre of their own care says Mercedes Bonet Medical Officer in the WHO Department of Sexual and Reproductive Health and Research including HRP UNDP UNFPA UNICEF WHO World Bank Special Programme of Research Development and Research Training in Human Reproduction Beyond the partographThe Labour Care Guide revises and replaces the traditional WHO partograph a labour monitoring tool which is now inconsistent with the latest evidence about labour duration triggers for clinical interventions and the importance of respectful maternity care Many women do not experience a labour that fits the expected rate of the original WHO partograph For instance there is no evidence supporting the use of a cervical dilatation rate of 1 cm hour as a screening tool to trigger medical interventions or referral Instead the Labour Care Guide includes updated evidence based reference ranges of labour progress By recording and reviewing their observations against these references health personnel are encouraged to think critically avoid unnecessary interventions and act on warning signs They can also include each woman in decision making about her own labour part of the Labour Care Guide s emphasis on the importance of a woman and her baby s experiences of childbirth A revolution in maternal health quality of careThe Labour Care Guide has been evaluated in six countries using a mixed methods study recently published in BIRTH It was found to be feasible and acceptable for use across different clinical settings promoting woman centered care and improving outcomes Using the Labour Care Guide we show more care to our patients than before we provided them what they needed So we had less complications and less interventions due to early detection and decision making explained a midwife who evaluated the tool in Nigeria Achieving the best possible physical emotional and psychological outcomes for every woman and child requires health systems to support a model of person centred care which both empowers the user and enables health personnel In this way the Labour Care Guide is much more than a technical tool for monitoring labour progress It represents revolutionary steps towards evidence based individualized labour care', 'https://www.who.int/news/item/15-12-2020-monitoring-childbirth-in-a-new-era-for-maternal-health', 22, 'pending', '2020-12-20 12:17:04', NULL),
(537, 'Updated WHO Information Note: Ensuring continuity of TB services during the COVID-19 pandemic', 'As the world comes together to tackle the COVID 19 pandemic it is important to ensure that essential health services and operations are continued to protect the lives of people with TB and other diseases or health conditions Health services including national programmes to combat TB need to be actively engaged in ensuring an effective and rapid response to COVID 19 while ensuring that TB services are maintained In the lead up to World TB Day Dr Tedros Adhanom Ghebreyesus WHO Director General emphasized in a news release COVID 19 is highlighting just how vulnerable people with lung diseases and weakened immune systems can be The world committed to end TB by 2030 improving prevention is key to making this happen WHO Global TB Programme along with WHO regional and country offices has developed an information note in collaboration with stakeholders This note is intended to assist national TB programmes and health personnel to urgently maintain continuity of essential services for people affected with TB during the COVID 19 pandemic driven by innovative people centred approaches as well as maximizing joint support to tackle both diseases We stand in solidarity with those affected by COVID 19 and those at the frontlines of the fight to combat the disease said Dr Tereza Kasaeva Director of the WHO Global TB Programme We need to act with urgency to ensure that in line with our vision of Health for All no one with TB COVID 19 or any health condition will miss out on the prevention and care they need It s time for action This information note was originally published on 20 March 2020 and later updated on 4 April 12 May and 15 December', 'https://www.who.int/news/item/15-12-2020-updated-who-information-note-ensuring-continuity-of-tb-services-during-the-covid-19-pandemic', 22, 'pending', '2020-12-20 12:17:04', NULL),
(538, 'Covid-19: SAGE members&amp;#x2019; interests published by government 10 months into pandemic', 'The government has published a register listing the interests of expert members of the Scientific Advisory Group for Emergencies 1 after criticism about the group s lack of transparency The BMJ', 'http://feeds.bmj.com/~r/bmj/recent/~3/NWc9yx-Z4uo/bmj.m4911.short', 26, 'pending', '2020-12-20 12:17:07', NULL),
(539, 'Air pollution from road traffic contributed to girl&amp;#x2019;s death from asthma, coroner concludes', 'A coroner has concluded that air pollution from road traffic made a significant contribution to the death of a 9 year old girl with asthma in a groundbreaking case The case of Ella Adoo', 'http://feeds.bmj.com/~r/bmj/recent/~3/LFOe5zdnyLc/bmj.m4902.short', 26, 'pending', '2020-12-20 12:17:07', NULL),
(540, 'Wallace Foulds: founding president of the Royal College of Ophthalmologists', 'bmj 371 dec17 8 m4854 FAF1faPhoto credit Royal College of OphthalmologistsIn 1951 Wallace Foulds who has died aged 96 was appointed registrar at Moorfields Eye Hospital in London where he', 'http://feeds.bmj.com/~r/bmj/recent/~3/kYB4nmt4thI/bmj.m4854.short', 26, 'pending', '2020-12-20 12:17:07', NULL),
(541, 'Covid-19: Wales tightens Christmas restrictions as four nations&amp;#x2019; rules diverge', 'The Welsh government has broken ranks with the rest of the UK by imposing stronger restrictions over the Christmas period limiting the number of households that can meet to two 1 Rules have also', 'http://feeds.bmj.com/~r/bmj/recent/~3/oaqQa9CZejc/bmj.m4906.short', 26, 'pending', '2020-12-20 12:17:07', NULL),
(542, 'Update to living systematic review on drug treatments for covid-19', 'This living systematic review by Siemieniuk and colleagues BMJ 2020 370 m2980 has been updated For the latest update visit doi 10 1136 bmj m2980 The latest version of this living systematic', 'http://feeds.bmj.com/~r/bmj/recent/~3/lkzPUB7Lsyg/bmj.m4852.short', 26, 'pending', '2020-12-20 12:17:07', NULL),
(543, 'Update to living WHO guideline on drugs for covid-19', 'This living guideline by Lamontagne and colleagues BMJ 2020 370 m3379 has been updated For the latest update visit doi 10 1136 bmj m3379 The latest version of this WHO living guidance provides', 'http://feeds.bmj.com/~r/bmj/recent/~3/udxdawNXJY8/bmj.m4779.short', 26, 'pending', '2020-12-20 12:17:07', NULL),
(544, '[Evaluation of the efficacy of Chinese Children\'s Asthma Action Plan on the long-term management of children with asthma at home].', 'Evaluation of the efficacy of Chinese Children s Asthma Action Plan on the long term management of children with asthma at home Zhonghua Yi Xue Za Zhi 2020 Dec 15 100 46 3702 3705 Authors Zhang B Jin R Guan RZ Lin RJ Chang DY Zhang LH Ding J Abstract Objective During the COVID 19 pandemic the electronic questionnaire star was employed to investigate the general situation medication situation and pandemic impact of children diagnosed with asthma in our hospital and enrolled in the electronic platform of the Chinese Children s Asthma Action Plan CCAAP The internet technology and big data were used to grasp the trend and asthma control of children who had been at home for a long time due to the pandemic so as to facilitate the management Methods By random cluster sampling survey method according to the needs and medication adherence score the electronic questionnaire star was designed to conduct a survey among children 0 to 14 years old who diagnosed with asthma and joined the CCAAP on the basis of bronchial asthma medication adherence scale Finally the results of electronic questionnaire survey were analyzed Results A total of 423 questionnaires were sent out 422 of which were valid with an effective response rate of 99 7 The results of questionnaire survey showed that 296 cases were male accounting for 70 1 and 126 cases were female accounting for 29 9 with an average age of 5 4 2 6 years old The average age of males and females was 5 3 2 6 and 5 4 2 6 years old respectively There were more children aged 5 years than children who were younger than 5 years Additionally 13 95 of the parents thought that the pandemic had more than moderate impact on children with asthma and 76 12 of the children were in the green zone and had no asthma attack The proportion of green zone inhaled drugs 79 8 was higher than yellow zone and red zone 49 8 After using the CCAAP platform the dissatisfaction rate was only 1 42 Moreover 71 87 of the children s medical expenses decreased and the proportion of frequent use and intermittent use of antibiotics reduced however the proportion of occasional use and never use of antibiotics increased significantly all P 0 05 The average score of drug compliance was 4 56 and the more frequently the platform was used the higher the score of medication compliance was P 0 05 Conclusions After using CCAAP management with the aid of internet technology children with asthma who had been isolated at home for a long time were less affected by COVID 19 with high medication compliance generally lower medical expenses significantly reduced use of antibiotics and high satisfaction This management mode provides a new idea for internet medicine PMID 33342148 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33342148?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL);
INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(545, 'Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.', 'Related Articles Long term Overall Survival Outcomes in Patients with Early Stage Peripherally Located Non small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non academic Cancer Centre Clin Oncol R Coll Radiol 2020 Dec 16 Authors Wood A Aynsley E Kumar G Masinghe S Anderson M Veeratterapillay J Huntley C Blower A Green J Johnson D Daniel J Curtis H Reynolds J Turnbull M Harland K Swingler A Banham E Burke K Bradley J Greenhalgh A Peedell C Abstract AIMS To report long term outcomes of patients treated with stereotactic ablative radiotherapy SABR for early stage peripherally located non small cell lung cancer MATERIALS AND METHODS Data were collected retrospectively between September 2009 and May 2019 Electronic medical records were reviewed for baseline characteristics treatment details and outcomes All patients were treated according to local protocol based on the national UK SABR Consortium guidelines Risk adapted treatment schedules were used depending on the size and the location of the tumour 54 Gy in three fractions 55 Gy in five fractions 60 Gy in eight fractions or 50 Gy in 10 fractions Overall survival outcomes were evaluated using the Kaplan Meier method RESULTS In total 412 patients were included in the analysis The median age was 76 years range 48 93 years Histological confirmation was obtained in 233 cases 56 6 The median overall survival for all patients was 42 3 months 95 confidence interval 37 3 47 3 months with 3 and 5 year overall survival of 52 8 and 37 3 respectively For biopsy proven patients 56 6 3 and 5 year overall survival was 57 3 and 40 1 respectively With respect to overall survival univariate and multivariate analysis revealed no significant difference in survival by technique volume modulated arc therapy versus conformal three dimensional computed tomography versus four dimensional computed tomography tumour location smoking status at first contact pre treatment tumour stage or pre treatment standardised uptake value Survival was poorer for patients who received the 50 Gy in 10 fractions schedule Treatment was very well tolerated with very low rates of grade 3 4 toxicity 1 CONCLUSIONS SABR for peripherally located medically inoperable non small cell lung cancer can be safely and effectively implemented in a non academic institution with appropriate equipment and training Overall survival outcomes and toxicity rates are comparable with internationally published studies Patients treated with 50 Gy in 10 fractions had a poorer survival outcome PMID 33341333 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341333?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(546, 'Recommendations on intervention for hepatobiliary oncological surgery during the COVID-19 pandemic.', 'Related Articles Recommendations on intervention for hepatobiliary oncological surgery during the COVID 19 pandemic Cir Esp 2020 Dec 16 Authors Garc a Botella A G mez Bravo MA Di Martino M Gastaca M Mart n P rez E S nchez Cab s S S nchez P rez B L pez Ben S Rodr guez Sanju n JC L pez And jar R Barrera M Grupo colaborativo Cirug a AEC COVID 19 Grupo colaborativo Cirug a AEC COVID 19 Balibrea JM Rubio P rez I Badia JM Martin Antona E lvarez Pe a E Garcia Botella A Mart n P rez E lvarez Gallego M Mart nez Cortijo S Pascual Miguel ez I P rez D az L Ramos Rodr quez JL Esp n Basany E S nchez Santos R Guirao Garriga X Aranda Narv ez JM Morales Conde S Abstract The SARS CoV 2 COVID 19 pandemic requires an analysis in the field of oncological surgery both on the risk of infection with very relevant clinical consequences and on the need to generate plans to minimize the impact on possible restrictions on health resources The AEC is making a proposal for the management of patients with hepatopancreatobiliary HPB malignancies in the different pandemic scenarios in order to offer the maximum benefit to patients minimising the risks of COVID 19 infection and optimising the healthcare resources available at any time This requires the coordination of the different treatment options between the departments involved in the management of these patients medical oncology radiotherapy oncology surgery anaesthesia radiology endoscopy department and intensive care The goal is offer effective treatments adapted to the available resources without compromising patients and healthcare professionals safety PMID 33341242 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341242?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(547, 'The COVID-19 Pandemic: The effect on open lower limb fractures in a London major trauma centre - a plastic surgery perspective.', 'Related Articles The COVID 19 Pandemic The effect on open lower limb fractures in a London major trauma centre a plastic surgery perspective Injury 2020 Dec 11 Authors Campbell E Zahoor U Payne A Popova D Welman T Pahal GS Sadigh P Abstract BACKGROUND COVID 19 has created huge pressures on healthcare systems The ongoing provision of major trauma services during this time has proved challenging We report our experience of managing open lower limb fractures oLLFs during the pandemic in a London major trauma centre MTC METHODS This was a prospective study of all open lower limb fractures presenting to our unit over the initial 48 days of UK government lockdown 24th March till 10th May 2020 Results were compared to the same time period in 2019 retrospectively Epidemiological data mechanism Gustilo Anderson G A severity grading time to initial debridement and definitive coverage were analysed RESULTS There was a 64 reduction in emergency department ED attendances 25 264 vs 9042 There was an 18 reduction in oLLFs 22 vs 18 Approximately three quarters of injuries were in males across both cohorts 77 vs 78 and tended to occur in younger patients median age 37 vs 35 Road traffic accidents RTAs were the most common injury mechanism in both 2019 and lockdown but a rise in jumpers from height was seen in the latter A similar pattern of G A severities were seen however only 3 injuries during lockdown required major soft tissue reconstruction There was no significant difference in times taken for initial debridement p 0 72786 or definitive wound coverage p 0 16152 A greater proportion of independent operating was seen during lockdown between orthopaedics and plastic surgery CONCLUSIONS Despite government lockdown measures oLLFs still placed significant burden on our MTC Notwithstanding significant staffing alterations and theatre pressures we have been able to ensure these lower limb emergencies remain a surgical priority and have managed to utilise resources appropriately PMID 33341244 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341244?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(548, 'BCG vaccine: Worrying proposal for COVID-19.', 'Related Articles BCG vaccine Worrying proposal for COVID 19 Vaccine 2020 Dec 13 Authors Sarinho E Goudouris E Sol D Abstract Bacille Calmette Gu rin BCG vaccine is proven to be effective in protecting against severe tuberculosis It has been suggested to be able to exert a non specific beneficial effect as protection against other infectious diseases The duration of protection against tuberculosis is estimated to be from 10 to 15 years but the duration of the protection against other infections is not known maybe up to 20 years maybe much shorter than that We don t know it for sure BCG induced trained immunity paradigm is based on experimental models cohort studies with low number of individuals and some epidemiological data in which other possible interfering factors are not controlled The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG before its effectiveness is confirmed and recommendations are published Besides revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency Maybe BCG vaccine is effective in preventing COVID 19 deaths or reducing its severity but may the effect of this vaccine be relevant even with poor health politics and assistance It is very difficult to compare the epidemiologic data about COVID 19 in different countries There are countless factors mainly social and related to the healthcare system which can be more decisive than the hypothesis of trained immunity induced by BCG Until now we can say that BCG s protective role is at least insufficient given many other factors that corroborate SARS CoV 2 infection and or its severity PMID 33341305 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341305?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(549, 'Global production capacity of seasonal and pandemic influenza vaccines in 2019.', 'Related Articles Global production capacity of seasonal and pandemic influenza vaccines in 2019 Vaccine 2020 Dec 16 Authors Sparrow E Wood JG Chadwick C Newall AT Torvaldsen S Moen A Torelli G Abstract Vaccines will be an important element in mitigating the impact of an influenza pandemic While research towards developing universal influenza vaccines is ongoing the current strategy for vaccine supply in a pandemic relies on seasonal influenza vaccine production to be switched over to pandemic vaccines Understanding how much vaccine could be produced in which regions of the world and in what timeframe is critical to informing influenza pandemic preparedness Through the Global Action Plan for Influenza Vaccines 2006 2016 WHO promoted an increase in vaccine production capacity and monitors the landscape through periodically surveying influenza vaccine manufacturers This study compares global capacity for production of influenza vaccines in 2019 with estimates from previous surveys provides an overview of countries with established production facilities presents vaccine production by type and manufacturing process and discusses limitations to these estimates Results of the current survey show that estimated annual seasonal influenza vaccine production capacity changed little since 2015 increasing from 1 47 billion to 1 48 billion doses with potential maximum annual influenza pandemic vaccine production capacity increasing from 6 37 billion to 8 31 billion doses However this figure should be interpreted with caution as it presents a best case scenario with several assumptions which may impact supply Further pandemic vaccines would not be immediately available and could take four to six months for first supplies with several more months needed to reach maximum capacity A moderate case scenario is also presented of 4 15 billion doses of pandemic vaccine in 12 months It is important to note that two doses of pandemic vaccine are likely to be required to elicit an adequate immune response Continued efforts are needed to ensure the sustainability of this production and to conduct research for vaccines that are faster to produce and more broadly protective taking into account lessons learned from COVID 19 vaccine development PMID 33341308 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341308?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(550, 'Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.', 'Related Articles Key criteria for the ethical acceptability of COVID 19 human challenge studies Report of a WHO Working Group Vaccine 2020 Oct 28 Authors Jamrozik E Littler K Bull S Emerson C Kang G Kapulu M Rey E Saenz C Shah S Smith PG Upshur R Weijer C Selgelid MJ WHO Working Group for Guidance on Human Challenge Studies in COVID 19 Abstract This report of the WHO Working Group for Guidance on Human Challenge Studies in COVID 19 outlines ethical standards for COVID 19 challenge studies It includes eight Key Criteria related to scientific justification risk benefit assessment consultation and engagement co ordination of research site selection participant selection expert review and informed consent The document aims to provide comprehensive guidance to scientists research ethics committees funders policymakers and regulators in deliberations regarding SARS CoV 2 challenge studies by outlining criteria that would need to be satisfied in order for such studies to be ethically acceptable PMID 33341309 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341309?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(551, 'Does tetanus vaccination contribute to reduced severity of the COVID-19 infection?', 'Related Articles Does tetanus vaccination contribute to reduced severity of the COVID 19 infection Med Hypotheses 2020 Nov 28 110395 Authors Rickett CD Maschhoff KJ Sukumar SR Abstract We present the hypothesis to the scientific community actively designing clinical trials and recommending public health guidelines to control the pandemic that Tetanus vaccination may be contributing to reduced severity of the COVID 19 infection and urge further research to validate or invalidate the effectiveness of the tetanus toxoid vaccine against COVID 19 This hypothesis was revealed by an explainable artificial intelligence system unleashed on open public biomedical datasets As a foundation for scientific rigor we describe the data and the artificial intelligence system document the provenance and methodology used to derive the hypothesis and also gather potentially relevant data evidence from recent studies We conclude that while correlations may not be reason for causation correlations from multiple sources is more than a serendipitous coincidence that is worthy of further and deeper investigation PMID 33341328 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341328?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(552, 'Corticosteroids and rehabilitation in COVID-19 survivors.', 'Related Articles Corticosteroids and rehabilitation in COVID 19 survivors J Formos Med Assoc 2020 Dec 09 Authors Lal A Mishra AK John K Akhtar J PMID 33341350 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341350?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(553, 'COVID-19 pandemic and the skin: what should dermatologists know?', 'Related Articles COVID 19 pandemic and the skin what should dermatologists know Clin Dermatol 2020 Nov Dec 38 6 785 787 Authors Darlenski R Tsankov N Abstract The world has changed dramatically since the COVID 19 pandemic began In addition to our social occupational and personal lives the new coronavirus also poses novel challenges for all physicians including dermatologists Several skin conditions have emerged mainly as a result of prolonged contact with personal protective equipment and excessive personal hygiene Pressure injury contact dermatitis itch pressure urticaria and exacerbation of preexisting skin diseases including seborrheic dermatitis and acne have been described We have focused on the dermatologic aspects of the COVID 19 infection so that dermatologists are aware of the skin complications and preventive measures can be taken in the COVID 19 pandemic PMID 33341217 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341217?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(554, 'Physical activity, mental health and well-being of adults during initial COVID-19 containment strategies: A multi-country cross-sectional analysis.', 'Related Articles Physical activity mental health and well being of adults during initial COVID 19 containment strategies A multi country cross sectional analysis J Sci Med Sport 2020 Dec 03 Authors Faulkner J O Brien WJ McGrane B Wadsworth D Batten J Askew CD Badenhorst C Byrd E Coulter M Draper N Elliot C Fryer S Hamlin MJ Jakeman J Mackintosh KA McNarry MA Mitchelmore A Murphy J Ryan Stewart H Saynor Z Schaumberg M Stone K Stoner L Stuart B Lambrick D Abstract OBJECTIVES To assess physical activity PA mental health and well being of adults in the United Kingdom UK Ireland New Zealand and Australia during the initial stages of National governments Coronavirus disease COVID 19 containment responses DESIGN Observational cross sectional METHODS An online survey was disseminated to adults n 8 425 44 5 14 8y residing in the UK Ireland New Zealand and Australia within the first 2 6 weeks of government mandated COVID 19 restrictions Main outcome measures included Stages of Change scale for exercise behaviour change International Physical Activity Questionnaire short form World Health Organisation 5 Well being Index and the Depression Anxiety and Stress Scale 9 RESULTS Participants who reported a negative change in exercise behaviour from before initial COVID 19 restrictions to during the initial COVID 19 restrictions demonstrated poorer mental health and well being compared to those demonstrating either a positive or no change in their exercise behaviour p 0 001 Whilst women reported more positive changes in exercise behaviour young people 18 29y reported more negative changes both p 0 001 Individuals who had more positive exercise behaviours reported better mental health and well being p 0 001 Although there were no differences in PA between countries individuals in New Zealand reported better mental health and well being p 0 001 CONCLUSION The initial COVID 19 restrictions have differentially impacted upon PA habits of individuals based upon their age and sex and therefore have important implications for international policy and guideline recommendations Public health interventions that encourage PA should target specific groups e g men young adults who are most vulnerable to the negative effects of physical distancing and or self isolation PMID 33341382 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341382?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(555, 'Operation mode of plastic surgery during COVID-19 epidemic: The experience of the department of plastic surgery in Zibo Central Hospital.', 'Related Articles Operation mode of plastic surgery during COVID 19 epidemic The experience of the department of plastic surgery in Zibo Central Hospital J Plast Reconstr Aesthet Surg 2020 Dec 13 Authors Yang A Zhu L Zuo J Yao X PMID 33341384 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341384?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(556, 'Evaluating risk to people with epilepsy during the COVID-19 pandemic: Preliminary findings from the COV-E study.', 'Related Articles Evaluating risk to people with epilepsy during the COVID 19 pandemic Preliminary findings from the COV E study Epilepsy Behav 2020 Nov 28 107658 Authors Thorpe J Ashby S Hallab A Ding D Andraus M Dugan P Perucca P Costello D French JA O Brien TJ Depondt C Andrade DM Sengupta R Delanty N Jette N Newton CR Brodie MJ Devinsky O Helen Cross J Sander JW Hanna J Sen A COVID 19 and Epilepsy COV E Study Group Abstract The COVID 19 pandemic has caused global anguish unparalleled in recent times As cases rise increased pressure on health services combined with severe disruption to people s everyday lives can adversely affect individuals living with chronic illnesses including people with epilepsy Stressors related to disruption to healthcare finances mental well being relationships schooling physical activity and increased isolation could increase seizures and impair epilepsy self management We aim to understand the impact that COVID 19 has had on the health and well being of people with epilepsy focusing on exposure to increased risk of seizures associated comorbidity and mortality We designed two online surveys with one addressing people with epilepsy directly and the second for caregivers to report on behalf of a person with epilepsy The survey is ongoing and has yielded 463 UK based responses by the end of September 2020 Forty percent of respondents reported health changes during the pandemic n 185 Respondents cited a change in seizures 19 n 88 mental health difficulties 34 n 161 and sleep disruption 26 n 121 as the main reasons Thirteen percent found it difficult to take medication on time A third had difficulty accessing medical services n 154 with 8 having had an appointment canceled n 39 Only a small proportion reported having had discussions about epilepsy related risks such as safety precautions 16 n 74 mental health 29 n 134 sleep 30 n 140 and Sudden Unexpected Death in Epilepsy SUDEP 15 n 69 in the previous 12 months These findings suggest that people with epilepsy are currently experiencing health changes coupled with inadequate access to services Also there seems to be a history of poor risk communication in the months preceding the pandemic As the UK witnesses a second COVID 19 wave those involved in healthcare delivery must ensure optimal care is provided for people with chronic conditions such as epilepsy to ensure that avoidable morbidity and mortality is prevented during the pandemic and beyond PMID 33341393 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341393?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(557, 'Improving health care for disabled people in COVID-19 and beyond: Lessons from Australia and England.', 'Related Articles Improving health care for disabled people in COVID 19 and beyond Lessons from Australia and England Disabil Health J 2020 Dec 05 101050 Authors Kavanagh A Dickinson H Carey G Llewellyn G Emerson E Disney G Hatton C Abstract COVID 19 has exacerbated pre existing difficulties children and adults with disability face accessing quality health care Some people with disability are at greater risk of contracting COVID 19 because they require support for personal care and are unable to physically distance e g those living in congregate settings Additionally some people with disability have health conditions that put them at higher risk of poor outcomes if they become infected Despite this governments have been slow to recognise and respond to the unique and diverse health care needs of people with disability during COVID 19 While some countries including Australia have improved access to high quality health care for people with disability others like England have failed to support their citizens with disability In this Commentary we describe the health care responses of England and Australia and make recommendations for rapidly improving health care for people with disability in the pandemic and beyond PMID 33341397 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341397?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(558, 'Cardiac Magnetic Resonance Findings in Patients Recovered From COVID-19: Initial Experiences in Elite Athletes.', 'Related Articles Cardiac Magnetic Resonance Findings in Patients Recovered From COVID 19 Initial Experiences in Elite Athletes JACC Cardiovasc Imaging 2020 Dec 10 Authors Vago H Szabo L Dohy Z Merkely B PMID 33341416 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341416?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(559, 'Comments on \"Benefits of Sexual Activity on Psychological, Relational, and Sexual Health During the COVID-19 Breakout\".', 'Related Articles Comments on Benefits of Sexual Activity on Psychological Relational and Sexual Health During the COVID 19 Breakout J Sex Med 2020 Dec 16 Authors Chatterjee S Kar SK PMID 33341420 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341420?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(560, 'The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?', 'Related Articles The broad spectrum host directed agent ivermectin as an antiviral for SARS CoV 2 Biochem Biophys Res Commun 2020 Oct 21 Authors Jans DA Wagstaff KM Abstract FDA approved for parasitic indications the small molecule ivermectin has been the focus of growing attention in the last 8 years due to its potential as an antiviral We first identified ivermectin in a high throughput compound library screen as an agent potently able to inhibit recognition of the nuclear localizing Human Immunodeficiency Virus 1 HIV 1 integrase protein by the host importin IMP 1 heterodimer and recently demonstrated its ability to bind directly to IMP to cause conformational changes that prevent its function in nuclear import of key viral as well as host proteins Cell culture experiments have shown robust antiviral action towards a whole range of viruses including HIV 1 dengue Zika and West Nile Virus Venezuelan equine encephalitis virus Chikungunya pseudorabies virus adenovirus and SARS CoV 2 COVID 19 Close to 70 clinical trials are currently in progress worldwide for SARS CoV 2 Although few of these studies have been completed the results that are available as well as those from observational retrospective studies indicate clinical benefit Here we discuss the case for ivermectin as a host directed broad spectrum antiviral agent including for SARS CoV 2 PMID 33341233 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341233?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(561, 'Introducing special cutaneous \"sign\" tribute to health care workers managing \"SARS-CoV-2\" (COVID-19).', 'Related Articles Introducing special cutaneous sign tribute to health care workers managing SARS CoV 2 COVID 19 Clin Dermatol 2020 Nov Dec 38 6 784 Authors Kannangara AP PMID 33341216 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341216?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(562, 'Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation.', 'Related Articles Ischemic gastrointestinal complications of COVID 19 a systematic review on imaging presentation Clin Imaging 2020 Dec 08 73 86 95 Authors Keshavarz P Rafiee F Kavandi H Goudarzi S Heidari F Gholamrezanezhad A Abstract BACKGROUND Limited data is available addressing gastrointestinal GI ischemia in coronavirus disease 2019 COVID 19 We reviewed the clinical and radiologic features of GI ischemia and its related complications in thirty one COVID 19 patients reported in literature METHODS A systematic literature review was performed using a search strategy on all studies published from January 1 2020 to June 13 2020 and updated on September 6 2020 on databases from PubMed Scopus Embase Web of Science and Google Scholar Every study with at least one presentation of COVID 19 related GI ischemia complication and one GI imaging finding was included RESULTS In total twenty two studies and thirty one patients with the mean age of 59 12 7 age range 28 80 years old were included of which 23 74 2 patients were male 7 22 5 female and one unknown gender The significant GI imaging findings include mesenteric arterial or venous thromboembolism followed by small bowel ischemia Nine patients 29 presented with arterial compromise due to superior mesenteric thromboembolism resulting in bowel ischemia Also 6 patients 19 3 demonstrated occlusive thrombosis of the portal system and superior mesenteric vein More than two thirds of patients 20 64 5 required laparotomy and bowel resection Eventually five 16 1 patients were discharged of whom four cases 12 9 readmitted Five 16 1 patients remained ICU hospitalized at the report time and 12 38 7 patients died CONCLUSION Macrovascular arterial venous thrombosis is identified in almost half of COVID 19 patients with bowel ischemia Overall mortality in COVID 19 patients with GI ischemia and radiologically evident mesenteric thrombotic occlusion was 38 7 and 40 retrospectively PMID 33341452 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341452?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(563, 'Remdesivir for COVID-19 in Europe: will it provide value for money?', 'Related Articles Remdesivir for COVID 19 in Europe will it provide value for money Lancet Respir Med 2020 Dec 17 Authors Dal R R Banzi R Georgin Lavialle S Porcher R Sofat R Zeitlinger M Rosendaal FR PMID 33341157 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341157?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(564, 'Cuts in cancer research funding due to COVID-19.', 'Related Articles Cuts in cancer research funding due to COVID 19 Lancet Oncol 2020 Dec 17 Authors Burki TK PMID 33341123 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341123?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(565, 'Persistence of IgG response to SARS-CoV-2.', 'Related Articles Persistence of IgG response to SARS CoV 2 Lancet Infect Dis 2020 Dec 17 Authors Duysburgh E Mortgat L Barbezange C Dierick K Fischer N Heyndrickx L Hutse V Thomas I Van Gucht S Vuylsteke B Arien K Desombere I PMID 33341124 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341124?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(566, 'Science during COVID-19: where do we go from here?', 'Related Articles Science during COVID 19 where do we go from here Lancet 2021 Dec 19 396 10267 1941 Authors The Lancet PMID 33341126 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341126?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(567, 'Offline: The lessons of smallpox eradication for COVID-19.', 'Related Articles Offline The lessons of smallpox eradication for COVID 19 Lancet 2021 Dec 19 396 10267 1951 Authors Horton R PMID 33341128 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341128?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:23', NULL),
(568, 'COVID-19 is not influenza.', 'Related Articles COVID 19 is not influenza Lancet Respir Med 2020 Dec 17 Authors Petersen E PMID 33341154 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341154?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(569, 'Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study.', 'Related Articles Comparison of the characteristics morbidity and mortality of COVID 19 and seasonal influenza a nationwide population based retrospective cohort study Lancet Respir Med 2020 Dec 17 Authors Piroth L Cottenet J Mariet AS Bonniaud P Blot M Tubert Bitter P Quantin C Abstract BACKGROUND To date influenza epidemics have been considered suitable for use as a model for the COVID 19 epidemic given that they are respiratory diseases with similar modes of transmission However data directly comparing the two diseases are scarce METHODS We did a nationwide retrospective cohort study using the French national administrative database PMSI which includes discharge summaries for all hospital admissions in France All patients hospitalised for COVID 19 from March 1 to April 30 2020 and all patients hospitalised for influenza between Dec 1 2018 and Feb 28 2019 were included The diagnosis of COVID 19 International Classification of Diseases 10th edition codes U07 10 U07 11 U07 12 U07 14 or U07 15 or influenza J09 J10 or J11 comprised primary related or associated diagnosis Comparisons of risk factors clinical characteristics and outcomes between patients hospitalised for COVID 19 and influenza were done with data also stratified by age group FINDINGS 89 530 patients with COVID 19 and 45 819 patients with influenza were hospitalised in France during the respective study periods The median age of patients was 68 years IQR 52 82 for COVID 19 and 71 years 34 84 for influenza Patients with COVID 19 were more frequently obese or overweight and more frequently had diabetes hypertension and dyslipidaemia than patients with influenza whereas those with influenza more frequently had heart failure chronic respiratory disease cirrhosis and deficiency anaemia Patients admitted to hospital with COVID 19 more frequently developed acute respiratory failure pulmonary embolism septic shock or haemorrhagic stroke than patients with influenza but less frequently developed myocardial infarction or atrial fibrillation In hospital mortality was higher in patients with COVID 19 than in patients with influenza 15 104 16 9 of 89 530 vs 2640 5 8 of 45 819 with a relative risk of death of 2 9 95 CI 2 8 3 0 and an age standardised mortality ratio of 2 82 Of the patients hospitalised the proportion of paediatric patients 18 years was smaller for COVID 19 than for influenza 1227 1 4 vs 8942 19 5 but a larger proportion of patients younger than 5 years needed intensive care support for COVID 19 than for influenza 14 2 3 of 613 vs 65 0 9 of 6973 In adolescents 11 17 years the in hospital mortality was ten times higher for COVID 19 than for influenza five 1 1 of 458 vs one 0 1 of 804 and patients with COVID 19 were more frequently obese or overweight INTERPRETATION The presentation of patients with COVID 19 and seasonal influenza requiring hospitalisation differs considerably Severe acute respiratory syndrome coronavirus 2 is likely to have a higher potential for respiratory pathogenicity leading to more respiratory complications and to higher mortality In children although the rate of hospitalisation for COVID 19 appears to be lower than for influenza in hospital mortality is higher however low patient numbers limit this finding These findings highlight the importance of appropriate preventive measures for COVID 19 as well as the need for a specific vaccine and treatment FUNDING French National Research Agency PMID 33341155 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341155?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(570, 'COVID-19 offers an opportunity to reform mental health in India.', 'Related Articles COVID 19 offers an opportunity to reform mental health in India Lancet Psychiatry 2021 Jan 8 1 9 11 Authors Dandona R Sagar R PMID 33341174 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341174?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(571, 'Reply: Introducing special cutaneous \"sign\" tribute to health care workers managing new coronavirus disease 2019 (COVID-19).', 'Related Articles Reply Introducing special cutaneous sign tribute to health care workers managing new coronavirus disease 2019 COVID 19 Clin Dermatol 2020 Nov Dec 38 6 782 783 Authors Darlenski R Tsankov N PMID 33341215 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341215?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(572, 'Management strategies for dermatomyositis during the coronavirus disease 2019 outbreak.', 'Related Articles Management strategies for dermatomyositis during the coronavirus disease 2019 outbreak Clin Dermatol 2020 Nov Dec 38 6 731 733 Authors Pi Z Chen P Zhan Y Xiao R Abstract In late 2019 the coronavirus disease 2019 COVID 19 broke out in Wuhan and then spread over China which greatly affected the medical practices and health care systems With most of the hospital s outpatient services closed the routine clinical diagnosis and treatment for patients with dermatomyositis has been disturbed We conducted telephone follow up for 52 patients to know the changes in the condition and the continuation of drug therapy and to ensure the continuity safety and effectiveness of the treatment of patients with dermatomyositis during COVID 19 PMID 33341205 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341205?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(573, 'Domestic violence in the coronavirus disease 2019 era: Insights from a survivor.', 'Related Articles Domestic violence in the coronavirus disease 2019 era Insights from a survivor Clin Dermatol 2020 Nov Dec 38 6 737 743 Authors Hudson LC Lowenstein EJ Hoenig LJ Abstract Amid the coronavirus disease 2019 COVID 19 pandemic there has been an alarming rise in domestic violence worldwide Factors believed to be fueling this escalation in domestic violence include increasing social confinement at home during lockdowns and mounting stress levels from unemployment that have resulted from the economic uncertainties of these times This contribution explores some of the challenges faced by physicians in clinically assessing victims of domestic violence during the COVID 19 era One such challenge is the increased reliance on telemedicine during the pandemic a medium of communication that offers a narrower clinical view of patients than is what is usually provided by an in person examination In this contribution we offer suggestions on how best to screen for domestic violence whether through telemedicine or during an in person encounter The history and physical findings that suggest domestic violence are reviewed along with recommendations on how to make the clinical examination more sensitive and compassionate to the needs of the victims One of the authors of this contribution L C H is herself a survivor of domestic violence and has courageously shared in these pages details of her harrowing near murder by an abusing husband From this case history it is hoped that readers will gain wider insights into what domestic violence means from the perspective of a victim and how we can better help save victims from this widespread and devastating social problem PMID 33341207 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341207?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(574, 'Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-CoV-2 in pemphigus cases.', 'Related Articles Systemic steroids and risk of fecal oral shedding and increased transmission of SARS CoV 2 in pemphigus cases Clin Dermatol 2020 Nov Dec 38 6 750 756 Authors Pawar M Singh M Abstract Pemphigus and its variants viz vulgaris foliaceous vegetans Ig A pemphigus paraneoplastic pemphigus and Senear Usher syndrome are rare autoimmune blistering diseases of the skin and or mucous membranes The autoantibodies involved in the pathogenesis of pemphigus against desmoglein result in the breach of the skin and mucosal barrier which acts as the first line of defence against pathogens In this paper we underscore the importance of the integumentary system as a shield against the acquisition as well as transmission of SARS CoV 2 virion We have also made an attempt to delineate the various treatment modalities available and the viral drug dynamics involved in choosing the optimum therapeutic modality PMID 33341209 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341209?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(575, 'Paraviral eruptions in the era of COVID-19: Do some skin manifestations point to a natural resistance to SARS-CoV-2?', 'Related Articles Paraviral eruptions in the era of COVID 19 Do some skin manifestations point to a natural resistance to SARS CoV 2 Clin Dermatol 2020 Nov Dec 38 6 757 761 Authors Lipsker D Abstract Paraviral eruptions such as the papular purpuric gloves and socks syndrome or eruptive pseudoangiomatosis share the following features that distinguish them from a classic viral eruption they are highly recognizable the eruption usually lasts a few weeks many different viruses and sometimes other agents can trigger them on microscopic examination there is no specific cytopathogenic viral effect Severe acute respiratory syndrome coronavirus 2 SARS CoV 2 can induce both a classic viral eruption and a paraviral eruption the meaning of which in terms of pathophysiology and prognosis is very different Some patients infected with coronavirus disease 2019 COVID 19 have a papulovesicular eruption involving mainly the trunk Those patients have active viremia and some have developed pneumonia and died Biopsy of the eruption revealed cytopathogenic viral effect and thus there is a direct interaction of the virus with the skin it is therefore a classic viral exanthema Others mainly young patients developed chilblains of the fingers and toes 3 or 4 weeks after minor signs of COVID 19 or after contact with a diseased person They did not develop severe COVID 19 Biopsy revealed classic findings of chilblains without cytopathogenic viral effect Most of those patients did not develop specific antibodies Those chilblains can be considered as paraviral Classic viral manifestations are the consequence of a direct interaction of the skin with the virus whereas paraviral manifestations result from the activation of the immune system In the case of paraviral chilblains I hypothesize that it is the innate immune system that rejects SARS CoV 2 Chilblains are also observed in rare monogenic disorders called type 1 interferonopathies where antiviral innate imunity is abormally activated This would explain why these individuals do not develop specific antibodies because they are probably naturally resistant to SARS CoV 2 infection via their innate immuen system PMID 33341210 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341210?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(576, 'Could injured skin be a reservoir for SARS-CoV-2 virus spread?', 'Related Articles Could injured skin be a reservoir for SARS CoV 2 virus spread Clin Dermatol 2020 Nov Dec 38 6 762 763 Authors Elgarhy LH Salem ML PMID 33341211 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341211?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(577, 'COVID toes or pernio?', 'Related Articles COVID toes or pernio Clin Dermatol 2020 Nov Dec 38 6 764 767 Authors Zaladonis A Huang S Hsu S Abstract COVID toes are a new phenomenon of pernio like lesions that has been associated with coronavirus disease 2019 COVID 19 infection As dermatology practices reopen and increase patient volumes amid the waning of the coronavirus pandemic it is important to consider the finding of pernio and pernio like lesions in the context of both COVID 19 and its other possible etiologies This contribution will discuss possible causes of pernio and pernio like lesions and offer suggestions for appropriate diagnostic workup and management when indicated PMID 33341212 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341212?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(578, 'A case for palliative dermatology: COVID-19-related dermatoses.', 'Related Articles A case for palliative dermatology COVID 19 related dermatoses Clin Dermatol 2020 Nov Dec 38 6 768 769 Authors Ho B Ray A Abstract The unprecedented coronavirus disease 2019 COVID 19 pandemic has challenged health care systems in different ways In the United Kingdom various subspecialties are deployed to the wards to help medical workforce in the frontlines with dermatologists helping with general medical wards and on calls We present a case of COVID 19 related urticaria manifesting in a palliative setting and responding well to systemic antihistamine This pandemic has highlighted a new subspecialty that should be explored and researched palliative dermatology bridging elements of dermatology with the concepts of palliative medicine As dermatologists we should be in the position to help with the last stages of a patient s journey PMID 33341213 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341213?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(579, 'Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).', 'Related Articles Management of digestive cancers during the COVID 19 second wave A French intergroup point of view SNFGE FFCD GERCOR UNICANCER SFCD SFED SFRO ACHBT SFR Dig Liver Dis 2020 Dec 16 Authors Tougeron D Michel P Li vre A Ducreux M Gaujoux S Guiu B Huguet F Lecomte T Lepage C Louvet C Maggiori L Mariani P Aparicio T Bouch O Th saurus National de Canc rologie Digestive TNCD Soci t Nationale Fran aise de Gastroent rologie SNFGE F d ration Francophone de Canc rologie Digestive FFCD Groupe Coop rateur multidisciplinaire en Oncologie GERCOR F d ration Nationale des Centres de Lutte Contre le Cancer UNICANCER Soci t Fran aise de Chirurgie Digestive SFCD Soci t Fran aise d Endoscopie Digestive SFED Soci t Fran aise de Radioth rapie Oncologique SFRO Association de Chirurgie H pato Bilio Pancr atique et Transplantation ACHBT Soci t Fran aise de Radiologie SFR PMID 33341421 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341421?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(580, 'Possible immunity, inflammation, and oxidative stress mechanisms of Alzheimer\'s disease in COVID-19 patients.', 'Related Articles Possible immunity inflammation and oxidative stress mechanisms of Alzheimer s disease in COVID 19 patients Clin Neurol Neurosurg 2020 Dec 05 201 106414 Authors Wang H Qin R Zhang J Chen Y PMID 33341456 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341456?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(581, '[Protective measures during tracheostomy for patients with novel coronavirus pneumonia: report of 4 cases].', 'Protective measures during tracheostomy for patients with novel coronavirus pneumonia report of 4 cases Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2020 Dec 07 55 12 1172 1174 Authors He LC Sun YQ Wang YS Wang SJ Wang SC Fan YP Zhang D PMID 33342135 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33342135?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(582, 'From fragmented levels of care to integrated health care: Framework toward improved maternal and newborn health.', 'Related Articles From fragmented levels of care to integrated health care Framework toward improved maternal and newborn health Int J Gynaecol Obstet 2020 Dec 20 Authors Barnea ER Nicholson W Theron G Ramasaukaite D Stark M Albini SM Nassar AH FIGO Safe Motherhood Newborn Health Committee Abstract Worldwide health systems and care approaches vary widely due to local reality distance to facilities cultural norms resources staff availability geography and politics Consequently globally maternal newborn dyad care and outcomes are highly variable leading to approximately 800 maternal deaths daily with a 100 fold difference among high and low resource days Irrespective of where care is received maternal safety and wellbeing should be preserved Despite ongoing efforts however this is not the case Large gaps exist between spending and clinical outcomes Segmented health care coupled with poor planning and inadequate resource distribution results in failure to provide essential life saving treatment The proposed solution is a regional integrated care model from midwife to advanced level III IV care and the newborn unit achieved through effective coordination by site staff and clinicians This model has been successfully implemented in high to low resource countries in the past 20 years In the large diverse population of the United States constructive steps have been implemented to reduce high maternal mortality in black and rural communities The COVID 19 pandemic demonstrates the feasibility of rapid resources coordination to provide effective advanced care The proposed integration of resources will have a major positive impact on the maternal newborn dyad PMID 33341938 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341938?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(583, 'Stroke Care in the First Affiliated Hospital of Chengdu Medical College during the COVID-19 Outbreak.', 'Related Articles Stroke Care in the First Affiliated Hospital of Chengdu Medical College during the COVID 19 Outbreak Eur Neurol 2020 Dec 18 1 6 Authors Zhang LL Guo YJ Lin YP Hu RZ Yu JP Yang J Wang X Abstract Coronavirus disease 2019 COVID 19 has become a pandemic disease globally The First Affiliated Hospital of Chengdu Medical College has adopted telestroke to make stroke care accessible in remote areas During the period January 2020 to March 2020 there was no COVID 19 case reported in our stroke center A significant reduction of stroke admission was observed between the ischemic stroke group 235 vs 588 cases and the intracerebral hemorrhage group 136 vs 150 cases when compared with the same period last year p 0 001 The mean door to needle time DNT and door to puncture time DPT was 62 and 124 min respectively Compared to the same period last year a significant change was observed in DNT 62 12 vs 47 8 min p 0 019 but not in DPT 124 58 vs 135 23 min p 0 682 A total of 46 telestroke consultations were received from network hospitals Telestroke management in the central hospital was performed on 17 patients Of them 3 17 6 patients had brain hernia and died in hospital and 8 47 1 patients were able to ambulation at discharge and had a modified Rankin Scale of 0 2 at 3 months The COVID 19 pandemic impacted stroke care significantly in our hospital including prehospital and in hospital settings resulting in a significant drop in acute ischemic stroke admissions and a delay in DNT The construction of a telestroke network enabled us to extend health care resources and make stroke care accessible in remote areas Stroke education and public awareness should be reinforced during the COVID 19 pandemic PMID 33341815 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341815?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL);

INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(613, 'Wildland firefighter exposure to smoke and COVID-19: A new risk on the fire line.', 'Related Articles Wildland firefighter exposure to smoke and COVID 19 A new risk on the fire line Sci Total Environ 2020 Dec 11 760 144296 Authors Navarro KM Clark KA Hardt DJ Reid CE Lahm PW Domitrovich JW Butler CR Balmes JR Abstract Throughout the United States wildland firefighters respond to wildfires performing arduous work in remote locations Wildfire incidents can be an ideal environment for the transmission of infectious diseases particularly for wildland firefighters who congregate in work and living settings In this review we examine how exposure to wildfire smoke can contribute to an increased likelihood of SARS CoV 2 infection and severity of coronavirus disease COVID 19 Human exposure to particulate matter PM a component of wildfire smoke has been associated with oxidative stress and inflammatory responses increasing the likelihood for adverse respiratory symptomology and pathology In multiple epidemiological studies wildfire smoke exposure has been associated with acute lower respiratory infections such as bronchitis and pneumonia Co occurrence of SARS CoV 2 infection and wildfire smoke inhalation may present an increased risk for COVID 19 illness in wildland firefighters due to PM based transport of SARS CoV 2 virus and up regulation of angiotensin converting enzyme II ACE 2 i e ACE 2 functions as a trans membrane receptor allowing the SARS CoV 2 virus to gain entry into the epithelial cell Wildfire smoke exposure may also increase risk for more severe COVID 19 illness such as cytokine release syndrome hypotension and acute respiratory distress syndrome ARDS Current infection control measures including social distancing wearing cloth masks frequent cleaning and disinfecting of surfaces frequent hand washing and daily screening for COVID 19 symptoms are very important measures to reduce infections and severe health outcomes Exposure to wildfire smoke may introduce additive or even multiplicative risk for SARS CoV 2 infection and severity of disease in wildland firefighters Thus additional mitigative measures may be needed to prevent the co occurrence of wildfire smoke exposure and SARS CoV 2 infection PMID 33341613 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341613?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(614, 'Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors.', 'Related Articles Diverse chemical space of indoleamine 2 3 dioxygenase 1 Ido1 inhibitors Eur J Med Chem 2020 Dec 02 211 113071 Authors Singh R Salunke DB Abstract Indoleamine 2 3 dioxygenase 1 IDO1 catalyses the first and rate limiting step of kynurenine pathway accounting for the major contributor of L Tryptophan degradation The Kynurenine metabolites are identified as essential cofactors antagonists neurotoxins immunomodulators antioxidants as well as carcinogens The catalytic active site of IDO1 enzyme consists of hydrophobic Pocket A positioned in the distal heme site and remains connected to a second hydrophobic Pocket B towards the entrance of the active site IDO1 enzyme also relates directly to the modulation of the innate and adaptive immune system Various studies proved that the over expression of IDO1 enzyme play a predominant role in the escape of immunity during cancer progression Recently there has been considerable interest in evaluating the potential of IDO1 inhibitors to mobilize the body s immune system against solid tumours In the last two decades enormous attempts to advance new IDO1 inhibitors are on going both in pharmaceutical industries and in academia which resulted in the discovery of a diverse range of selective and potent IDO1 inhibitors The IDO1 inhibitors have therapeutic utility in various diseases and in the near future it may have utility in the treatment of COVID 19 Despite various reviews on IDO1 inhibitors in last five years none of the reviews provide a complete overview of diverse chemical space including naturally occurring and synthetic IDO1 inhibitors with detailed structure activity relationship studies The present work provides a complete overview on the IDO1 inhibitors known in the literature so far along with the Structure Activity Relationship SAR in each class of compounds PMID 33341650 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341650?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(615, 'Psychological impact of COVID-19 on Chinese health-care workers.', 'Related Articles Psychological impact of COVID 19 on Chinese health care workers JMIR Ment Health 2020 Dec 14 Authors Ni J Liu Y Wu M Jiang Y Zhou Y Sha D Abstract BACKGROUND The outbreak of the 2019 nCoV had dominated headlines throughout the world The number of infections continued to rise which had reached 30 thousand at the time of writing this editorial Because of the high risk of nosocomial transmission the medical health care workers might be experiencing significant psychological stress OBJECTIVE This descriptive study aimed to identify hospital staff s psychosocial effects associated with working in a hospital environment during the 2019 nCoV outbreak METHODS 57 frontline clinicians working in Wuhan First Hospital and 157 medical training students working in Jiangsu Provincial Peoples Hospital during this outbreak participated in our survey The questionnaire we adopted included questions regarding the participants personal well being sociodemographic characteristics and the psychological status RESULTS 2019 nCoV had psychological impacts both on formal workers and medical students The psychological effects included sleep disorders anxiety and depression There was no significant difference between the group of formal workers and medical students and nearly 50 of the respondents reported pandemic related mental disorders CONCLUSIONS Our study indicated that the high risk of 2019 nCoV exposure caused huge psychological stress on healthcare workers This finding emphasized the need of promoting psychological crisis intervention for medical personnel during this epidemic disease outbreak CLINICALTRIAL This was a cross sectional study including 57 frontline clinicians working in Wuhan First Hospital and 157 medical students working in Jiangsu Provincial Peoples Hospital during the 2019 nCoV outbreak Firstly we released the online questionnaires among the Wuhan First Hospital first line staff and collected 57 valid questionnaires on March 4th 2020 Later we conducted a survey among young medical students to investigate their psychological change associated with 2019 nCoV and collected 157 valid data PMID 33341754 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341754?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(616, 'Strategies for managing N95 mask shortages at water resource recovery facilities during pandemics: a review.', 'Related Articles Strategies for managing N95 mask shortages at water resource recovery facilities during pandemics a review Water Sci Technol 2020 Dec 82 12 2798 2812 Authors Maal Bared R Loudon J Abstract As the numbers of COVID 19 cases grew globally the severe shortages of health care respiratory protective equipment impacted the ability of water resource recovery facilities WRRFs to acquire N95 masks for worker protection While the Occupational Safety and Health Administration OSHA encourages WRRFs to conduct job safety assessments to mitigate risks from bioaerosols it does not provide clear guidance on respiratory protection requirements leaving the use of N95 masks across the industry non standardized and difficult to justify Strategies need to be developed to cope with shortages during pandemics and these should take into consideration a WRRF s size and disinfection equipment available Our objective is to provide an overview of respiratory protection related practices recommended for health care professionals that apply to WRRFs e g elimination substitution extended use reuse disinfection Reviewed N95 mask disinfection strategies included using hydrogen peroxide autoclaving moist heat dry heat ultraviolet germicidal irradiation UVGI ethylene oxide chlorine and ethanol Of these dry heat autoclaving and UVGI present the most promise for WRRFs with UVGI being limited to larger utilities We recommend that WRRFs work closely with disinfection technology manufacturers mask providers health and safety staff and inspectors to develop suitable programs to cope with N95 mask shortages during pandemics PMID 33341771 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341771?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(617, 'Coronavirus vaccine development: from SARS and MERS to COVID-19.', 'Related Articles Coronavirus vaccine development from SARS and MERS to COVID 19 J Biomed Sci 2020 Dec 20 27 1 104 Authors Li YD Chi WY Su JH Ferrall L Hung CF Wu TC Abstract Severe Acute Respiratory Syndrome Coronavirus 2 SARS CoV 2 is a new type of coronavirus that causes the Coronavirus Disease 2019 COVID 19 which has been the most challenging pandemic in this century Considering its high mortality and rapid spread an effective vaccine is urgently needed to control this pandemic As a result the academia industry and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace In this review we outline the essential coronavirus biological characteristics that are important for vaccine design In addition we summarize key takeaways from previous vaccination studies of Severe Acute Respiratory Syndrome Coronavirus SARS CoV and Middle East Respiratory Syndrome Coronavirus MERS CoV highlighting the pros and cons of each immunization strategy Finally based on these prior vaccination experiences we discuss recent progress and potential challenges of COVID 19 vaccine development PMID 33341119 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/33341119?dopt=Abstract', 21, 'pending', '2020-12-21 08:05:24', NULL),
(618, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +2088 new citations', '2088 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 12 23PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29', 21, 'published', '2020-12-23 06:23:32', '2020-12-23 11:37:46'),
(619, 'Behavioural considerations for acceptance and uptake of COVID-19 vaccines', 'The Behavioural Insights Unit of the WHO released a meeting report of the Technical Advisory Group TAG on the special session on acceptance and uptake of COVID 19 vaccines held on 15 October 2020 The meeting report outlines the factors that drive people s behaviour in relation to vaccine acceptance and uptake an enabling environment social influences and motivation The image above is a visual narration that captures highlights of the meeting on 15 October 2020 during which the TAG on Behavioural Insights and Sciences for Health discussed behavioural considerations in relation to COVID 19 vaccine acceptance and uptake The discussion was structured around three key questions Click here to download image in full size Download the graphic', 'https://www.who.int/news/item/21-12-2020-behavioural-considerations-for-acceptance-and-uptake-of-covid-19-vaccines', 22, 'pending', '2020-12-23 06:23:37', NULL),
(620, 'Joint statement calling for urgent country scale-up of access to optimal HIV treatment for infants and children living with HIV', 'Global partners that are committed to ending paediatric AIDS have come together to call on countries to rapidly scale up access to optimal child friendly HIV treatment for infants and children', 'https://www.who.int/news/item/22-12-2020-joint-statement-calling-for-urgent-country-scale-up-of-access-to-optimal-hiv-treatment-for-infants-and-children-living-with-hiv', 22, 'pending', '2020-12-23 06:23:37', NULL),
(621, 'SARS-CoV-2 Variant – United Kingdom of Great Britain and Northern Ireland', 'On 14 December 2020 authorities of the United Kingdom of Great Britain and Northern Ireland reported to WHO that a new SARS CoV 2 variant was identified through viral genomic sequencing This variant is referred to as SARS CoV 2 VUI 202012 01 Variant Under Investigation year 2020 month 12 variant 01', 'http://www.who.int/entity/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/index.html', 24, 'published', '2020-12-23 06:23:40', '2020-12-23 10:26:39'),
(622, 'Mobilizing youth to End TB', 'Since the global youth movement 1 1 youth Initiative was launched on World TB Day 2019 followed by the adoption of the Youth Declaration to End TB at the first ever Global Youth Townhall on ending TB there has been significant progress over the past year The 1 1 Initiative has expanded to include thousands of youth across the world in countries like Bangladesh Nepal India Indonesia Philippines and Vietnam The social media platforms set up as part of the 1 1 youth initiative are joined and followed by more than 15000 young people including WHO End TB forum Similarly Global TB Programme has established Youth2EndTB Global Youth Network where more than 1800 youths from 95 countries have already joined Besides in order to recognise the youth efforts and encourage youth engagement on ending TB youth story series was conducted Moreover 50 and more different youth led activities and virtual events on ending TB have been conducted worldwide This includes sensitizing young people peer education trainings in schools and universities and encouraging them to become TB advocates and supporting TB patients in the community with resources advice and encouragement In addition we are enthusiastic about cross country youth dialogue series that have been started where youths from different countries can participate and learn from each other For instance one of the inspiring examples is that of Nepal young people in this country have established national and provincial youth networks to help young people through capacity building and in ensuring their participation in policy making and community level awareness building programmes Likewise in March 2020 Vietnam National Tuberculosis program launched National Youth Movement against TB which aims on reaching 10 million young people as well as educating all primary school students with TB knowledge and good practices on combating TB and lung diseases Another exciting example is from Indonesia Their national youth movement against TB has been conducting Art exhibitions as well as creating TB awareness through social media campaign Furthermore WHO Global TB Program is currently developing training manual targeting End TB youth leaders young survivors and young health professionals It will be available at End TB channel of Open WHO platform after completing it s six regional youth consultations', 'https://www.who.int/news/item/21-12-2020-mobilizing-youth-to-end-tb-progress-update-2020', 22, 'pending', '2020-12-24 03:17:17', NULL),
(623, 'Yellow fever – Guinea', 'Between 6 November and 15 December 2020 52 suspected cases of yellow fever YF including 14', 'http://www.who.int/entity/csr/don/23-december-2020-yellow-fever-guinea/en/index.html', 24, 'pending', '2020-12-24 03:17:18', NULL),
(624, 'NICE guideline on long covid', 'The covid 19 pandemic has killed over 1 6 million people worldwide 1 caused the worst healthcare crisis of this century and put a huge dent in our economies The magnitude of the population still', 'http://feeds.bmj.com/~r/bmj/recent/~3/rOrZ5SymVtM/bmj.m4938.short', 26, 'pending', '2020-12-24 03:17:19', NULL),
(625, 'The BMJ wins libel case brought by gynaecologist', 'A High Court judge has dismissed a claim from a gynaecologist who sought damages from The BMJ for defamation after his fitness to practise case was reported in the journal In December 2016 The BMJ', 'http://feeds.bmj.com/~r/bmj/recent/~3/4Emuxd_YB6U/bmj.m4951.short', 26, 'pending', '2020-12-24 03:17:19', NULL),
(626, 'Covid-19: UK regulator approves lateral flow test for home use despite accuracy concerns', 'The UK s regulator has approved the Innova lateral flow covid 19 test for people to self administer despite warnings from some testing experts that it is inaccurate and may give people a false sense', 'http://feeds.bmj.com/~r/bmj/recent/~3/UWU6kJrV5ks/bmj.m4950.short', 26, 'pending', '2020-12-24 03:17:19', NULL),
(627, 'Methodological standards for qualitative and mixed methods patient centered outcomes research', 'Rigorous methodologies are critical for ensuring the trustworthiness of research results This paper will describe the process for synthesizing the current literature providing guidance on the use of', 'http://feeds.bmj.com/~r/bmj/recent/~3/r9BJrhJk4gI/bmj.m4435.short', 26, 'pending', '2020-12-24 03:17:19', NULL),
(628, 'Covid-19: Chaotic decision making and failure to communicate undermined government response, says report', 'Ministers must improve the way they use and communicate advice from scientists or risk repeating mistakes made earlier in the coronavirus pandemic a think tank has warned A report from the Institute', 'http://feeds.bmj.com/~r/bmj/recent/~3/PWZLrwNgQRg/bmj.m4940.short', 26, 'pending', '2020-12-24 03:17:19', NULL),
(629, 'Elimination could be the optimal response strategy for covid-19 and other emerging pandemic diseases', 'The covid 19 pandemic might be remembered for the astonishingly rapid development of effective vaccines But it should also be remembered as the first respiratory disease pandemic in which', 'http://feeds.bmj.com/~r/bmj/recent/~3/GejX8mYYCa8/bmj.m4907.short', 26, 'pending', '2020-12-24 03:17:19', NULL),
(630, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +229 new citations', '229 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 12 29PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F23%2007.05%22%5BMHDA%5D%3A%222020%2F12%2F29%2003.59%22%5BMHDA%5D%29', 21, 'pending', '2020-12-29 08:59:28', NULL),
(631, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +2897 new citations', '2897 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 12 31PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F29%2001.50%22%5BMHDA%5D%3A%222020%2F12%2F31%2003.28%22%5BMHDA%5D%29', 21, 'pending', '2020-12-31 08:28:55', NULL),
(632, 'COVID-19: One year later – WHO Director-General’s new year message', 'In his end of year message for 2020 WHO Director General says there is light at the end of the tunnel in the fight against COVID 19 But going into 2021 he urges countries and communities to work together in solidarity to overcome this and future health challenges', 'https://www.who.int/news/item/30-12-2020-covid-19-anniversary-and-looking-forward-to-2021', 22, 'pending', '2020-12-31 08:28:56', NULL),
(633, 'Yellow fever – Senegal', 'From October to December 2020 a total of seven confirmed cases of yellow fever YF have been reported from four health districts in three regions in Senegal', 'http://www.who.int/entity/csr/don/29-december-2020-yellow-fever-senegal/en/index.html', 24, 'pending', '2020-12-31 08:28:56', NULL),
(634, 'Covid-19: UK approves Oxford vaccine as cases of new variant surge', 'The UK s medicines regulator has approved the Oxford and AstraZeneca covid 19 vaccine which will be administered as two standard doses the second within 12 weeks of the first The Joint Committee on', 'http://feeds.bmj.com/~r/bmj/recent/~3/DeYTYA308cw/bmj.m4968.short', 26, 'pending', '2020-12-31 08:28:57', NULL),
(635, 'Argentina legalises abortion in historic vote', 'Argentina s senate has voted to legalise abortion becoming the third and by far the most populous country to do so in South America which has some of the world s most restrictive abortion', 'http://feeds.bmj.com/~r/bmj/recent/~3/ItBnO7NgI_Q/bmj.m4965.short', 26, 'pending', '2020-12-31 08:28:57', NULL),
(636, 'Covid-19: Doctors must be vaccinated without delay, says BMA', 'The BMA has called for frontline healthcare staff to be given the covid 19 vaccine as soon as possible The call came just a day before the UK Medicines and Healthcare Products Regulatory Agency', 'http://feeds.bmj.com/~r/bmj/recent/~3/r3LvAQPQTEI/bmj.m4964.short', 26, 'pending', '2020-12-31 08:28:57', NULL),
(637, 'Covid-19: Italian doctors are disciplined for anti-vaccination propaganda', 'An Italian doctors association has warned or disciplined 10 medics for promoting anti vaccination propaganda and is considering sanctions against three others who are accused of downplaying the', 'http://feeds.bmj.com/~r/bmj/recent/~3/tekJ8srM-CE/bmj.m4962.short', 26, 'pending', '2020-12-31 08:28:57', NULL),
(638, 'Covid-19: Antibodies protect against reinfection for at least six months, study finds', 'The presence of SARS CoV 2 antibodies confers subsequent immunity in most people for at least six months a study of healthcare workers in Oxford UK has found Writing in the New England Journal of', 'http://feeds.bmj.com/~r/bmj/recent/~3/Mfk0Q4kpZxI/bmj.m4961.short', 26, 'pending', '2020-12-31 08:28:57', NULL),
(639, 'Covid-19: How denialism led Mexico&amp;#x2019;s disastrous pandemic control effort', 'As the streets in Mexico City filled with cars crowds and Christmas excitement this December the traffic light system indicating the status of its covid 19 hospitals began to turn red Our', 'http://feeds.bmj.com/~r/bmj/recent/~3/TeLGtwjsfwk/bmj.m4952.short', 26, 'pending', '2020-12-31 08:28:57', NULL),
(640, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +1643 new citations', '1643 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2021 01 04PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F31%2001.58%22%5BMHDA%5D%3A%222021%2F01%2F04%2004.47%22%5BMHDA%5D%29', 21, 'pending', '2021-01-04 11:47:11', '2021-01-04 11:47:11'),
(642, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +1910 new citations', '1910 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2021 01 06PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222021%2F01%2F04%2001.41%22%5BMHDA%5D%3A%222021%2F01%2F06%2008.42%22%5BMHDA%5D%29', 21, 'pending', '2021-01-06 15:42:03', '2021-01-06 15:42:03'),
(643, 'Covid-19: Doctors and nurses demand better PPE for wider range of procedures', 'Healthcare workers are calling on the government to ensure that higher grade personal protective equipment PPE is mandatory for a range of procedures such as fitting nasogastric tubes because of', 'http://feeds.bmj.com/~r/bmj/recent/~3/_MdgiFOcQo8/bmj.n30.short', 26, 'pending', '2021-01-06 15:42:28', '2021-01-06 15:42:28'),
(644, 'Covid-19 vaccination: What&amp;#x2019;s the evidence for extending the dosing interval?', 'Why has the government taken the step to delay the second dose In a letter sent to healthcare staff on 30 December NHS England said the decision had been taken to prioritise giving the first doses of', 'http://feeds.bmj.com/~r/bmj/recent/~3/qs7bglxw4B8/bmj.n18.short', 26, 'pending', '2021-01-06 15:42:28', '2021-01-06 15:42:28'),
(645, 'Food banks may close as covid cases surge, charity warns', 'Food banks may be forced to close unless the UK government takes immediate action to reduce demand for their services a food aid charity has warned in a letter to the prime minister The coordinator', 'http://feeds.bmj.com/~r/bmj/recent/~3/CYs0v_R4TGo/bmj.n27.short', 26, 'pending', '2021-01-06 15:42:28', '2021-01-06 15:42:28'),
(646, 'David Oliver: The false dichotomies in pandemic commentary', 'Much like the Brexit debate the narrative on covid 19 has often been reductive tribally entrenched and polarised This has sometimes led to false dichotomies between seemingly contrasting', 'http://feeds.bmj.com/~r/bmj/recent/~3/h73zLUbgOew/bmj.m4937.short', 26, 'pending', '2021-01-06 15:42:28', '2021-01-06 15:42:28'),
(647, 'A child with multiple hypopigmented lesions', 'A 3 year old girl presented with multiple hypopigmented body lesions that had been present since birth On examination about 20 pale macules and patches were visible on her trunk and neck The', 'http://feeds.bmj.com/~r/bmj/recent/~3/409ScsThEXs/bmj.m4844.short', 26, 'pending', '2021-01-06 15:42:28', '2021-01-06 15:42:28'),
(648, 'Please see the whole picture of my eating disorder', 'Unexplained symptomsFor many years I experienced episodes following binge eating and vomiting where I felt clammy dizzy and disorientated At worst I experienced palpitations and difficulty', 'http://feeds.bmj.com/~r/bmj/recent/~3/4yHjLBS8hsI/bmj.m4569.short', 26, 'pending', '2021-01-06 15:42:28', '2021-01-06 15:42:28'),
(649, 'WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access', 'The World Health Organization WHO today listed the Comirnaty COVID 19 mRNA vaccine for emergency use making the Pfizer BioNTech vaccine the first to receive emergency validation from WHO since the outbreak began a year ago', 'https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access', 22, 'pending', '2021-01-06 15:12:42', NULL),
(650, 'WHO guideline on ensuring balanced national policies for access and safe use of controlled medicines', 'In June 2019 WHO announced the revision of two pain management guidelines A full web statement on this revision can be found here This page is dedicated to the revision of the document Ensuring balance in national policies on controlled substances Guidance for availability and accessibility of controlled medicines 2011 This guideline is being revised in accordance to the methods and procedures outlined in WHO Handbook for Guideline Development Further information and regular updates on the guideline can be found on this page WHO guideline on ensuring balanced national policies for access and safe use of controlled medicines Policy guideline Scope The proposed scope for this guideline has been developed and is available here Public hearing A public hearing regarding the scope of the guideline took place on 19 February 2020 The written statements submitted on the guideline have been consolidated and can be found here Synthesis of evidence WHO Procurement issued a Request for Proposals RFP from specialist technical experts A systematic review team has been selected GDG members The list of Guideline Development Group members has been confirmed and is available here Public comments on the proposed list were accepted until 9th February 2020 The first GDG meeting was held in June 2020 to finalise the scope of the guideline A second GDG meeting took place on 15th December 2020 to prioritise outcomes Further GDG meetings are planned for 2021 to review the outcomes of the systematic review and evidence synthesis External review group The composition of an external review group ERG for the revision of this guideline has been constituted TimelinesThe guideline is expected to be published in 2021 Interim guidance Whilst this document is being updated countries in need of guidance on pain management can use the list of resources for advice concerning access to appropriate medicines for pain and palliative care and orcontact WHO to request technical support at controlled medicines who int Contact usQueries specifically relating to the Ensuring Balance revision may be emailed to the Secretariat controlled medicines who int', 'https://www.who.int/news/item/22-12-2020-who-guideline-on-ensuring-balanced-national-policies-for-access-and-safe-use-of-controlled-medicines', 22, 'pending', '2021-01-06 15:12:42', NULL),
(651, 'Influenza A(H1N2) variant virus – Brazil', 'On 15 December 2020 the Brazil Ministry of Health reported the second confirmed human infection with influenza A H1N2 variant virus A H1N2 v in Brazil in 2020', 'http://www.who.int/entity/csr/don/04-january-2021-influenza-a-brazil/en/index.html', 24, 'pending', '2021-01-06 15:12:42', NULL),
(652, 'Cholera – Togo', 'From 11 November to 28 December 2020 a total of 67 suspected cholera cases presenting with diarrhea and vomiting including two deaths a case fatality ratio CFR 3 were reported from the municipalities Golfe 1 and Golfe 6 in Lom Togo A total of four health areas Katanga Adakpam Gb tsogb in Golfe 1 and Kangnikop in Golfe 6 in the affected municipalities reported at least one case On 17 November cholera was confirmed by culture in the laboratory of the National Institute of Hygiene INH in Lom Togo and WHO was informed On 19 November the Minister of Health Public Hygiene and Universal Access to Care of Togo issued a press release declaring a cholera outbreak and on 24 November WHO was officially notified From 11 November to 28 December 2020 a total of 17 out of 41 stool samples tested positive for Vibrio cholerae O1 serotype Ogawa by culture in the National Institute of Hygiene INH in Lom Togo', 'http://www.who.int/entity/csr/don/04-january-2021-cholera-togo/en/index.html', 24, 'pending', '2021-01-06 15:12:42', NULL),
(653, 'SARS-CoV-2 Variants', 'SARS CoV 2 the virus that causes COVID 19 has had a major impact on human health globally infecting a large number of people causing severe disease and associated long term health sequelae resulting in death and excess mortality especially among older and vulnerable populations interrupting routine healthcare services disruptions to travel trade education and many other societal functions and more broadly having a negative impact on peoples physical and mental health Since the start of the COVID 19 pandemic WHO has received several reports of unusual public health events possibly due to variants of SARS CoV 2 WHO routinely assesses if variants of SARS CoV 2 result in changes in transmissibility clinical presentation and severity or if they impact on countermeasures including diagnostics therapeutics and vaccines Previous reports of the D614G mutation and the recent reports of virus variants from the Kingdom of Denmark the United Kingdom of Great Britain and Northern Ireland and the Republic of South Africa have raised interest and concern in the impact of viral changes A variant of SARS CoV 2 with a D614G substitution in the gene encoding the spike protein emerged in late January or early February 2020 Over a period of several months the D614G mutation replaced the initial SARS CoV 2 strain identified in China and by June 2020 became the dominant form of the virus circulating globally Studies in human respiratory cells and in animal models demonstrated that compared to the initial virus strain the strain with the D614G substitution has increased infectivity and transmission The SARS CoV 2 virus with the D614G substitution does not cause more severe illness or alter the effectiveness of existing laboratory diagnostics therapeutics vaccines or public health preventive measures', 'http://www.who.int/entity/csr/don/31-december-2020-sars-cov2-variants/en/index.html', 24, 'pending', '2021-01-06 15:12:42', NULL),
(654, 'What does the UK-EU trade and cooperation agreement mean for health?', 'The announcement on Christmas Eve 2020 that the UK and the EU had agreed a trade and cooperation agreement1 was greeted with widespread sighs of relief But what does the deal mean for health', 'http://feeds.bmj.com/~r/bmj/recent/~3/6Fan7G8OXxQ/bmj.n17.short', 26, 'pending', '2021-01-07 13:07:53', NULL),
(655, 'Irritable bowel, Brachyspira, . . . and other stories', 'BrachyspiraBrachyspira is a genus of bacteria classified within the phylum Spirochaetes One species B hyodysenteriae is important to farmers because it causes diarrhoeal disease in young pigs', 'http://feeds.bmj.com/~r/bmj/recent/~3/92e6s35ZXV0/bmj.m4955.short', 26, 'pending', '2021-01-07 13:07:54', NULL),
(656, '&amp;#x201C;In the 1980s NHS there wasn&amp;#x2019;t today&amp;#x2019;s climate of fear around speaking out&amp;#x201D;&amp;#x2014;Allyson Pollock', 'Allyson Pollock professor of public health and co director of Newcastle University Centre of Research Excellence in Regulatory Science is the 2020 winner of The BMJ editors award for speaking', 'http://feeds.bmj.com/~r/bmj/recent/~3/mgwNaOGuj-Y/bmj.m4930.short', 26, 'pending', '2021-01-07 13:07:54', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `sent_emails`
--

CREATE TABLE `sent_emails` (
  `id` int(10) UNSIGNED NOT NULL,
  `hash` char(32) COLLATE utf8mb4_unicode_ci NOT NULL,
  `headers` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `sender` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `recipient` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `subject` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `content` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `opens` int(11) DEFAULT NULL,
  `clicks` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `message_id` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `meta` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `email_id` int(11) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `sent_emails`
--

INSERT INTO `sent_emails` (`id`, `hash`, `headers`, `sender`, `recipient`, `subject`, `content`, `opens`, `clicks`, `created_at`, `updated_at`, `message_id`, `meta`, `email_id`) VALUES
(28, 'QtBTBwQKfJfNGf6l959C1KlzySkDwczU', 'Message-ID: <764ea2dfdbede79b5fb255fb156d8e5a@127.0.0.1>\r\nDate: Mon, 28 Dec 2020 14:22:47 +0200\r\nSubject: crawling and rss \r\nFrom: EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>\r\nTo: m.abbas@intrazero.net\r\nMIME-Version: 1.0\r\nContent-Type: text/html; charset=utf-8\r\nContent-Transfer-Encoding: quoted-printable\r\nX-Model-ID: 40\r\nX-Mailer-Hash: QtBTBwQKfJfNGf6l959C1KlzySkDwczU\r\n', 'EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>', ' <m.abbas@intrazero.net>', 'crawling and rss ', '<p><img alt=\"\" src=\"https://kmport.emro.who.int/uploads/hkmpfinal4.png\" style=\"height:200px; width:400px\" /></p>\r\n\r\n<p>Dear Dr. mohamed,</p>\r\n\r\n<p>There is 52811 Publication.</p>\r\n\r\n<p>Check the latest articles</p>\r\n\r\n<p><a href=\'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29\'>2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat 2088 new citations </a>(source : COVID-19)<br><a href=\'https://www.oecd-ilibrary.org/docserver/b46c3c00-en.pdf?expires=1541510571&id=id&accname=guest&checksum=FFD4D08B0A98C85460E2DD39C7EE3315\'>Adverse Outcome Pathway on Inhibition of the mitochondrial complex I of nigro-striatal neurons leading to parkinsonian motor deficits </a>(source : National Institute for Health and Care Excellence (NICE))<br></p>\r\n', 0, 0, '2020-12-28 14:22:49', '2020-12-28 14:22:51', '764ea2dfdbede79b5fb255fb156d8e5a@127.0.0.1', '[]', 40),
(29, '9HG8t5pUg5S3ejl3ygPLc8M3qJO0sT0d', 'Message-ID: <0623bc8e62c2d6e5aa00bdbc4b021fd4@127.0.0.1>\r\nDate: Mon, 28 Dec 2020 14:23:01 +0200\r\nSubject: crawling and rss \r\nFrom: EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>\r\nTo: mmo7amed2010@gmail.com\r\nMIME-Version: 1.0\r\nContent-Type: text/html; charset=utf-8\r\nContent-Transfer-Encoding: quoted-printable\r\nX-Model-ID: 40\r\nX-Mailer-Hash: 9HG8t5pUg5S3ejl3ygPLc8M3qJO0sT0d\r\n', 'EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>', ' <mmo7amed2010@gmail.com>', 'crawling and rss ', '<p><img alt=\"\" src=\"https://kmport.emro.who.int/uploads/hkmpfinal4.png\" style=\"height:200px; width:400px\" /></p>\r\n\r\n<p>Dear Dr . mohamed,</p>\r\n\r\n<p>There is 52811 Publication.</p>\r\n\r\n<p>Check the latest articles</p>\r\n\r\n<p><a href=\'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29\'>2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat 2088 new citations </a>(source : COVID-19)<br><a href=\'https://www.oecd-ilibrary.org/docserver/b46c3c00-en.pdf?expires=1541510571&id=id&accname=guest&checksum=FFD4D08B0A98C85460E2DD39C7EE3315\'>Adverse Outcome Pathway on Inhibition of the mitochondrial complex I of nigro-striatal neurons leading to parkinsonian motor deficits </a>(source : National Institute for Health and Care Excellence (NICE))<br></p>\r\n', 0, 0, '2020-12-28 14:23:04', '2020-12-28 14:23:06', '0623bc8e62c2d6e5aa00bdbc4b021fd4@127.0.0.1', '[]', 40),
(30, 'xsnpzna8PyGLoKftkvIE0FlVYQkD778O', 'Message-ID: <6fd5847d715dfc5d135a45d55d969ba3@127.0.0.1>\r\nDate: Mon, 28 Dec 2020 14:26:35 +0200\r\nSubject: crawling and rss \r\nFrom: EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>\r\nTo: m.abbas@intrazero.net\r\nMIME-Version: 1.0\r\nContent-Type: text/html; charset=utf-8\r\nContent-Transfer-Encoding: quoted-printable\r\nX-Model-ID: 41\r\nX-Mailer-Hash: xsnpzna8PyGLoKftkvIE0FlVYQkD778O\r\n', 'EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>', ' <m.abbas@intrazero.net>', 'crawling and rss ', '<p><img alt=\"\" src=\"https://kmport.emro.who.int/uploads/hkmpfinal4.png\" style=\"height:200px; width:400px\" /></p>\r\n\r\n<p>Dear Dr. mohamed,</p>\r\n\r\n<p>There is 52811 Publication.</p>\r\n\r\n<p>Check the latest articles</p>\r\n\r\n<p><a href=\'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29\'>2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat 2088 new citations </a>(source : COVID-19)<br><a href=\'https://www.oecd-ilibrary.org/docserver/b46c3c00-en.pdf?expires=1541510571&id=id&accname=guest&checksum=FFD4D08B0A98C85460E2DD39C7EE3315\'>Adverse Outcome Pathway on Inhibition of the mitochondrial complex I of nigro-striatal neurons leading to parkinsonian motor deficits </a>(source : National Institute for Health and Care Excellence (NICE))<br></p>\r\n', 1, 3, '2020-12-28 14:26:38', '2020-12-28 14:26:40', '6fd5847d715dfc5d135a45d55d969ba3@127.0.0.1', '[]', 41),
(31, 'KtFrDl7dchLFGOIZea0Pl9ib3m3qPj7M', 'Message-ID: <53b17ef7c36c5a14cfafc4d6b3c034b6@127.0.0.1>\r\nDate: Mon, 28 Dec 2020 14:26:50 +0200\r\nSubject: crawling and rss \r\nFrom: EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>\r\nTo: mmo7amed2010@gmail.com\r\nMIME-Version: 1.0\r\nContent-Type: text/html; charset=utf-8\r\nContent-Transfer-Encoding: quoted-printable\r\nX-Model-ID: 41\r\nX-Mailer-Hash: KtFrDl7dchLFGOIZea0Pl9ib3m3qPj7M\r\n', 'EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>', ' <mmo7amed2010@gmail.com>', 'crawling and rss ', '<p><img alt=\"\" src=\"https://kmport.emro.who.int/uploads/hkmpfinal4.png\" style=\"height:200px; width:400px\" /></p>\r\n\r\n<p>Dear Dr . mohamed,</p>\r\n\r\n<p>There is 52811 Publication.</p>\r\n\r\n<p>Check the latest articles</p>\r\n\r\n<p><a href=\'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29\'>2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat 2088 new citations </a>(source : COVID-19)<br><a href=\'https://www.oecd-ilibrary.org/docserver/b46c3c00-en.pdf?expires=1541510571&id=id&accname=guest&checksum=FFD4D08B0A98C85460E2DD39C7EE3315\'>Adverse Outcome Pathway on Inhibition of the mitochondrial complex I of nigro-striatal neurons leading to parkinsonian motor deficits </a>(source : National Institute for Health and Care Excellence (NICE))<br></p>\r\n', 2, 4, '2020-12-28 14:26:52', '2020-12-28 14:26:54', '53b17ef7c36c5a14cfafc4d6b3c034b6@127.0.0.1', '[]', 41),
(32, 'K3vimYFk6Whvdjt1Gm4MQxh9qDjhfmZS', 'Message-ID: <8dede0ca8cdd18fe1f5f3aeb6d340e14@127.0.0.1>\r\nDate: Mon, 28 Dec 2020 18:04:24 +0200\r\nSubject: crawling and rss \r\nFrom: EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>\r\nTo: m.abbas@intrazero.net\r\nMIME-Version: 1.0\r\nContent-Type: text/html; charset=utf-8\r\nContent-Transfer-Encoding: quoted-printable\r\nX-Model-ID: 42\r\nX-Mailer-Hash: K3vimYFk6Whvdjt1Gm4MQxh9qDjhfmZS\r\n', 'EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>', ' <m.abbas@intrazero.net>', 'crawling and rss ', '<p><img alt=\"\" src=\"https://kmport.emro.who.int/uploads/hkmpfinal4.png\" style=\"height:200px; width:400px\" /></p>\r\n\r\n<p>Dear Dr. mohamed,</p>\r\n\r\n<p>There is 52811 Publication.</p>\r\n\r\n<p>Check the latest articles</p>\r\n\r\n<p><a href=\'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29\'>2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat 2088 new citations </a>(source : COVID-19)<br><a href=\'https://doi.org/10.1183/09031936.00099710\'>Non-CPAP therapies in obstructive sleep apnoea </a>(source : National Institute for Health and Care Excellence (NICE))<br></p>\r\n', 2, 0, '2020-12-28 18:04:27', '2020-12-29 10:14:04', '8dede0ca8cdd18fe1f5f3aeb6d340e14@127.0.0.1', '[]', 42),
(33, 'p1nqmXxRvVwlyv7rnbzFl5P4RQ0996hW', 'Message-ID: <c3a80ab2d4c8e619cfdce6e0ab32bfa0@127.0.0.1>\r\nDate: Mon, 28 Dec 2020 18:04:38 +0200\r\nSubject: crawling and rss \r\nFrom: EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>\r\nTo: mmo7amed2010@gmail.com\r\nMIME-Version: 1.0\r\nContent-Type: text/html; charset=utf-8\r\nContent-Transfer-Encoding: quoted-printable\r\nX-Model-ID: 42\r\nX-Mailer-Hash: p1nqmXxRvVwlyv7rnbzFl5P4RQ0996hW\r\n', 'EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>', ' <mmo7amed2010@gmail.com>', 'crawling and rss ', '<p><img alt=\"\" src=\"https://kmport.emro.who.int/uploads/hkmpfinal4.png\" style=\"height:200px; width:400px\" /></p>\r\n\r\n<p>Dear Dr . mohamed,</p>\r\n\r\n<p>There is 52811 Publication.</p>\r\n\r\n<p>Check the latest articles</p>\r\n\r\n<p><a href=\'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29\'>2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat 2088 new citations </a>(source : COVID-19)<br><a href=\'https://doi.org/10.1183/09031936.00099710\'>Non-CPAP therapies in obstructive sleep apnoea </a>(source : National Institute for Health and Care Excellence (NICE))<br></p>\r\n', 0, 0, '2020-12-28 18:04:40', '2020-12-28 18:04:42', 'c3a80ab2d4c8e619cfdce6e0ab32bfa0@127.0.0.1', '[]', 42),
(34, '9IdTVqqno9wePWKwsPta5zQsrY26J64v', 'Message-ID: <8a6358e0aff2157dbb1247d40e4adb86@127.0.0.1>\r\nDate: Mon, 28 Dec 2020 18:06:12 +0200\r\nSubject: crawling and rss \r\nFrom: EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>\r\nTo: m.abbas@intrazero.net\r\nMIME-Version: 1.0\r\nContent-Type: text/html; charset=utf-8\r\nContent-Transfer-Encoding: quoted-printable\r\nX-Model-ID: 43\r\nX-Mailer-Hash: 9IdTVqqno9wePWKwsPta5zQsrY26J64v\r\n', 'EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>', ' <m.abbas@intrazero.net>', 'crawling and rss ', '<p><img alt=\"\" src=\"https://kmport.emro.who.int/uploads/hkmpfinal4.png\" style=\"height:200px; width:400px\" /></p>\r\n\r\n<p>Dear Dr. mohamed,</p>\r\n\r\n<p>There is 52811 Publication.</p>\r\n\r\n<p>Check the latest articles</p>\r\n\r\n<p><a href=\'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29\'>2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat 2088 new citations </a>(source : COVID-19)<br><a href=\'https://www.sages.org/publications/guidelines/guidelines-for-the-management-of-hiatal-hernia/?format=pdf\'>Guidelines for the management of hiatal hernia </a>(source : National Institute for Health and Care Excellence (NICE))<br></p>\r\n', 5, 2, '2020-12-28 18:06:14', '2020-12-31 10:31:33', '8a6358e0aff2157dbb1247d40e4adb86@127.0.0.1', '[]', 43),
(35, 'DBsyM6KpZBFyPD53koPjBpVz9tVvgWkC', 'Message-ID: <69189c62d892a9758d238506ee59e558@127.0.0.1>\r\nDate: Mon, 28 Dec 2020 18:06:25 +0200\r\nSubject: crawling and rss \r\nFrom: EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>\r\nTo: mmo7amed2010@gmail.com\r\nMIME-Version: 1.0\r\nContent-Type: text/html; charset=utf-8\r\nContent-Transfer-Encoding: quoted-printable\r\nX-Model-ID: 43\r\nX-Mailer-Hash: DBsyM6KpZBFyPD53koPjBpVz9tVvgWkC\r\n', 'EM RGO/SID/Health Knowledge Management Portal <emrgohkmp@who.int>', ' <mmo7amed2010@gmail.com>', 'crawling and rss ', '<p><img alt=\"\" src=\"https://kmport.emro.who.int/uploads/hkmpfinal4.png\" style=\"height:200px; width:400px\" /></p>\r\n\r\n<p>Dear Dr . mohamed,</p>\r\n\r\n<p>There is 52811 Publication.</p>\r\n\r\n<p>Check the latest articles</p>\r\n\r\n<p><a href=\'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29\'>2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat 2088 new citations </a>(source : COVID-19)<br><a href=\'https://www.sages.org/publications/guidelines/guidelines-for-the-management-of-hiatal-hernia/?format=pdf\'>Guidelines for the management of hiatal hernia </a>(source : National Institute for Health and Care Excellence (NICE))<br></p>\r\n', 0, 0, '2020-12-28 18:06:28', '2020-12-28 18:06:30', '69189c62d892a9758d238506ee59e558@127.0.0.1', '[]', 43);

-- --------------------------------------------------------

--
-- Table structure for table `sent_emails_url_clicked`
--

CREATE TABLE `sent_emails_url_clicked` (
  `id` int(10) UNSIGNED NOT NULL,
  `sent_email_id` int(10) UNSIGNED NOT NULL,
  `url` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `hash` char(32) COLLATE utf8mb4_unicode_ci NOT NULL,
  `clicks` int(11) NOT NULL DEFAULT 1,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `sent_emails_url_clicked`
--

INSERT INTO `sent_emails_url_clicked` (`id`, `sent_email_id`, `url`, `hash`, `clicks`, `created_at`, `updated_at`) VALUES
(4, 34, 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&db=pubmed&term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F12%2F21%2006.54%22%5BMHDA%5D%3A%222020%2F12%2F23%2009.23%22%5BMHDA%5D%29', '9IdTVqqno9wePWKwsPta5zQsrY26J64v', 1, '2020-12-28 18:07:58', '2020-12-28 18:07:58'),
(5, 34, 'https://www.sages.org/publications/guidelines/guidelines-for-the-management-of-hiatal-hernia/?format=pdf', '9IdTVqqno9wePWKwsPta5zQsrY26J64v', 1, '2020-12-29 09:54:12', '2020-12-29 09:54:12');

-- --------------------------------------------------------

--
-- Table structure for table `settings`
--

CREATE TABLE `settings` (
  `id` int(11) NOT NULL,
  `about_us` text CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `settings`
--

INSERT INTO `settings` (`id`, `about_us`, `created_at`, `updated_at`) VALUES
(1, 'about us 1 2 3 4', '2019-09-15 17:00:45', '2021-01-05 15:55:34');

-- --------------------------------------------------------

--
-- Table structure for table `sheet1`
--

CREATE TABLE `sheet1` (
  `id` int(3) DEFAULT NULL,
  `name` varchar(56) DEFAULT NULL,
  `created_at` varchar(19) DEFAULT NULL,
  `updated_at` varchar(10) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `sheet1`
--

INSERT INTO `sheet1` (`id`, `name`, `created_at`, `updated_at`) VALUES
(1, 'Abbreviations', '2020-02-07 17:17:39', NULL),
(2, 'Abstracts', '2020-02-07 17:17:39', NULL),
(3, 'Academic Dissertations', '2020-02-07 17:17:39', NULL),
(4, 'Account Books', '2020-02-07 17:17:39', NULL),
(5, 'Addresses', '2020-02-07 17:17:39', NULL),
(6, 'Advertisements', '2020-02-07 17:17:39', NULL),
(7, 'Almanacs', '2020-02-07 17:17:39', NULL),
(8, 'Anecdotes', '2020-02-07 17:17:39', NULL),
(9, 'Animation', '2020-02-07 17:17:39', NULL),
(10, 'Annual Reports', '2020-02-07 17:17:39', NULL),
(11, 'Aphorisms and Proverbs', '2020-02-07 17:17:39', NULL),
(12, 'Architectural Drawings', '2020-02-07 17:17:39', NULL),
(13, 'Atlases', '2020-02-07 17:17:39', NULL),
(14, 'Autobiography', '2020-02-07 17:17:39', NULL),
(15, 'Bibliography', '2020-02-07 17:17:39', NULL),
(16, 'Biobibliography', '2020-02-07 17:17:39', NULL),
(17, 'Biography', '2020-02-07 17:17:39', NULL),
(18, 'Book Illustrations', '2020-02-07 17:17:39', NULL),
(19, 'Book Reviews', '2020-02-07 17:17:39', NULL),
(20, 'Bookplates', '2020-02-07 17:17:39', NULL),
(21, 'Broadsides', '2020-02-07 17:17:39', NULL),
(22, 'Caricatures', '2020-02-07 17:17:39', NULL),
(23, 'Cartoons', '2020-02-07 17:17:39', NULL),
(24, 'Case Reports', '2020-02-07 17:17:39', NULL),
(25, 'Catalogs', '2020-02-07 17:17:39', NULL),
(26, 'CD-DVD', '2020-02-07 17:17:39', NULL),
(27, 'Charts', '2020-02-07 17:17:39', NULL),
(28, 'Chronology', '2020-02-07 17:17:39', NULL),
(29, 'Classical Article', '2020-02-07 17:17:39', NULL),
(30, 'Clinical Conference', '2020-02-07 17:17:39', NULL),
(31, 'Clinical Trial', '2020-02-07 17:17:39', NULL),
(32, 'Clinical Trial, Phase I', '2020-02-07 17:17:39', NULL),
(33, 'Clinical Trial, Phase II', '2020-02-07 17:17:39', NULL),
(34, 'Clinical Trial, Phase III', '2020-02-07 17:17:39', NULL),
(35, 'Clinical Trial, Phase IV', '2020-02-07 17:17:39', NULL),
(36, 'Collected Correspondence', '2020-02-07 17:17:39', NULL),
(37, 'Collected Works', '2020-02-07 17:17:39', NULL),
(38, 'Collections', '2020-02-07 17:17:39', NULL),
(39, 'Comment', '2020-02-07 17:17:39', NULL),
(40, 'Comparative study', '2020-02-07 17:17:39', NULL),
(41, 'Congresses', '2020-02-07 17:17:39', NULL),
(42, 'Consensus Development Conference', '2020-02-07 17:17:39', NULL),
(43, 'Consensus Development Conference, NIH', '2020-02-07 17:17:39', NULL),
(44, 'Consultant reports', '2020-02-07 17:17:39', NULL),
(45, 'Controlled Clinical Trial', '2020-02-07 17:17:39', NULL),
(46, 'Cookbooks', '2020-02-07 17:17:39', NULL),
(47, 'Corrected and Republished Article', '2020-02-07 17:17:39', NULL),
(48, 'Country Cooperation Strategy', '2020-02-07 17:17:39', NULL),
(49, 'Country Office publications', '2020-02-07 17:17:39', NULL),
(50, 'Country profile', '2020-02-07 17:17:39', NULL),
(51, 'Database', '2020-02-07 17:17:39', NULL),
(52, 'Dataset', '2020-02-07 17:17:39', NULL),
(53, 'Diaries', '2020-02-07 17:17:39', NULL),
(54, 'Dictionary', '2020-02-07 17:17:39', NULL),
(55, 'Directories', '2020-02-07 17:17:39', NULL),
(56, 'Directory', '2020-02-07 17:17:39', NULL),
(57, 'Document', '2020-02-07 17:17:39', NULL),
(58, 'Documentaries and Factual Films', '2020-02-07 17:17:39', NULL),
(59, 'Drawings', '2020-02-07 17:17:39', NULL),
(60, 'Duplicate Publication', '2020-02-07 17:17:39', NULL),
(61, 'Editorial', '2020-02-07 17:17:39', NULL),
(62, 'Electronic Supplementary Materials', '2020-02-07 17:17:39', NULL),
(63, 'Encyclopedias', '2020-02-07 17:17:39', NULL),
(64, 'English Abstract', '2020-02-07 17:17:39', NULL),
(65, 'Ephemera', '2020-02-07 17:17:39', NULL),
(66, 'Essays', '2020-02-07 17:17:39', NULL),
(67, 'Eulogies', '2020-02-07 17:17:39', NULL),
(68, 'Evaluation Studies', '2020-02-07 17:17:39', NULL),
(69, 'Examination Questions', '2020-02-07 17:17:39', NULL),
(70, 'Executive action documents', '2020-02-07 17:17:39', NULL),
(71, 'Exhibitions', '2020-02-07 17:17:39', NULL),
(72, 'Festschrift', '2020-02-07 17:17:39', NULL),
(73, 'Fictional Works', '2020-02-07 17:17:39', NULL),
(74, 'Forms', '2020-02-07 17:17:39', NULL),
(75, 'Formularies', '2020-02-07 17:17:39', NULL),
(76, 'Funeral Sermons', '2020-02-07 17:17:39', NULL),
(77, 'General speeches and messages', '2020-02-07 17:17:39', NULL),
(78, 'General speeches and messages [Webcast]', '2020-02-07 17:17:39', NULL),
(79, 'Government Publications', '2020-02-07 17:17:39', NULL),
(80, 'Guidebooks', '2020-02-07 17:17:39', NULL),
(81, 'Guideline', '2020-02-07 17:17:39', NULL),
(82, 'Handbooks', '2020-02-07 17:17:39', NULL),
(83, 'Herbals', '2020-02-07 17:17:39', NULL),
(84, 'Historical Article', '2020-02-07 17:17:39', NULL),
(85, 'Humor', '2020-02-07 17:17:39', NULL),
(86, 'In vitro', '2020-02-07 17:17:39', NULL),
(87, 'Incunabula', '2020-02-07 17:17:39', NULL),
(88, 'Indexes', '2020-02-07 17:17:39', NULL),
(89, 'Information circulars', '2020-02-07 17:17:39', NULL),
(90, 'Instructional Films and Videos', '2020-02-07 17:17:39', NULL),
(91, 'Interactive Tutorial', '2020-02-07 17:17:39', NULL),
(92, 'Intercountry meeting reports', '2020-02-07 17:17:39', NULL),
(93, 'Interview', '2020-02-07 17:17:39', NULL),
(94, 'Introductory Journal Article', '2020-02-07 17:17:39', NULL),
(95, 'Journal Article', '2020-02-07 17:17:39', NULL),
(96, 'Juvenile Literature', '2020-02-07 17:17:39', NULL),
(97, 'Laboratory Manuals', '2020-02-07 17:17:39', NULL),
(98, 'Lecture Notes', '2020-02-07 17:17:39', NULL),
(99, 'Lectures', '2020-02-07 17:17:39', NULL),
(100, 'Legal Cases', '2020-02-07 17:17:39', NULL),
(101, 'Legislation', '2020-02-07 17:17:39', NULL),
(102, 'Letter', '2020-02-07 17:17:39', NULL),
(103, 'Manuscripts', '2020-02-07 17:17:39', NULL),
(104, 'Maps', '2020-02-07 17:17:39', NULL),
(105, 'Meeting Abstracts', '2020-02-07 17:17:39', NULL),
(106, 'Meta-Analysis', '2020-02-07 17:17:39', NULL),
(107, 'Multicenter Study', '2020-02-07 17:17:39', NULL),
(108, 'News', '2020-02-07 17:17:39', NULL),
(109, 'Newspaper Article', '2020-02-07 17:17:39', NULL),
(110, 'Nurses\' Instruction', '2020-02-07 17:17:39', NULL),
(111, 'Observational Study', '2020-02-07 17:17:39', NULL),
(112, 'Outlines', '2020-02-07 17:17:39', NULL),
(113, 'Overall', '2020-02-07 17:17:39', NULL),
(114, 'Patents', '2020-02-07 17:17:39', NULL),
(115, 'Patient Education Handout', '2020-02-07 17:17:39', NULL),
(116, 'Periodical Index', '2020-02-07 17:17:39', NULL),
(117, 'Periodicals and Newsletters', '2020-02-07 17:17:39', NULL),
(118, 'Personal Narratives', '2020-02-07 17:17:39', NULL),
(119, 'Pharmacopoeias', '2020-02-07 17:17:39', NULL),
(120, 'Photographs', '2020-02-07 17:17:39', NULL),
(121, 'Phrases', '2020-02-07 17:17:39', NULL),
(122, 'Pictorial Works', '2020-02-07 17:17:39', NULL),
(123, 'Poetry', '2020-02-07 17:17:39', NULL),
(124, 'Popular Works', '2020-02-07 17:17:39', NULL),
(125, 'Portraits', '2020-02-07 17:17:39', NULL),
(126, 'Postcards', '2020-02-07 17:17:39', NULL),
(127, 'Posters', '2020-02-07 17:17:39', NULL),
(128, 'Practice Guideline', '2020-02-07 17:17:39', NULL),
(129, 'Pragmatic Clinical Trial', '2020-02-07 17:17:39', NULL),
(130, 'Price Lists', '2020-02-07 17:17:39', NULL),
(131, 'Problems and Exercises', '2020-02-07 17:17:39', NULL),
(132, 'Programmed Instruction', '2020-02-07 17:17:39', NULL),
(133, 'Programs', '2020-02-07 17:17:39', NULL),
(134, 'Prospectuses', '2020-02-07 17:17:39', NULL),
(135, 'Publication Components', '2020-02-07 17:17:39', NULL),
(136, 'Publication Formats', '2020-02-07 17:17:39', NULL),
(137, 'Publications', '2020-02-07 17:17:39', NULL),
(138, 'Published Erratum', '2020-02-07 17:17:39', NULL),
(139, 'Randomized Controlled Trial', '2020-02-07 17:17:39', NULL),
(140, 'Research Support, American Recovery and Reinvestment Act', '2020-02-07 17:17:39', NULL),
(141, 'Research Support, N.I.H.,Extramural', '2020-02-07 17:17:39', NULL),
(142, 'Research Support, N.I.H.,Intramural', '2020-02-07 17:17:39', NULL),
(143, 'Research Support, Non-U.S. Gov\'t', '2020-02-07 17:17:39', NULL),
(144, 'Research Support, U.S. Government', '2020-02-07 17:17:39', NULL),
(145, 'Research Support, U.S. Gov\'t, Non-P.H.S.', '2020-02-07 17:17:39', NULL),
(146, 'Research Support, U.S. Gov\'t, P.H.S.', '2020-02-07 17:17:39', NULL),
(147, 'Resource Guides', '2020-02-07 17:17:39', NULL),
(148, 'Retracted Publication', '2020-02-07 17:17:39', NULL),
(149, 'Retraction of Publication', '2020-02-07 17:17:39', NULL),
(150, 'Review', '2020-02-07 17:17:39', NULL),
(151, 'Scientific Integrity Review', '2020-02-07 17:17:39', NULL),
(152, 'Sermons', '2020-02-07 17:17:39', NULL),
(153, 'Staff mission reports', '2020-02-07 17:17:39', NULL),
(154, 'Statistics', '2020-02-07 17:17:39', NULL),
(155, 'Study Characteristics', '2020-02-07 17:17:39', NULL),
(156, 'Support of Research', '2020-02-07 17:17:39', NULL),
(157, 'Tables', '2020-02-07 17:17:39', NULL),
(158, 'Technical Committee reports', '2020-02-07 17:17:39', NULL),
(159, 'Technical Report', '2020-02-07 17:17:39', NULL),
(160, 'Technical working papers', '2020-02-07 17:17:39', NULL),
(161, 'Terminology', '2020-02-07 17:17:39', NULL),
(162, 'Textbooks', '2020-02-07 17:17:39', NULL),
(163, 'Twin Study', '2020-02-07 17:17:39', NULL),
(164, 'Unedited Footage', '2020-02-07 17:17:39', NULL),
(165, 'Union Lists', '2020-02-07 17:17:39', NULL),
(166, 'Unpublished Works', '2020-02-07 17:17:39', NULL),
(167, 'Validation Studies', '2020-02-07 17:17:39', NULL),
(168, 'Video-Audio Media', '2020-02-07 17:17:39', NULL),
(169, 'Webcasts', '2020-02-07 17:17:39', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `sources`
--

CREATE TABLE `sources` (
  `id` int(10) UNSIGNED NOT NULL,
  `name` varchar(191) COLLATE utf8_unicode_ci NOT NULL,
  `category_id` int(10) UNSIGNED NOT NULL DEFAULT 1,
  `resource_type_id` int(11) DEFAULT NULL,
  `status` enum('allowed','suspended') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'allowed',
  `title_xpath` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `link_xpath` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `body_xpath` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `publication_date_xpath` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `doi_xpath` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `link` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `source_image` varchar(255) COLLATE utf8_unicode_ci NOT NULL DEFAULT 'http://whoportal.intrazero.com/assets2/media//products/product10.jpg',
  `speciality_id` int(10) UNSIGNED NOT NULL,
  `type` enum('api','plain','other') COLLATE utf8_unicode_ci DEFAULT NULL,
  `title_name` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `body_name` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `href_name` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `api_data_path` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `doi` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `first_published_date_name` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `website_url` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `descriptive_name` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `c_order` int(11) NOT NULL DEFAULT 0,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `sources`
--

INSERT INTO `sources` (`id`, `name`, `category_id`, `resource_type_id`, `status`, `title_xpath`, `link_xpath`, `body_xpath`, `publication_date_xpath`, `doi_xpath`, `link`, `source_image`, `speciality_id`, `type`, `title_name`, `body_name`, `href_name`, `api_data_path`, `doi`, `first_published_date_name`, `website_url`, `descriptive_name`, `c_order`, `created_at`, `updated_at`) VALUES
(2, 'cdc', 15, 16, 'allowed', '//*[@id=\"allresults\"]/div/div/div[1]/a', '//*[@id=\"allresults\"]/div/div/div[1]/a', '//*[@id=\"allresults\"]/div/div[2]/div[1]/a', '', NULL, 'https://search.cdc.gov/srch/internet/browse2?wt=json&q=59aeb2c9970b7b25be2fab23ACOUNT;a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb&rows=10&start=0&hl=on&df=description,title&hl.simple.pre=%3Cstrong%3E&hl.simple.post=%3C/strong%3E&hl.fragsize=200&affiliate=cdc-main&json.wrf=jQuery341042649176868052363_1585252146782&_=1585252146783', 'uploads/sources/cdc.png', 1, 'api', 'title', 'description[0]', 'url', 'response$%@#$%l^docs', NULL, NULL, NULL, 'CDC', 1, '2019-07-21 14:56:33', '2020-12-29 09:05:29'),
(3, 'cnn', 2, 16, 'suspended', '//h3[contains(@class,\'cnn-search__result-headline\')]/a', '//h3[contains(@class,\'cnn-search__result-headline\')]/a', '//div[contains(@class, \'cnn-search__result-body\')]', NULL, NULL, 'https://search.api.cnn.io/content?size=10&q=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT', 'uploads/sources/cnn.png', 1, 'api', 'headline', 'body', 'url', 'result', NULL, 'lastPublishDate', NULL, 'CNN', 1, '2019-07-21 14:55:42', '2020-12-29 09:05:27'),
(4, 'medscape', 1, 16, 'suspended', '//div[contains(@id,\'allSearchResults\')]//p[contains(@class,\'searchResultTitle\')]/a', '//div[contains(@id,\'allSearchResults\')]//p[contains(@class,\'searchResultTitle\')]/a', '//div[contains(@id,\'allSearchResults\')]//div[contains(@class,\'searchResultTeaser\')]', NULL, NULL, 'https://search.medscape.com/search/?q=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&sort=pubdate&contenttype=Journal+Articles', 'uploads/sources/medscape.png', 1, 'api', 'title', 'description', 'clientUrl', 'profnewsref$%@#$%l^data$%@#$%l^response$%@#$%l^docs', NULL, 'publicationDate', NULL, 'medscape', 0, '2019-07-21 14:56:33', '2020-12-29 09:05:31'),
(5, 'nypost', 2, 16, 'suspended', '//h3[contains(@class,\'entry-heading\')]/a', '//h3[contains(@class,\'entry-heading\')]/a', '//div[contains(@class, \'entry-content\')]', '//*[@class=\"entry-meta\"]/p[2]', NULL, 'https://nypost.com/search/a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT/', 'uploads/sources/nypost.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'NY Post', 3, '2019-07-21 14:56:33', '2020-12-29 09:05:33'),
(6, 'pubmed', 1, 16, 'allowed', '//*[@id=\"search-results\"]/section[1]/div[1]/div/article/div[2]/div[1]/a', '//*[@id=\"search-results\"]/section[1]/div[1]/div/article/div[2]/div[1]/a', '//*[@id=\"search-results\"]/section[1]/div[1]/div/article/div[2]/div[1]/div[2]/div[1]', '//*[@id=\"search-results\"]/section[1]/div[1]/div/article/div[2]/div[1]/div[1]/span[3]', NULL, 'https://pubmed.ncbi.nlm.nih.gov/?term=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT&filter=dates.2020%2F4%2F1-2099%2F4%2F1&sort=pubdate&size=200', 'uploads/sources/pubmed.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://pubmed.ncbi.nlm.nih.gov', 'PubMed', 5, '2019-07-21 14:55:34', '2020-12-29 11:04:37'),
(7, 'reuters', 2, 16, 'suspended', ' //h3[contains(@class, \'search-result-title\')]/a', ' //h3[contains(@class, \'search-result-title\')]/a', '//div[contains(@class, \'search-result-excerpt\')]', '//*[@class=\"search-result-timestamp\"]', NULL, 'https://www.reuters.com/search/news?blob=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT&sortBy=date&dateRange=all', 'uploads/sources/reuters.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://www.reuters.com', 'Reuters', 2, '2019-07-21 14:55:34', '2020-12-29 11:04:27'),
(8, 'toronto', 1, 16, 'suspended', '//div[contains(@class, \'searchtitle\')]/h2/a', '//div[contains(@class, \'searchtitle\')]/h2/a', '//div[contains(@class, \'searchdesc\')]', '//*[@class=\"searchdate\"]', NULL, 'https://find.toronto.ca/searchblox/servlet/SearchServlet?query=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+AND+59aeb2c9970b7b25be2fab23ACOUNT&cname=www1', 'uploads/sources/toronto.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'toronto', 0, '2019-07-21 14:56:33', '2020-12-29 11:04:09'),
(9, 'vlibraryIDR', 1, 18, 'allowed', '//*[@class=\"recordtitle\"]', '//*[@class=\"recordtitle\"]', '//*[@class=\"recordsmeta\"]', '//*[@class=\"recordspubmeta\"]', NULL, 'https://vlibrary.emro.who.int/searchd/?skeyword=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&journal_title=&fauthor_title%5B%5D=&mesh_title%5B%5D=&relation=AND&index_option=title&format=summary&sort=MostRecent&perpage=100&database=idr_records&rc_verification_id=&country=&category=&syear=&year_from=&year_to=&typepublication=&fulltextlanguage=&records=', 'uploads/sources/idr.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Institutional Digital Library (IDR)', 2, '2019-07-21 14:56:33', '2020-12-30 10:28:49'),
(10, 'vlibraryIMEMR', 1, 18, 'allowed', '//*[@class=\"recordtitle\"]', '//*[@class=\"recordtitle\"]', '//*[@class=\"recordsmeta\"]', '//*[@class=\"recordspubmeta\"]', NULL, 'https://vlibrary.emro.who.int/searchd/?skeyword=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&journal_title=&fauthor_title%5B%5D=&mesh_title%5B%5D=&relation=AND&index_option=title&format=summary&sort=MostRecent&perpage=100&database=imemr&rc_verification_id=&country=&category=&syear=&year_from=&year_to=&typepublication=&fulltextlanguage=&records=', 'uploads/sources/imemr.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Index Medicus for the Eastern Mediterranean Region (IMEMR)', 3, '2019-07-21 14:56:33', '2020-12-30 10:28:43'),
(11, 'National Institute for Health and Care Excellence (NICE)', 14, 16, 'allowed', '//h4[contains(@class,\'media-heading\')]/a', '//h4[contains(@class,\'media-heading\')]/a', '//div[contains(@class, \'abstract\')]', '//*[@class=\"media-published-date\"]', NULL, 'https://www.evidence.nhs.uk/search?q=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT&s=Date', 'uploads/sources/nice.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'National Institute for Health and Care Excellence (NICE)', 1, '2019-07-21 14:56:33', '2020-12-29 09:05:38'),
(12, 'Turning Research Into Practice (TRIP)', 3, 16, 'suspended', '//div[contains(@class,\'result\')]/h3/a', '//div[contains(@class,\'result\')]/h3/a', '//div[contains(@class, \'snippet\')]', '//*[@class=\"year\"]/span', NULL, 'https://www.tripdatabase.com/search?sort=y&criteria=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT', 'uploads/sources/trip.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Turning Research Into Practice (TRIP)', 0, '2019-07-21 14:56:33', '2020-12-29 11:04:01'),
(13, 'Cochrane Collaboration', 3, 16, 'allowed', '//h3[contains(@class,\'result-title\')]/a', '//h3[contains(@class,\'result-title\')]/a', '//div[contains(@class, \'search-result-preview\')]', '//*[@class=\"search-result-date\"]', NULL, 'https://www.cochranelibrary.com/en/search?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=1&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&orderBy=displayDate-true', 'uploads/sources/cochrane.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://www.cochranelibrary.com/', 'Cochrane Library', 1, '2019-07-21 14:56:33', '2020-12-29 09:05:40'),
(14, 'NLM Gateway', 1, 16, 'suspended', '//a[contains(@class,\'recordTitle\')]', '//a[contains(@class,\'recordTitle\')]', '//div[contains(@class, \'recordText\')]', NULL, NULL, 'https://gateway.nlm.nih.gov/search?UserSearchText=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&Perform_Search.x=Search&amsort=PubDate&amhighlight=Yes&query=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&pagenumber=1', 'uploads/sources/nlm.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://gateway.nlm.nih.gov/', 'NLM Gateway', 0, '2019-07-21 14:56:33', '2020-12-29 09:05:42'),
(15, 'Campbell Collaboration', 3, 16, 'allowed', '//dt[contains(@class,\'result-title\')]/a', '//dt[contains(@class,\'result-title\')]/a', '//dd[contains(@class, \'result-text\')]', NULL, NULL, 'https://www.campbellcollaboration.org/website-search.html?searchword=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&searchphrase=all&limit=20', 'uploads/sources/campbellcollaboration.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://www.campbellcollaboration.org', 'Campbell Collaboration', 0, '2019-07-21 14:56:33', '2020-12-29 09:05:47'),
(16, 'Centre for Reviews and Dissemination (CRD)', 4, 16, 'suspended', '//h2[contains(@class,\'c-listings-item__title\')]', '//a[contains(@class,\'c-listings-item__link\')]', '//div[contains(@class,\'c-listings-item__description\')]', NULL, NULL, 'https://www.york.ac.uk/search?site=yorkweb&q=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT', 'uploads/sources/crd.jpg', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Centre for Reviews and Dissemination (CRD)', 0, '2019-10-08 14:17:58', '2020-12-29 09:05:50'),
(18, 'Evidence Aid', 1, 16, 'suspended', '//div[contains(@class,\'ais-hits--content\')]/h2/a', '//div[contains(@class,\'ais-hits--content\')]/h2/a', '//span[contains(@class,\'suggestion-post-content\')]', NULL, NULL, 'https://www.evidenceaid.org/search/a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT/feed/rss2/', 'uploads/sources/Evidence_Aid.png', 1, 'other', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Evidence Aid', 0, '2019-10-09 14:01:04', '2020-12-29 09:05:53'),
(19, 'Institutional Repository for Information Sharing (IRIS)', 1, 16, 'allowed', '//h4[contains(@class,\'artifact-title\')]/a', '//h4[contains(@class,\'artifact-title\')]/a', '//div[contains(@class,\'artifact-info\')]', NULL, NULL, 'https://apps.who.int/iris/discover?filtertype_1=title&filter_relational_operator_1=contains&filter_1=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb&filtertype_2=title&filter_relational_operator_2=contains&filter_2=59aeb2c9970b7b25be2fab23ACOUNT&filtertype_3=subject&filter_relational_operator_3=contains&filter_3=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb&submit_apply_filter=&query=', 'uploads/sources/iris.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://apps.who.int', 'Institutional Repository for Information Sharing (IRIS)', 4, '2019-10-09 14:01:04', '2020-12-29 09:05:55'),
(20, 'Hinari Research for Health', 1, 16, 'suspended', '//div[contains(@class,\'summary\')]/h3/span/a', '//div[contains(@class,\'summary\')]/h3/span', '//div[contains(@class,\'shortSummary\')]', NULL, NULL, 'http://hinari.summon.serialssolutions.com/api/search?screen_res=W1440H648&__refererURL=&pn=1&ho=t&fvf%5B%5D=ContentType%2CJournal%20Article%2Cf&fvf%5B%5D=ContentType%2CBook%20%2F%20eBook%2Cf&fvf%5B%5D=ContentType%2CJournal%20%2F%20eJournal%2Cf&l=en&q=(TitleCombined%3A(a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb))%20AND%20(TitleCombined%3A(59aeb2c9970b7b25be2fab23ACOUNT))', 'uploads/sources/hinari.png', 1, 'api', 'full_title', 'abstracts[0].abstract', 'fulltext_link', 'documents', 'dois[0]', 'publication_date', NULL, 'Hinari Research for Health', 0, '2019-10-09 14:01:04', '2020-12-29 09:05:57'),
(21, 'PMC', 5, 16, 'allowed', '//*[@class=\"title\"]/a', '//*[@class=\"title\"]/a', '//*[@class=\"details\"]', '//*[@class=\"rprtid\"]', NULL, 'https://www.ncbi.nlm.nih.gov/pmc/?term=(%22a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT%22)+AND+(%222020%2F04%2F01%22%5BPubDate%5D+%3A+%222099%2F12%2F31%22%5BPubDate%5D)&cmd=DetailsSearch', 'uploads/sources/pmc.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://www.ncbi.nlm.nih.gov', 'PubMed Medical Center (PMC)', 4, '2019-07-21 14:55:34', '2020-12-29 11:04:45'),
(22, 'Nature', 5, 16, 'allowed', '//*[@class=\"h3 extra-tight-line-height\"]/a', '//*[@class=\"h3 extra-tight-line-height\"]/a', '//*[@class=\"mb20 pb20 cleared\"]/div/div/div[1]', '//*[@itemprop=\"datePublished\"]', NULL, 'https://www.nature.com/search?q=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&order=date_desc&date_range=last_year', 'uploads/sources/nature.svg', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://www.nature.com', 'Nature', 2, '2019-07-21 14:55:34', '2020-12-29 09:06:00'),
(23, 'oxford', 5, 16, 'allowed', '//*[@id=\"ContentColumn\"]/div/h4/a', '//*[@id=\"ContentColumn\"]/div/h4/a', '//*[@id=\"ContentColumn\"]/div/div[7]', '//*[@id=\"ContentColumn\"]/div/div[6]', NULL, 'https://academic.oup.com/journals/search-results?page=1&q=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%20AND%2059aeb2c9970b7b25be2fab23ACOUNT&fl_SiteID=5567&SearchSourceType=1&allJournals=1&sort=Date+%e2%80%93+Newest+First', 'uploads/sources/oxford.svg', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://academic.oup.com', 'Oxford Academic', 3, '2019-07-21 14:55:34', '2020-12-29 11:04:54'),
(24, 'sciencedirect', 5, 16, 'allowed', '//*[@class=\"result-list-title-link u-font-serif text-s\"]', '//*[@class=\"result-list-title-link u-font-serif text-s\"]', '//*[@class=\"SubType hor\"]', NULL, NULL, 'https://www.sciencedirect.com/search/advanced?qs=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2059aeb2c9970b7b25be2fab23ACOUNT&sortBy=date&show=50', 'uploads/sources/sciencedirect.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://www.sciencedirect.com', 'ScienceDirect', 5, '2019-07-21 14:55:34', '2020-12-29 11:04:18'),
(25, 'wiley', 5, 18, 'allowed', '//*[@class=\"hlFld-Title\"]/a', '//*[@class=\"hlFld-Title\"]/a', '//*[@class=\"meta__info\"]/ul', '//*[@class=\"meta__epubDate\"]', NULL, 'https://onlinelibrary.wiley.com/action/doSearch?AllField=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb%2659aeb2c9970b7b25be2fab23ACOUNT&startPage=0&sortBy=Earliest', 'uploads/sources/wiley.png', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://onlinelibrary.wiley.com', 'Wiley Online Library', 6, '2019-07-21 14:55:34', '2020-12-30 10:28:39'),
(26, 'GIM', 1, 16, 'allowed', '//*[@class=\"titleArt\"]/a[1]/@title', '//*[@class=\"titleArt\"]/a[1]', '//*[@class=\"author\"]', '//*[@class=\"dataArticle\"]', NULL, 'https://pesquisa.bvsalud.org/gim/?output=site&lang=en&from=0&sort=YEAR_DESC&format=summary&count=20&fb=&page=1&index=tw&q=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT', 'uploads/sources/gim.svg', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, '', 'Global Index Medicus (GIM)', 1, '2019-07-21 14:55:34', '2020-12-29 09:06:05'),
(27, 'bookshelf', 5, 16, 'allowed', '//*[@class=\"title\"]/a', '//*[@class=\"book_toc\"]', '//*[@class=\"desc\"]', '//*[@class=\"details\"]', NULL, 'https://www.ncbi.nlm.nih.gov/books/?term=a4T^Hh$r9=x@#PMdyUT7u8TWm=HbCLb+59aeb2c9970b7b25be2fab23ACOUNT', 'uploads/sources/bookshelf.gif', 1, 'plain', NULL, NULL, NULL, NULL, NULL, NULL, 'https://www.ncbi.nlm.nih.gov', 'Bookshelf', 1, '2019-07-21 14:55:34', '2021-01-04 11:36:58');

-- --------------------------------------------------------

--
-- Table structure for table `sources_order`
--

CREATE TABLE `sources_order` (
  `id` int(11) NOT NULL,
  `user_id` int(10) UNSIGNED NOT NULL,
  `source_id` int(10) UNSIGNED NOT NULL,
  `order` int(11) NOT NULL,
  `type` enum('connector','rss') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'connector',
  `updated_at` timestamp NULL DEFAULT current_timestamp(),
  `created_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `sources_order`
--

INSERT INTO `sources_order` (`id`, `user_id`, `source_id`, `order`, `type`, `updated_at`, `created_at`) VALUES
(1545, 35, 2, 0, 'connector', '2019-10-20 21:33:25', '2019-10-20 21:33:25'),
(1546, 35, 7, 1, 'connector', '2019-10-20 21:33:25', '2019-10-20 21:33:25'),
(1547, 35, 3, 2, 'connector', '2019-10-20 21:33:25', '2019-10-20 21:33:25'),
(1548, 35, 9, 3, 'rss', '2019-10-20 21:33:25', '2019-10-20 21:33:25'),
(1829, 42, 6, 0, 'connector', '2020-02-05 17:00:17', '2020-02-05 17:00:17'),
(1830, 42, 19, 1, 'connector', '2020-02-05 17:00:17', '2020-02-05 17:00:17'),
(1831, 42, 7, 2, 'connector', '2020-02-05 17:00:17', '2020-02-05 17:00:17'),
(1832, 42, 6, 3, 'rss', '2020-02-05 17:00:17', '2020-02-05 17:00:17'),
(1833, 42, 16, 4, 'connector', '2020-02-05 17:00:17', '2020-02-05 17:00:17'),
(1888, 31, 11, 0, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1889, 31, 6, 1, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1890, 31, 9, 2, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1891, 31, 10, 3, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1892, 31, 14, 4, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1893, 31, 8, 5, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1894, 31, 18, 6, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1895, 31, 19, 7, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1896, 31, 7, 8, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1897, 31, 13, 9, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1898, 31, 12, 10, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1899, 31, 15, 11, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1900, 31, 6, 12, 'rss', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1901, 31, 16, 13, 'connector', '2020-02-07 20:37:21', '2020-02-07 20:37:21'),
(1948, 48, 26, 0, 'connector', '2020-02-17 12:25:56', '2020-02-17 12:25:56'),
(1949, 48, 9, 1, 'connector', '2020-02-17 12:25:56', '2020-02-17 12:25:56'),
(1950, 48, 10, 2, 'connector', '2020-02-17 12:25:56', '2020-02-17 12:25:56'),
(1951, 48, 7, 3, 'connector', '2020-02-17 12:25:56', '2020-02-17 12:25:56'),
(1954, 36, 23, 0, 'connector', '2020-03-26 17:14:16', '2020-03-26 17:14:16'),
(1955, 36, 24, 1, 'connector', '2020-03-26 17:14:16', '2020-03-26 17:14:16');

-- --------------------------------------------------------

--
-- Table structure for table `specialities`
--

CREATE TABLE `specialities` (
  `id` int(10) UNSIGNED NOT NULL,
  `parent_id` int(10) UNSIGNED DEFAULT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `status` enum('allowed','suspended') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'allowed',
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `specialities`
--

INSERT INTO `specialities` (`id`, `parent_id`, `name`, `status`, `created_at`, `updated_at`) VALUES
(1, NULL, 's', 'allowed', '2019-08-27 19:43:59', '2021-01-04 18:22:01'),
(3, NULL, 'y', 'allowed', '2019-08-27 19:43:59', '2020-02-05 22:53:14'),
(4, NULL, 'z', 'allowed', '2020-02-05 20:46:36', '2020-02-05 22:53:20'),
(5, NULL, 'm', 'allowed', '2020-02-05 20:46:47', '2020-02-05 22:53:26'),
(6, NULL, 'n', 'allowed', '2020-02-05 20:48:40', '2020-02-05 22:53:31'),
(7, NULL, 'o', 'allowed', '2020-02-05 20:48:52', '2020-02-05 22:53:36'),
(8, 1, 'aaa', 'allowed', '2021-01-04 18:22:25', '2021-01-04 18:22:25');

-- --------------------------------------------------------

--
-- Table structure for table `topics_of_interests`
--

CREATE TABLE `topics_of_interests` (
  `id` int(11) NOT NULL,
  `name` varchar(255) CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `topics_of_interests`
--

INSERT INTO `topics_of_interests` (`id`, `name`, `created_at`, `updated_at`) VALUES
(1, 'Abortion', '2020-02-09 12:11:57', NULL),
(2, 'Accidents, Radiation', '2020-02-09 12:11:57', NULL),
(3, 'Addictive behaviours', '2020-02-09 12:11:57', NULL),
(4, 'Adolescent health', '2020-02-09 12:11:57', NULL),
(5, 'Adolescent pregnancy', '2020-02-09 12:11:57', NULL),
(6, 'Ageing', '2020-02-09 12:11:57', NULL),
(7, 'Air pollution', '2020-02-09 12:11:57', NULL),
(8, 'Alcohol', '2020-02-09 12:11:57', NULL),
(9, 'Ambient (outdoor) air quality and health', '2020-02-09 12:11:57', NULL),
(10, 'Anaemia', '2020-02-09 12:11:57', NULL),
(11, 'Animal bites', '2020-02-09 12:11:57', NULL),
(12, 'Anthrax', '2020-02-09 12:11:57', NULL),
(13, 'Antimicrobial resistance', '2020-02-09 12:11:57', NULL),
(14, 'Antiretroviral therapy', '2020-02-09 12:11:57', NULL),
(15, 'Arsenic', '2020-02-09 12:11:57', NULL),
(16, 'Asbestos', '2020-02-09 12:11:57', NULL),
(17, 'Assistive technology', '2020-02-09 12:11:57', NULL),
(18, 'Asthma', '2020-02-09 12:11:57', NULL),
(19, 'Autism spectrum disorders', '2020-02-09 12:11:57', NULL),
(20, 'Avian influenza', '2020-02-09 12:11:57', NULL),
(21, 'Biological weapons', '2020-02-09 12:11:57', NULL),
(22, 'Biologicals', '2020-02-09 12:11:57', NULL),
(23, 'Blindness and vision loss', '2020-02-09 12:11:57', NULL),
(24, 'Blood products and related biologicals', '2020-02-09 12:11:57', NULL),
(25, 'Blood safety and availability', '2020-02-09 12:11:57', NULL),
(26, 'Blood transfusion safety', '2020-02-09 12:11:57', NULL),
(27, 'Botulism', '2020-02-09 12:11:57', NULL),
(28, 'Breastfeeding', '2020-02-09 12:11:57', NULL),
(29, 'Brucellosis', '2020-02-09 12:11:57', NULL),
(30, 'Burns', '2020-02-09 12:11:57', NULL),
(31, 'Buruli ulcer', '2020-02-09 12:11:57', NULL),
(32, 'Campylobacter', '2020-02-09 12:11:57', NULL),
(33, 'Cancer', '2020-02-09 12:11:57', NULL),
(34, 'Cardiovascular disease', '2020-02-09 12:11:57', NULL),
(35, 'Cataract', '2020-02-09 12:11:57', NULL),
(36, 'Cervical cancer', '2020-02-09 12:11:57', NULL),
(37, 'Chagas disease', '2020-02-09 12:11:57', NULL),
(38, 'Chemical incidents', '2020-02-09 12:11:57', NULL),
(39, 'Chemical safety', '2020-02-09 12:11:57', NULL),
(40, 'Chikungunya', '2020-02-09 12:11:57', NULL),
(41, 'Child development', '2020-02-09 12:11:57', NULL),
(42, 'Child growth standards', '2020-02-09 12:11:57', NULL),
(43, 'Child health', '2020-02-09 12:11:57', NULL),
(44, 'Child maltreatment', '2020-02-09 12:11:57', NULL),
(45, 'Children\'s environmental health', '2020-02-09 12:11:57', NULL),
(46, 'Cholera', '2020-02-09 12:11:57', NULL),
(47, 'Chronic diseases and health promotion', '2020-02-09 12:11:57', NULL),
(48, 'Chronic obstructive pulmonary disease', '2020-02-09 12:11:57', NULL),
(49, 'Chronic respiratory diseases', '2020-02-09 12:11:57', NULL),
(50, 'Civil registration', '2020-02-09 12:11:57', NULL),
(51, 'Classifications', '2020-02-09 12:11:57', NULL),
(52, 'Climate change', '2020-02-09 12:11:57', NULL),
(53, 'Clinical trials', '2020-02-09 12:11:57', NULL),
(54, 'Common good for health', '2020-02-09 12:11:57', NULL),
(55, 'Communicating for health', '2020-02-09 12:11:57', NULL),
(56, 'Condoms', '2020-02-09 12:11:57', NULL),
(57, 'Congenital anomalies', '2020-02-09 12:11:57', NULL),
(58, 'Contracting and performance incentives', '2020-02-09 12:11:57', NULL),
(59, 'Coronavirus (CoV)', '2020-02-09 12:11:57', NULL),
(60, 'Crimean-Congo haemorrhagic fever', '2020-02-09 12:11:57', NULL),
(61, 'Deafness', '2020-02-09 12:11:57', NULL),
(62, 'Death', '2020-02-09 12:11:57', NULL),
(63, 'Deliberate events', '2020-02-09 12:11:57', NULL),
(64, 'Dementia', '2020-02-09 12:11:57', NULL),
(65, 'Dengue', '2020-02-09 12:11:57', NULL),
(66, 'Depression', '2020-02-09 12:11:57', NULL),
(67, 'Diabetes', '2020-02-09 12:11:57', NULL),
(68, 'Diagnostic imaging', '2020-02-09 12:11:57', NULL),
(69, 'Diarrhoea', '2020-02-09 12:11:57', NULL),
(70, 'Diet', '2020-02-09 12:11:57', NULL),
(71, 'Digital health', '2020-02-09 12:11:57', NULL),
(72, 'Dioxins', '2020-02-09 12:11:57', NULL),
(73, 'Diphtheria', '2020-02-09 12:11:57', NULL),
(74, 'Disability', '2020-02-09 12:11:57', NULL),
(75, 'Disease Control in Humanitarian Emergencies', '2020-02-09 12:11:57', NULL),
(76, 'Disease outbreaks', '2020-02-09 12:11:57', NULL),
(77, 'Dracunculiasis eradication', '2020-02-09 12:11:57', NULL),
(78, 'Drought', '2020-02-09 12:11:57', NULL),
(79, 'Drinking water', '2020-02-09 12:11:57', NULL),
(80, 'Drowning', '2020-02-09 12:11:57', NULL),
(81, 'Drug information', '2020-02-09 12:11:57', NULL),
(82, 'Drug resistance', '2020-02-09 12:11:57', NULL),
(83, 'Drugs (psychoactive)', '2020-02-09 12:11:57', NULL),
(84, 'Early child development', '2020-02-09 12:11:57', NULL),
(85, 'Earthquakes', '2020-02-09 12:11:57', NULL),
(86, 'Ebola virus disease', '2020-02-09 12:11:57', NULL),
(87, 'Echinococcosis', '2020-02-09 12:11:57', NULL),
(88, 'Education, Medical', '2020-02-09 12:11:57', NULL),
(89, 'eHealth', '2020-02-09 12:11:57', NULL),
(90, 'Elder abuse', '2020-02-09 12:11:57', NULL),
(91, 'Electromagnetic fields', '2020-02-09 12:11:57', NULL),
(92, 'Emergencies', '2020-02-09 12:11:57', NULL),
(93, 'Emergencies preparedness, response', '2020-02-09 12:11:57', NULL),
(94, 'Emergency and essential surgical care', '2020-02-09 12:11:57', NULL),
(95, 'Emergency and trauma care', '2020-02-09 12:11:57', NULL),
(96, 'Environmental health', '2020-02-09 12:11:57', NULL),
(97, 'Environmental health in emergencies', '2020-02-09 12:11:57', NULL),
(98, 'Epidemiology', '2020-02-09 12:11:57', NULL),
(99, 'Epilepsy', '2020-02-09 12:11:57', NULL),
(100, 'Equity', '2020-02-09 12:11:57', NULL),
(101, 'Escherichia coli infections', '2020-02-09 12:11:57', NULL),
(102, 'Essential medicines', '2020-02-09 12:11:57', NULL),
(103, 'Essential medicines for children', '2020-02-09 12:11:57', NULL),
(104, 'Essential medicines selection', '2020-02-09 12:11:57', NULL),
(105, 'Ethics and health', '2020-02-09 12:11:57', NULL),
(106, 'Evaluation', '2020-02-09 12:11:57', NULL),
(107, 'Eye care', '2020-02-09 12:11:57', NULL),
(108, 'Falls', '2020-02-09 12:11:57', NULL),
(109, 'Family planning', '2020-02-09 12:11:57', NULL),
(110, 'Female genital mutilation', '2020-02-09 12:11:57', NULL),
(111, 'Filariasis', '2020-02-09 12:11:57', NULL),
(112, 'Floods', '2020-02-09 12:11:57', NULL),
(113, 'Food additives', '2020-02-09 12:11:57', NULL),
(114, 'Food safety', '2020-02-09 12:11:57', NULL),
(115, 'Food, Genetically modified', '2020-02-09 12:11:57', NULL),
(116, 'Foodborne diseases', '2020-02-09 12:11:57', NULL),
(117, 'Foodborne trematode infections', '2020-02-09 12:11:57', NULL),
(118, 'Gender', '2020-02-09 12:11:57', NULL),
(119, 'Gender, equity and human rights', '2020-02-09 12:11:57', NULL),
(120, 'Gene editing', '2020-02-09 12:11:57', NULL),
(121, 'Genomics', '2020-02-09 12:11:57', NULL),
(122, 'Global burden of disease', '2020-02-09 12:11:57', NULL),
(123, 'Growth reference 5-19 years', '2020-02-09 12:11:57', NULL),
(124, 'Guillain?Barre syndrome', '2020-02-09 12:11:57', NULL),
(125, 'Haemophilus influenzae type B', '2020-02-09 12:11:57', NULL),
(126, 'Haemorrhagic fevers, Viral', '2020-02-09 12:11:57', NULL),
(127, 'Health Accounts', '2020-02-09 12:11:57', NULL),
(128, 'Health budget', '2020-02-09 12:11:57', NULL),
(129, 'Health economics', '2020-02-09 12:11:57', NULL),
(130, 'Health financing', '2020-02-09 12:11:57', NULL),
(131, 'Health Impact Assessment', '2020-02-09 12:11:57', NULL),
(132, 'Health law', '2020-02-09 12:11:57', NULL),
(133, 'Health promotion', '2020-02-09 12:11:57', NULL),
(134, 'Health services', '2020-02-09 12:11:57', NULL),
(135, 'Health statistics and information systems', '2020-02-09 12:11:57', NULL),
(136, 'Health system responsiveness', '2020-02-09 12:11:57', NULL),
(137, 'Health systems', '2020-02-09 12:11:57', NULL),
(138, 'Health systems governance', '2020-02-09 12:11:57', NULL),
(139, 'Health taxes', '2020-02-09 12:11:57', NULL),
(140, 'Health technology assessment', '2020-02-09 12:11:57', NULL),
(141, 'Health through the life-course', '2020-02-09 12:11:57', NULL),
(142, 'Health workforce', '2020-02-09 12:11:57', NULL),
(143, 'Healthy settings', '2020-02-09 12:11:57', NULL),
(144, 'Heatwaves', '2020-02-09 12:11:57', NULL),
(145, 'Helminthiasis', '2020-02-09 12:11:57', NULL),
(146, 'Hendra virus', '2020-02-09 12:11:57', NULL),
(147, 'Hepatitis', '2020-02-09 12:11:57', NULL),
(148, 'Hepatitis A', '2020-02-09 12:11:57', NULL),
(149, 'Hepatitis B', '2020-02-09 12:11:57', NULL),
(150, 'Hepatitis C', '2020-02-09 12:11:57', NULL),
(151, 'Hepatitis D', '2020-02-09 12:11:57', NULL),
(152, 'Hepatitis E', '2020-02-09 12:11:57', NULL),
(153, 'Herpes simplex virus', '2020-02-09 12:11:57', NULL),
(154, 'HIV/AIDS', '2020-02-09 12:11:57', NULL),
(155, 'Hospitals', '2020-02-09 12:11:57', NULL),
(156, 'Household air pollution', '2020-02-09 12:11:57', NULL),
(157, 'Household water treatment', '2020-02-09 12:11:57', NULL),
(158, 'Human papillomavirus and cervical cancer', '2020-02-09 12:11:57', NULL),
(159, 'Human rights', '2020-02-09 12:11:57', NULL),
(160, 'Humanitarian health action', '2020-02-09 12:11:57', NULL),
(161, 'Hypertension', '2020-02-09 12:11:57', NULL),
(162, 'Immunization coverage', '2020-02-09 12:11:57', NULL),
(163, 'Immunization standards', '2020-02-09 12:11:57', NULL),
(164, 'Immunization, vaccines and biologicals', '2020-02-09 12:11:57', NULL),
(165, 'In vitro diagnostics and laboratory technology', '2020-02-09 12:11:57', NULL),
(166, 'Indoor air pollution', '2020-02-09 12:11:57', NULL),
(167, 'Infant nutrition', '2020-02-09 12:11:57', NULL),
(168, 'Infant, Newborn', '2020-02-09 12:11:57', NULL),
(169, 'Infection control', '2020-02-09 12:11:57', NULL),
(170, 'Infertility', '2020-02-09 12:11:57', NULL),
(171, 'Influenza', '2020-02-09 12:11:57', NULL),
(172, 'Influenza (Seasonal)', '2020-02-09 12:11:57', NULL),
(173, 'Injuries', '2020-02-09 12:11:57', NULL),
(174, 'Injuries, Traffic', '2020-02-09 12:11:57', NULL),
(175, 'Innovation', '2020-02-09 12:11:57', NULL),
(176, 'Intellectual property', '2020-02-09 12:11:57', NULL),
(177, 'International Classification of Diseases', '2020-02-09 12:11:57', NULL),
(178, 'International Classification of Functioning, Disability and Health', '2020-02-09 12:11:57', NULL),
(179, 'International Health Regulations', '2020-02-09 12:11:57', NULL),
(180, 'International Nonproprietary Names', '2020-02-09 12:11:57', NULL),
(181, 'International travel and health', '2020-02-09 12:11:57', NULL),
(182, 'Intimate partner and sexual violence', '2020-02-09 12:11:57', NULL),
(183, 'Japanese encephalitis', '2020-02-09 12:11:57', NULL),
(184, 'Knowledge transfer and training for outbreaks', '2020-02-09 12:11:57', NULL),
(185, 'Laboratory and in vitro diagnostics', '2020-02-09 12:11:57', NULL),
(186, 'Landslides', '2020-02-09 12:11:57', NULL),
(187, 'Lassa fever', '2020-02-09 12:11:57', NULL),
(188, 'Lead poisoning', '2020-02-09 12:11:57', NULL),
(189, 'Legionellosis', '2020-02-09 12:11:57', NULL),
(190, 'Leishmaniasis', '2020-02-09 12:11:57', NULL),
(191, 'Leprosy', '2020-02-09 12:11:57', NULL),
(192, 'Leptospirosis', '2020-02-09 12:11:57', NULL),
(193, 'Listeriosis', '2020-02-09 12:11:57', NULL),
(194, 'Lymphatic filariasis', '2020-02-09 12:11:57', NULL),
(195, 'Macroeconomics', '2020-02-09 12:11:57', NULL),
(196, 'Malaria', '2020-02-09 12:11:57', NULL),
(197, 'Malnutrition', '2020-02-09 12:11:57', NULL),
(198, 'Management', '2020-02-09 12:11:57', NULL),
(199, 'Marburg virus disease', '2020-02-09 12:11:57', NULL),
(200, 'Maternal health', '2020-02-09 12:11:57', NULL),
(201, 'Maternal mortality', '2020-02-09 12:11:57', NULL),
(202, 'Maternal, newborn, child and adolescent health', '2020-02-09 12:11:57', NULL),
(203, 'Measles', '2020-02-09 12:11:57', NULL),
(204, 'Medical devices', '2020-02-09 12:11:57', NULL),
(205, 'Medicines and health products', '2020-02-09 12:11:57', NULL),
(206, 'Melamine', '2020-02-09 12:11:57', NULL),
(207, 'Meningitis', '2020-02-09 12:11:57', NULL),
(208, 'Mental disorders', '2020-02-09 12:11:57', NULL),
(209, 'Mental health', '2020-02-09 12:11:57', NULL),
(210, 'Mental health in emergencies', '2020-02-09 12:11:57', NULL),
(211, 'Mental health of older adults', '2020-02-09 12:11:57', NULL),
(212, 'Mercury', '2020-02-09 12:11:57', NULL),
(213, 'Microcephaly', '2020-02-09 12:11:57', NULL),
(214, 'Middle East respiratory syndrome coronavirus (MERS-CoV)', '2020-02-09 12:11:57', NULL),
(215, 'Midwifery', '2020-02-09 12:11:57', NULL),
(216, 'Millennium Development Goals', '2020-02-09 12:11:57', NULL),
(217, 'Mobile phones', '2020-02-09 12:11:57', NULL),
(218, 'Monkeypox', '2020-02-09 12:11:57', NULL),
(219, 'Mortality', '2020-02-09 12:11:57', NULL),
(220, 'Mumps', '2020-02-09 12:11:57', NULL),
(221, 'Musculoskeletal conditions', '2020-02-09 12:11:57', NULL),
(222, 'Mycetoma', '2020-02-09 12:11:57', NULL),
(223, 'Mycobacterium ulcerans (Buruli ulcer)', '2020-02-09 12:11:57', NULL),
(224, 'NCD Surveillance', '2020-02-09 12:11:57', NULL),
(225, 'Neglected tropical diseases', '2020-02-09 12:11:57', NULL),
(226, 'Neurology', '2020-02-09 12:11:57', NULL),
(227, 'New and Under-utilized Vaccines Implementation', '2020-02-09 12:11:57', NULL),
(228, 'Newborn health', '2020-02-09 12:11:57', NULL),
(229, 'Nipah virus infection', '2020-02-09 12:11:57', NULL),
(230, 'Noncommunicable diseases', '2020-02-09 12:11:57', NULL),
(231, 'Noncommunicable diseases and mental health', '2020-02-09 12:11:57', NULL),
(232, 'Noncommunicable diseases and their risk factors', '2020-02-09 12:11:57', NULL),
(233, 'Nursing', '2020-02-09 12:11:57', NULL),
(234, 'Nursing and midwifery resource centre', '2020-02-09 12:11:57', NULL),
(235, 'Nutrition', '2020-02-09 12:11:57', NULL),
(236, 'Obesity', '2020-02-09 12:11:57', NULL),
(237, 'Occupational health', '2020-02-09 12:11:57', NULL),
(238, 'Onchocerciasis (River blindness)', '2020-02-09 12:11:57', NULL),
(239, 'Oral health', '2020-02-09 12:11:57', NULL),
(240, 'Palliative care', '2020-02-09 12:11:57', NULL),
(241, 'Patient safety', '2020-02-09 12:11:57', NULL),
(242, 'Pertussis', '2020-02-09 12:11:57', NULL),
(243, 'Pesticides', '2020-02-09 12:11:57', NULL),
(244, 'Pharmaceutical products', '2020-02-09 12:11:57', NULL),
(245, 'Physical activity', '2020-02-09 12:11:57', NULL),
(246, 'Plague', '2020-02-09 12:11:57', NULL),
(247, 'Pneumonia', '2020-02-09 12:11:57', NULL),
(248, 'Poisons', '2020-02-09 12:11:57', NULL),
(249, 'Poliomyelitis (polio)', '2020-02-09 12:11:57', NULL),
(250, 'Pregnancy', '2020-02-09 12:11:57', NULL),
(251, 'Prequalification of medicines', '2020-02-09 12:11:57', NULL),
(252, 'Preterm birth', '2020-02-09 12:11:57', NULL),
(253, 'Primary health care', '2020-02-09 12:11:57', NULL),
(254, 'Prisons', '2020-02-09 12:11:57', NULL),
(255, 'Public Health and Environment', '2020-02-09 12:11:57', NULL),
(256, 'Public health surveillance', '2020-02-09 12:11:57', NULL),
(257, 'Public Health, Innovation, Intellectual Property and Trade', '2020-02-09 12:11:57', NULL),
(258, 'Rabies', '2020-02-09 12:11:57', NULL),
(259, 'Radiation', '2020-02-09 12:11:57', NULL),
(260, 'Radiation emergencies', '2020-02-09 12:11:57', NULL),
(261, 'Refugee and migrant health', '2020-02-09 12:11:57', NULL),
(262, 'Rehabilitation', '2020-02-09 12:11:57', NULL),
(263, 'Reproductive health', '2020-02-09 12:11:57', NULL),
(264, 'Research', '2020-02-09 12:11:57', NULL),
(265, 'Rift valley fever', '2020-02-09 12:11:57', NULL),
(266, 'Risk communication', '2020-02-09 12:11:57', NULL),
(267, 'Road traffic injuries', '2020-02-09 12:11:57', NULL),
(268, 'Rubella', '2020-02-09 12:11:57', NULL),
(269, 'Salmonella', '2020-02-09 12:11:57', NULL),
(270, 'Salt reduction', '2020-02-09 12:11:57', NULL),
(271, 'Sanitation', '2020-02-09 12:11:57', NULL),
(272, 'Schistosomiasis', '2020-02-09 12:11:57', NULL),
(273, 'Schizophrenia', '2020-02-09 12:11:57', NULL),
(274, 'School and youth health', '2020-02-09 12:11:57', NULL),
(275, 'Sepsis', '2020-02-09 12:11:57', NULL),
(276, 'Severe acute respiratory syndrome', '2020-02-09 12:11:57', NULL),
(277, 'Sexual and reproductive health', '2020-02-09 12:11:57', NULL),
(278, 'Sexual health', '2020-02-09 12:11:57', NULL),
(279, 'Sexually transmitted infections', '2020-02-09 12:11:57', NULL),
(280, 'Smallpox', '2020-02-09 12:11:57', NULL),
(281, 'Snakebite', '2020-02-09 12:11:57', NULL),
(282, 'Social determinants of health', '2020-02-09 12:11:57', NULL),
(283, 'Soil-transmitted helminths', '2020-02-09 12:11:57', NULL),
(284, 'Spinal cord injury', '2020-02-09 12:11:57', NULL),
(285, 'Stroke, Cerebrovascular accident', '2020-02-09 12:11:57', NULL),
(286, 'Substance abuse', '2020-02-09 12:11:57', NULL),
(287, 'Substandard and falsified medical products', '2020-02-09 12:11:57', NULL),
(288, 'Suicide', '2020-02-09 12:11:57', NULL),
(289, 'Surgery', '2020-02-09 12:11:57', NULL),
(290, 'Sustainable development', '2020-02-09 12:11:57', NULL),
(291, 'Sustainable Development Goals', '2020-02-09 12:11:57', NULL),
(292, 'Taeniasis', '2020-02-09 12:11:57', NULL),
(293, 'Tetanus', '2020-02-09 12:11:57', NULL),
(294, 'Tick-borne encephalitis', '2020-02-09 12:11:57', NULL),
(295, 'Tobacco', '2020-02-09 12:11:57', NULL),
(296, 'Trachoma', '2020-02-09 12:11:57', NULL),
(297, 'Trade, foreign policy, diplomacy and health', '2020-02-09 12:11:57', NULL),
(298, 'Traditional, complementary and integrative medicine', '2020-02-09 12:11:57', NULL),
(299, 'Travel', '2020-02-09 12:11:57', NULL),
(300, 'Travel and health', '2020-02-09 12:11:57', NULL),
(301, 'Tropical cyclones', '2020-02-09 12:11:57', NULL),
(302, 'Tropical diseases', '2020-02-09 12:11:57', NULL),
(303, 'Tsunamis', '2020-02-09 12:11:57', NULL),
(304, 'Trypanosomiasis, African', '2020-02-09 12:11:57', NULL),
(305, 'Tuberculosis', '2020-02-09 12:11:57', NULL),
(306, 'Tularaemia', '2020-02-09 12:11:57', NULL),
(307, 'Typhoid fever', '2020-02-09 12:11:57', NULL),
(308, 'Ultraviolet radiation', '2020-02-09 12:11:57', NULL),
(309, 'Universal health coverage', '2020-02-09 12:11:57', NULL),
(310, 'Urban health', '2020-02-09 12:11:57', NULL),
(311, 'Vaccine safety', '2020-02-09 12:11:57', NULL),
(312, 'Vaccines', '2020-02-09 12:11:57', NULL),
(313, 'Vector control', '2020-02-09 12:11:57', NULL),
(314, 'Violence', '2020-02-09 12:11:57', NULL),
(315, 'Violence and Injury Prevention and Disability', '2020-02-09 12:11:57', NULL),
(316, 'Vitamin and Mineral Nutrition', '2020-02-09 12:11:57', NULL),
(317, 'Volcanic eruptions', '2020-02-09 12:11:57', NULL),
(318, 'Water, sanitation and hygiene', '2020-02-09 12:11:57', NULL),
(319, 'West Nile virus', '2020-02-09 12:11:57', NULL),
(320, 'Wildfires', '2020-02-09 12:11:57', NULL),
(321, 'Women\'s health', '2020-02-09 12:11:57', NULL),
(322, 'Workers? health', '2020-02-09 12:11:57', NULL),
(323, 'Workforce', '2020-02-09 12:11:57', NULL),
(324, 'Yaws', '2020-02-09 12:11:57', NULL),
(325, 'Yellow fever', '2020-02-09 12:11:57', NULL),
(326, 'Youth violence', '2020-02-09 12:11:57', NULL),
(327, 'Zika virus', '2020-02-09 12:11:57', NULL),
(328, 'Zoonoses', '2020-02-09 12:11:57', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `users`
--

CREATE TABLE `users` (
  `id` int(10) UNSIGNED NOT NULL,
  `title` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `m_name` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `l_name` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `email` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `orchid_id` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `password` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `image` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `remember_token` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `country_id` int(11) DEFAULT NULL,
  `speciality_id` int(10) UNSIGNED DEFAULT NULL,
  `sub_speciality_ids` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `type` enum('user','admin','junior reviewer','senior reviewer','root') COLLATE utf8mb4_unicode_ci NOT NULL DEFAULT 'user',
  `main_keyword1` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `main_keyword2` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `keywords1` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `keywords2` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `sources` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `rss` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `role_id` int(10) UNSIGNED DEFAULT NULL,
  `confirmed` tinyint(1) NOT NULL DEFAULT 0,
  `status` enum('approved','suspended') COLLATE utf8mb4_unicode_ci NOT NULL DEFAULT 'approved',
  `provider` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `provider_id` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `article_notification` tinyint(1) DEFAULT 0,
  `verification_code` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `verified` tinyint(1) NOT NULL DEFAULT 0,
  `describe_yourself` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `area_of_interest` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `topics_of_interest` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `user_group_id` int(11) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `users`
--

INSERT INTO `users` (`id`, `title`, `name`, `m_name`, `l_name`, `email`, `orchid_id`, `password`, `image`, `remember_token`, `created_at`, `updated_at`, `country_id`, `speciality_id`, `sub_speciality_ids`, `type`, `main_keyword1`, `main_keyword2`, `keywords1`, `keywords2`, `sources`, `rss`, `role_id`, `confirmed`, `status`, `provider`, `provider_id`, `article_notification`, `verification_code`, `verified`, `describe_yourself`, `area_of_interest`, `topics_of_interest`, `user_group_id`) VALUES
(1, NULL, 'Owner2', NULL, NULL, 'owner@intrazero.com', NULL, '$2y$12$44vjXj5mX5n7VS4.JJ1XaeKRzaXu9E3XSl0IB5DqA/EcmNpdhgBo.', '', 'sooNIG22tRNy5DdW0qB3nsAAwru5DtaI7q6pP7EIcm4ZdhCzemJKkVmusS5y', NULL, '2019-09-04 22:50:02', 0, NULL, NULL, 'admin', '', NULL, '', NULL, '', NULL, 1, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, NULL, NULL, NULL),
(8, 'Mr.', 'jreviewer', NULL, '2', 'jreviewer@project.com', NULL, '$2y$10$OGavy2shQ4ok2u0A8N.tieXtPHtwgdpNetq8g2ftaq9fNXDNz/y9.', NULL, 'UGscTwBMMT5HkrwNPEtoOt1p07Ps1JPhq545WWkGJbHPGDrLqwXTsd1WYFnb', '2019-08-19 02:59:50', '2021-01-04 10:44:58', 4, 1, NULL, 'junior reviewer', '1', '', '4', '', 'cdc,cnn,medscape,pubmed', NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '126', NULL, NULL),
(9, 'Mr.', 'Senior', NULL, '1', 'sreviewer@project.com', 'masmsakd sadasdkasd skad askd ask', '$2y$12$44vjXj5mX5n7VS4.JJ1XaeKRzaXu9E3XSl0IB5DqA/EcmNpdhgBo.', 'C:\\xampp\\tmp\\php6ECF.tmp', 'M6diRJMGM1xYSSjmFpwna6U2sTda8uwo3kJ1Krp6fs8fIdjOxWlbBBRWetGX', '2019-08-19 02:59:50', '2020-03-24 09:33:29', 4, 1, NULL, 'senior reviewer', '1', '', '4', '', 'cdc,cnn,medscape,pubmed', NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, 'Faculty Staff', '126', '5,6', NULL),
(10, 'Mr.', 'mohamed', NULL, 'abbas', 'Researcher@project.com', '5464s6a4da6s54d56asd465', '$2y$10$JHN4S3vB4MuVFukyQbq8v.YX39MrLFBRsJ6I1fKXPSy2Rx7ygLBmi', NULL, 'ib2f7lquPC18ruE1zYqzd474GuQLiiy7F1bmUW2Zhof4Nj4of1Q7nljHRlas', '2019-08-27 05:31:59', '2021-01-04 10:42:56', 4, 1, '2', 'user', '126', NULL, '8,19,22,113', '', 'vlibraryIDR,vlibraryIMEMR', '22', NULL, 1, 'approved', NULL, NULL, 0, NULL, 0, 'Faculty Staff', '28', '4', 2),
(14, 'Dr.', 'senior', NULL, 'test', 'mmo7amed2010@gmail.com2', '4564656465s4d56as4d56as4d6asd456as5d46', '$2y$10$h/UrIY0CAv.Ei/Cxcsmz8OZ/vkDSOWDWNh6Diqd53fV/Zof4lyDUW', 'C:\\xampp\\tmp\\phpF902.tmp', NULL, '2019-09-02 00:55:07', '2020-02-13 18:12:57', 4, 1, NULL, 'senior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '28', NULL, NULL),
(31, 'Mr.', 'Mahmoud', NULL, 'Ghonemi', 'maghonemi@gmail.com', '312', '$2y$12$44vjXj5mX5n7VS4.JJ1XaeKRzaXu9E3XSl0IB5DqA/EcmNpdhgBo.', '/tmp/phpCLsCIq', '80iTR3vf5HKs3WUhBuH5Yx3MrWFvhuk8R3LWcV0cYlOtUyRNy0RKBerfsvng', '2019-09-14 13:20:59', '2020-02-07 20:36:33', 4, 1, '2', 'user', '1', '28', '2,3,4', '31,33,34,35', 'pubmed,reuters,toronto,vlibraryIDR,vlibraryIMEMR,National Institute for Health and Care Excellence (NICE),Turning Research Into Practice (TRIP),Cochrane Collaboration,NLM Gateway,Campbell Collaboration,Centre for Reviews and Dissemination (CRD),Evidence Aid,Institutional Repository for Information Sharing (IRIS)', '6', NULL, 1, 'approved', 'linkedin', 'rQv3QHhVvh', 0, NULL, 0, NULL, NULL, NULL, NULL),
(39, NULL, 'root', NULL, NULL, 'root@project.com', NULL, '$2y$12$44vjXj5mX5n7VS4.JJ1XaeKRzaXu9E3XSl0IB5DqA/EcmNpdhgBo.', '', 'lshmiItCXg1ZqdlJ9rNn9UUDbuOXmFUDg6O0Yrrrl6adCdQO66m68cQzobUX', NULL, '2019-10-23 22:16:32', 0, NULL, NULL, 'root', '', NULL, '', NULL, '', NULL, 2, 1, 'approved', NULL, NULL, 0, NULL, 0, NULL, NULL, NULL, NULL),
(40, NULL, 'Mohamed Gamal Abbas', NULL, 'sss', 'mmmo7amed1914@yahoo.com', NULL, '$2y$10$NpAg7waK95gt8YOEnUSBRu3gI0RQ4GJySu.bf.oQfHeNQRgpCt7DK', NULL, 'PodIV8xz9KMaAtgbPIwG1TZk5FKn6gSuhOGX57GyYiEuOB8icHelQCdnYa2U', '2019-10-23 09:36:09', '2019-10-23 09:36:09', NULL, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', 'facebook', '2710544028958698', 0, NULL, 0, NULL, NULL, NULL, NULL),
(42, 'Dr.', 'mohamed', NULL, 'gamal', 'customer@email.com1112', '54s6dsa6d54s56d4s65ad564sa4d56', '$2y$10$2CF85CTZqsLnaHZSjrHZuOIrUpDgowiYtbRPAIyIZ1Yg5IMHqW84C', '/tmp/php7ei8bY', 'U1SDtHHxuZQAexjgNyBsPFgYuc0zgxB9SmLepEsLKG8qMA7FZGSWWH5O8ERY', '2020-01-14 18:07:00', '2020-02-10 09:46:50', 4, 1, '2', 'user', '46', '65', '49,50,51', '75,79', 'pubmed,reuters,Centre for Reviews and Dissemination (CRD),Institutional Repository for Information Sharing (IRIS)', '6', NULL, 1, 'approved', 'linkedin', 'TNb0bdn64o', 1, NULL, 0, 'Faculty Staff', '59', '36,39', NULL),
(43, 'admin', 'mohamed', NULL, 'gamal', 'm.abbas@intrazero.netkewkwke', 'kpkspdkap[dakspd', '$2y$10$KDO9ygOgQFZNwZ9ArWk1c.NLSp49sX0P9zBtQZ.4G2bQsBtTL6IpK', '/tmp/phpUy6p4X', NULL, '2020-02-05 13:51:39', '2020-02-05 15:19:27', 4, 1, '2', 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, NULL, NULL, NULL),
(48, 'Dr.', 'mohamed', NULL, 'gamal', 'm.abbas@intrazero.net', NULL, '$2y$10$6cj9eqUMbuHj7pJjJS1a3ekbQIzMdgUIrU.JmzSaHvFHLsji75xQa', NULL, 'JCkCII1yiZhZEAtTsTRLZk1VAUKWUqWeCCrT9Ck7JgzaBDhvAzcvRXMWlsY3', '2020-02-06 13:35:19', '2020-02-17 12:23:12', 4, NULL, NULL, 'user', '1', '37', '8,16,17,18,19', '55,56,57,58', 'reuters,vlibraryIDR,vlibraryIMEMR,GIM', '6,9', NULL, 1, 'approved', NULL, NULL, 1, NULL, 1, 'Researcher', '1', '2,3,4', NULL),
(63, 'admin', 'mohamed', NULL, 'gamal', 'mmo7amed2000@gma1il.com', NULL, '$2y$10$VnIbk8Pp9HkDfBQIdNhs8en1KyYOrARQ8Lj/1TNYvaEWDWk931CUK', NULL, NULL, '2020-02-06 17:45:00', '2020-02-06 17:45:00', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, 'ZJaPrDa7uSzncmJlsecSzjtG9wTJPkA37WrCKhLbllaTNjCecA6xTUL70smd0dSknEYNe9bloy3YgAZWuYvY3qNEbBYiuimvWjeZ', 0, NULL, NULL, NULL, NULL),
(73, 'Mr.', 'Mohamed', 'Gamal', 'Abbas', 'mmo7amed2012@gmail.com', NULL, '$2y$10$Ff5xxPe61gcPiNSm5aavKO4v2HywKU0se0/5ChKTr75TfFHZ1UBXm', NULL, 'YKmejTuw7cUMBEM93kNPjRpyrWR1MzVFbPzg2rHBYnVAKWw40Voz7V3Tm64O', '2020-02-09 14:42:05', '2020-04-02 14:24:05', 1, NULL, NULL, 'user', '1', '59', '2,3,4,5,7,8', '61,62,63,64', 'toronto,vlibraryIDR,Evidence Aid,Institutional Repository for Information Sharing (IRIS)', '9', NULL, 0, 'approved', NULL, NULL, 1, 'EfbTr53sZVm7WXucdPoOwz2l5uGALOy3FUER6xhIugPgLiqvIBEIq0wKkC1fJjTagoRGSS09X6UmUKliQ8S5zd1BBM3G7PjCvXns', 1, 'General Practitioner', '28', '34', NULL),
(74, 'Dr.', 'mohamed', NULL, 'gamal', 'customer@email.comww', NULL, '$2y$10$qfaZHHG0wFXWiNjhlZua5.w9DZqXH5hldaZNoZberka8aNnTtra4e', NULL, 'ApaiEHrPNWtcga4oIFSXLDbqRMzU1QLBTxNoqGSMrmn5u6DMhyBWayS9GPKx', '2020-02-09 16:30:53', '2020-02-09 16:32:01', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 1, 'approved', NULL, NULL, 0, 'hpGZ961lH3Hq2levVWl8z3POhxgyoXLKsKEOn2ZvhdouSKtAbe1bH1OLPlUDVwt4gGA388p4lX3jvDmCu8QkZh5KmOaU9Zx9Kkef', 1, 'Faculty Staff', '1', '3,4,5', NULL),
(75, 'Dr.', 'mohamed', NULL, 'gamal', 'customer@email.com33', NULL, '$2y$10$4JnbNei7fT3myv0gVrhDe.EZXAQZNcBelfCds.2LhZHiTE9u8ntZa', NULL, NULL, '2020-02-09 16:33:13', '2020-02-09 16:33:13', 3, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 1, 'approved', NULL, NULL, 0, NULL, 1, 'Others', '99', '27,32', NULL),
(76, 'Dr.', 'mohamed', NULL, 'gamal', 'customer@email.com', NULL, '$2y$10$75MdzUOmHgJ2wd4Qldvmyexnkp/mC21PZ2o8Y5kwCtspKVSubkEIK', NULL, 'wzjqfAkxc8jOV9847amnYpy2FcbXaDtJp63nnzUTfiLfNkNB2aZ2vK145jgC', '2020-02-09 17:14:21', '2020-02-09 17:14:21', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, 'gQt6tUUVDNcoBzlOl9kKK9f6lwE78o3exqNQSXtTKGsrnSFBAyoFx6ElvwgM5NRc7kG5GelT9xrs8iiaAZhoHHwyP4fO46BNZvGL', 0, 'Health Information Specialist', '28', '2,3,4', NULL),
(77, 'Dr.', 'mohamed', NULL, 'gamal', 'customer@email.com331', NULL, '$2y$10$TNjR7IxxOZmsuFNe24wrlOxFrUfYOQBiDf9yR7fwA0S./hzvxFyyy', NULL, NULL, '2020-02-09 17:18:15', '2020-02-09 17:18:41', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 1, 'approved', NULL, NULL, 0, NULL, 1, 'General Practitioner', '37', '4,6,7,8', NULL),
(79, 'Dr.', 'Mahmoud', NULL, 'Ghonemi', 'maghonemi2@gmail.com', NULL, '$2y$10$gVmw9mtybwNzdLRR58iOf.0Dbp/JMI7ke5An2VfDoi7io639FVDiK', NULL, 'NgoOhWJMYiokTXeshwEypBRFumRcrlOSnLc2fhs3YvEfSOmov4FpOJyoZOEi', '2020-02-09 21:41:25', '2020-02-10 09:38:17', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, '78XIIX0JP8no6AW7sLWoLE3rNcLs3QAudjVd4c2IrNHZ9AE2M9gLZ0P8nSNAuZlllqSYJNkBDsveeZB4H7ZU7TCtWKZjdpY38kEP', 0, 'Others', '81', '3,5', NULL),
(84, 'Dr.', 'Mahmoud', NULL, 'Ghonemi', 'info@intrazero.net', NULL, '$2y$10$PoOy/T6dsuSLxZtFwr39peVX6Eb5xKSXwY0KzwfzKrVMQQ/fgMzfO', NULL, 'aLyWRzOYjRNCgfIcB3dEEkQwYaAwfKJGbvm6gFWZLUsFCiLn3buKqSHxuCVW', '2020-02-10 18:44:04', '2020-02-13 18:19:01', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 1, 'approved', NULL, NULL, 0, 'pRugO1oLQab9cv9CMwX7JJm07yoHgzy3WD0XdHsCI319sWNItqBLi0b3dopfOHTLlS5uppHh6nQ7nsavPdZjUmVQoURzVXC9yGpS', 1, 'Faculty Staff', '1', '2,3,4', NULL),
(86, 'Mr.', 'CD First Reviewer', NULL, 'Reviewer', 'CD1review@project.com', NULL, '$2y$10$NTRSi0Z9x3IXgpPsJxXxAenlrj5s.GFFmgId7Ei9cLFSg4NGQldtK', NULL, 'sp3HZmf316nsq6EbEvQDig6bDvtCddelrOMvCI2iKCCDJoHQIgwwhnmPKyfp', '2020-02-18 04:23:37', '2020-02-18 04:56:18', 4, NULL, NULL, 'junior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '1', NULL, NULL),
(87, 'Dr.', 'CD Second Reviewer', NULL, 'Reviewer', 'CD2review@project.com', NULL, '$2y$10$JkSgU9QBrZ1BHP94RwIn3u5mDBE0BodI5bOGd61pY/zymhBCpLoGq', NULL, 'ZNIHWUkHpRh3txhtrBIffBF87YM2awsdN1v4huqV9jTacL6QznjPdoAcEVCj', '2020-02-18 04:29:10', '2020-02-18 04:55:08', 9, NULL, NULL, 'senior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '1', NULL, NULL),
(88, 'Dr.', 'HE First Reviewer', NULL, 'Reviewer', 'HE1review@project.com', NULL, '$2y$10$vW.lrqFSI9oPRpaIqEYn0OxJT1Ku/W8HF4Lidj9g7FCwcfN4qMsDe', NULL, '0Zv6xeDszXN7hQfmvEm3rks1Vt0tmttGuwWO9Zjpfsug8y7Ns0cwzSM06TDt', '2020-02-18 04:31:38', '2020-02-18 04:57:50', 4, NULL, NULL, 'junior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '28', NULL, NULL),
(89, 'Dr.', 'HE Second Reviewer', NULL, 'Reviewer', 'HE2review@project.com', NULL, '$2y$10$ZL0iS2j1wsNBCpdzRHvDLO9jUOmk9nDi8B3Z4lTozqBiEDwB.5mFO', NULL, 'yKHlHEFdoRxyIWJD92PvxHFVhxWZyYt30b9SNxNPkMfIfIkJiwfhAFTJZMTw', '2020-02-18 04:33:45', '2020-02-18 04:58:44', 20, NULL, NULL, 'senior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '28', NULL, NULL),
(90, 'Mr.', 'HP First Reviewer', NULL, 'Reviewer', 'HP1review@project.com', NULL, '$2y$10$v97kfOfZURN2F79wWme2KeIOlI8Zi34KGTdqU2nAKapisnmQorvVO', NULL, 'TbXjwWQZqaum9JjpCELL4Z6QRagrlGLW3Z0V6JxZtCjANUwOnUvE6nZaIX2H', '2020-02-18 04:35:57', '2020-02-18 04:59:37', 4, NULL, NULL, 'junior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '37', NULL, NULL),
(91, 'Prof.', 'HP Second Reviewer', NULL, 'Reviewer', 'HP2review@project.com', NULL, '$2y$10$.BEkyoNIi42KZuZiZfx2juPw5OA7YudyZxZmAROHEVH/mE4nmz0we', NULL, '8OdUcqPhPkTGrXA4uydwGnGyvZOkbbJOvDUG2VGnbNPso8Fluzio7vQAEINv', '2020-02-18 04:37:16', '2020-02-18 05:00:47', 4, NULL, NULL, 'senior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '37', NULL, NULL),
(92, 'Ms.', 'HS First Reviewer', NULL, 'Reviewer', 'HS1review@project.com', NULL, '$2y$10$uQTmsnsiriZt63dvZZJgieojImL498SGSeMIrp8uyH7NgDnSOiAvm', NULL, 'TshwA59ghAO5FBlQhigV6UHWfQWezOMzKN0y6QVxibXuCS97TxpjUVgXyJeg', '2020-02-18 04:39:49', '2020-12-31 16:48:38', 4, NULL, NULL, 'junior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '59', NULL, NULL),
(93, 'Mr.', 'HS Second Reviewer', NULL, 'Reviewer', 'HS2review@project.com', NULL, '$2y$10$6mAK/6ArvIiN7lME0/f0sOpMwX/1S45Wx9nyCvtFyPPhntWmDN3ta', NULL, 'DLEX2Jr670j5yTHOrkcWJIbbjum2w2wN2swjVYW3JN37S8LTlqAU5t11I5vs', '2020-02-18 04:41:07', '2020-02-18 05:03:19', 4, NULL, NULL, 'senior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '59', NULL, NULL),
(94, 'Ms.', 'NCD First Reviewer', NULL, 'Reviewer', 'NCD1review@project.com', NULL, '$2y$10$kUQfJOcCLKbQrbayZGy7NObbAUtpVjn8ZX56JvwEARJWxOb7IeFWq', NULL, 'YGC3HFW8y7txDFxv2BMp84mX6WrWfzimNXU7crxMN3gxQv2tDQMgXXJi3Tzh', '2020-02-18 04:42:27', '2020-02-18 05:04:15', 4, NULL, NULL, 'junior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '81', NULL, NULL),
(95, 'Ms.', 'NCD Second Reviewer', NULL, 'Reviewer', 'NCD2review@project.com', NULL, '$2y$10$4PmUkfMTrjh8DACv8Fnzqe/Y4FAbyOaDw8jpVHMlqUqSoJAIZ5EdO', NULL, 'zK14qwNrIPQ2281UPgzRmzQYWL3wJV6KBPWFcD9MTV807bCSDu0e9qXBl1zI', '2020-02-18 04:43:58', '2020-02-18 05:05:12', 4, NULL, NULL, 'senior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '81', NULL, NULL),
(96, 'Dr.', 'SID First Reviewer', NULL, 'Reviewer', 'SID1review@project.com', NULL, '$2y$10$aBdDqeG2R1lcrQDuLAF/zu2ZTM/LBSGpESTKr0niC3omdTW9BrKWG', NULL, 'pKWtyi6zsOttrxLUg5UeMizACOTlsPq8K5zG2BcCfDfeLjGSbTIYA51jp4Wv', '2020-02-18 04:46:16', '2020-02-18 05:06:39', 7, NULL, NULL, 'junior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '99', NULL, NULL),
(97, 'Dr.', 'SID Second Reviewer', NULL, 'Reviewer', 'SID2review@project.com', NULL, '$2y$10$pPxIoIfVoJN5NatPepJz1ua8TZ.9xmhoAluzY30YYM1.LNv1MELdK', NULL, 'JKc07OJmXcIu2W42ECJ4W6ZimFPP7Lqv5WK7RtaL4eM3LSD2CWq6zPjX3YQ9', '2020-02-18 04:47:28', '2020-02-18 05:07:32', 5, NULL, NULL, 'senior reviewer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '99', NULL, NULL),
(98, 'Dr .', 'mohamed', NULL, 'gamal', 'mmo7amed2010@gmail.com', NULL, '$2y$10$/0IoFArUSpuiszP1lvkOxe9o7.7NaIbCdYPy54q.spnMDr/S4vhmK', NULL, NULL, '2020-03-26 17:10:11', '2020-03-26 17:10:11', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 1, 'approved', NULL, NULL, 0, NULL, 1, NULL, NULL, NULL, NULL),
(100, 'Dr.', 'Mohamed', 'Gamal', 'Abbas', 'mmo7amed2011@gmail.com', NULL, '$2y$10$yimK0AGlORnHoy1C5g1X7OU7BsHWw//x.ESSqU7.SFoR..iGjAC5O', NULL, NULL, '2020-04-02 14:42:17', '2020-04-02 14:43:22', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 1, 'approved', NULL, NULL, 0, 'TuPVPpnt7ZguSaUsgRHjXlNqIOWnyJpL6rElSmtDnWbWHmJ2lHvC10g4DK3CBoaVmu4MVTdYzLqwZYnqYvU7isHF1RmiFwSmuNu0', 1, 'Medical Librarian', '81', '3,4', NULL),
(101, 'Dr.', 'Mahmoud', NULL, 'Ghonemi', 'info@intrazero.com', NULL, '$2y$10$hXtlocBG./Fx.s0D9S2EU.LuD9HW//PJH9Tr7wsr7QPEhy6x37yTe', NULL, 'Eemp3stDaxC2FHxEskOBMITLmRXAAuqiThXjkw4Pu2aYpC8tL7J1B5lvsgPG', '2020-04-02 16:21:18', '2020-04-12 10:58:21', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 1, 'approved', NULL, NULL, 0, 'pMziFqcxSiRnon74aql9prUCN3qI7Mo5Feq0JtC78KtRbo6bXH5Mt7h9HwK2XNRWsRJu7fFPD4rPTk6kR9l3bCTuyisla8T0mno9', 1, 'Health Professionals', '1', '2,5', NULL),
(102, 'Dr.', 'first', 'middle', 'last', 'hkmp@project.com', NULL, '$2y$10$OdljE50WH4QCZGE8zStqP.DuunpwXCTtjlQO0XkwKH0syVf2xkCje', NULL, '8rP0htfQvMon6pFe7rHlEbzKDBt7NfiZsvbnruojpXJRGRAQzas2k5n9obI7', '2020-05-17 15:49:15', '2020-12-24 07:09:46', 4, NULL, NULL, 'user', '1', '126', '4,5,16', '8,19,22,113,114,115,116,146', 'cdc,vlibraryIDR,vlibraryIMEMR,PMC,pubmed', '21,22,24', NULL, 1, 'approved', NULL, NULL, 0, 'IFLWFM8GWpnvSR35ih1aUTSSwFNox7l0jrYABV5aw1IO0GvXpgcpsxHLQ2CfLh38WDKLXGL9zM1aDmWWuRjUVx0wZHYtHqCZHDum', 0, 'Faculty Staff', '1', '2,5', NULL),
(103, 'Mr.', 'Sherouk', NULL, 'Abd El Mageed', 'sherouq.abdelmageed@gmail.com', NULL, '$2y$10$HNRVgXk6ACcu8Pk81oJ2iOOeROHVhWtULW8lr6x.Neda2pnoavptG', NULL, 'Dt1XRFlvi5imT8PIP7vNOsd8g4ps1G89yBK2G6IAxlgax3EJuC0U6LwsHt1e', '2020-07-07 16:32:47', '2020-12-24 05:53:33', 4, NULL, NULL, 'user', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 1, 'approved', NULL, NULL, 0, NULL, 1, 'Faculty Staff', '81', '1', 2),
(105, NULL, 'mohamedss', NULL, NULL, 'mmo7amed2010@gmail.com123ss', NULL, '$2y$10$rZMnczDn7vOf0gBvxK6LXuETJqWuYsTSvGrcwYoUG8W9V90qc/cXa', NULL, NULL, '2020-12-31 15:50:05', '2020-12-31 16:12:35', NULL, NULL, NULL, 'admin', NULL, NULL, NULL, NULL, NULL, NULL, 14, 0, 'approved', NULL, NULL, 0, NULL, 0, NULL, '28', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `users_groups`
--

CREATE TABLE `users_groups` (
  `id` int(11) NOT NULL,
  `title` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `users_groups`
--

INSERT INTO `users_groups` (`id`, `title`, `created_at`, `updated_at`) VALUES
(2, 'user group 2', '2020-12-24 05:46:09', '2021-01-04 11:15:44');

-- --------------------------------------------------------

--
-- Table structure for table `user_favourites`
--

CREATE TABLE `user_favourites` (
  `id` int(11) NOT NULL,
  `user_id` int(10) UNSIGNED NOT NULL,
  `article_id` int(10) UNSIGNED NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `user_favourites`
--

INSERT INTO `user_favourites` (`id`, `user_id`, `article_id`, `created_at`, `updated_at`) VALUES
(46, 35, 12196, '2019-10-08 14:49:09', '2019-10-08 14:49:09'),
(47, 35, 7989, '2019-10-08 14:54:11', '2019-10-08 14:54:11'),
(49, 35, 11926, '2019-10-08 14:59:34', '2019-10-08 14:59:34'),
(50, 35, 12361, '2019-10-08 15:19:26', '2019-10-08 15:19:26'),
(51, 1, 12294, '2019-10-09 15:43:57', '2019-10-09 15:43:57'),
(52, 35, 12083, '2019-10-09 16:36:47', '2019-10-09 16:36:47'),
(53, 35, 12344, '2019-10-09 16:36:54', '2019-10-09 16:36:54'),
(54, 35, 12202, '2019-10-09 16:37:01', '2019-10-09 16:37:01'),
(56, 35, 12418, '2019-10-16 19:48:22', '2019-10-16 19:48:22'),
(57, 35, 12417, '2019-10-16 19:48:34', '2019-10-16 19:48:34'),
(58, 35, 12397, '2019-10-16 19:50:48', '2019-10-16 19:50:48'),
(60, 35, 12415, '2019-10-17 22:07:25', '2019-10-17 22:07:25'),
(62, 31, 17310, '2019-10-17 17:44:13', '2019-10-17 17:44:13'),
(63, 31, 181446, '2019-11-06 18:28:14', '2019-11-06 18:28:14'),
(78, 36, 10547, '2020-01-30 14:47:06', '2020-01-30 14:47:06'),
(80, 31, 11198, '2020-02-04 19:50:52', '2020-02-04 19:50:52'),
(83, 42, 10526, '2020-02-05 16:57:16', '2020-02-05 16:57:16'),
(84, 42, 10550, '2020-02-05 16:57:25', '2020-02-05 16:57:25'),
(89, 42, 10699, '2020-02-05 17:29:54', '2020-02-05 17:29:54'),
(90, 42, 10722, '2020-02-05 17:30:08', '2020-02-05 17:30:08'),
(93, 31, 10527, '2020-02-07 20:16:53', '2020-02-07 20:16:53'),
(94, 31, 10526, '2020-02-07 20:16:54', '2020-02-07 20:16:54'),
(95, 31, 10549, '2020-02-07 20:16:57', '2020-02-07 20:16:57'),
(96, 31, 10547, '2020-02-07 20:16:59', '2020-02-07 20:16:59'),
(98, 48, 1, '2020-02-17 12:24:17', '2020-02-17 12:24:17'),
(99, 48, 2, '2020-02-17 12:53:10', '2020-02-17 12:53:10'),
(100, 48, 3, '2020-02-17 13:18:56', '2020-02-17 13:18:56'),
(101, 48, 42, '2020-02-17 15:14:29', '2020-02-17 15:14:29'),
(104, 10, 15, '2020-05-07 19:03:48', '2020-05-07 19:03:48'),
(108, 10, 25, '2020-05-07 19:14:51', '2020-05-07 19:14:51'),
(109, 10, 28, '2020-05-07 19:14:59', '2020-05-07 19:14:59'),
(110, 10, 57118, '2020-05-07 19:35:56', '2020-05-07 19:35:56'),
(111, 10, 14, '2020-05-07 19:46:44', '2020-05-07 19:46:44'),
(112, 102, 24, '2020-05-17 15:55:06', '2020-05-17 15:55:06'),
(113, 102, 13, '2020-05-17 15:55:11', '2020-05-17 15:55:11'),
(114, 102, 14, '2020-05-17 15:55:13', '2020-05-17 15:55:13'),
(118, 10, 41099, '2020-12-30 17:31:50', '2020-12-30 17:31:50'),
(119, 10, 41076, '2020-12-30 17:32:23', '2020-12-30 17:32:23'),
(120, 10, 41101, '2020-12-30 17:32:28', '2020-12-30 17:32:28');

-- --------------------------------------------------------

--
-- Table structure for table `user_saves`
--

CREATE TABLE `user_saves` (
  `id` int(11) NOT NULL,
  `user_id` int(10) UNSIGNED DEFAULT NULL,
  `title` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `countries_ids` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `sources` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `keywords` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `publication_type` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `orderBy` enum('latest','popular') COLLATE utf8_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `user_saves`
--

INSERT INTO `user_saves` (`id`, `user_id`, `title`, `countries_ids`, `sources`, `keywords`, `publication_type`, `orderBy`, `created_at`, `updated_at`) VALUES
(1, 102, NULL, NULL, NULL, '9,10,14,16', NULL, 'latest', '2020-05-17 15:58:25', '2020-05-17 15:58:25'),
(2, 10, 's', NULL, NULL, NULL, NULL, 'latest', '2020-12-30 17:35:03', '2020-12-30 17:35:03'),
(3, 10, NULL, NULL, 'GIM', NULL, NULL, 'latest', '2020-12-30 17:37:33', '2020-12-30 17:37:33'),
(4, 10, NULL, NULL, 'GIM,pubmed,wiley', NULL, NULL, 'latest', '2020-12-30 17:48:37', '2020-12-30 17:48:37');

--
-- Indexes for dumped tables
--

--
-- Indexes for table `activity_logs`
--
ALTER TABLE `activity_logs`
  ADD PRIMARY KEY (`id`),
  ADD KEY `activity_logs_user_id_foreign` (`user_id`);

--
-- Indexes for table `articles`
--
ALTER TABLE `articles`
  ADD PRIMARY KEY (`id`),
  ADD KEY `keyword_id` (`keyword_id`),
  ADD KEY `rss_id` (`rss_id`),
  ADD KEY `source` (`source`),
  ADD KEY `publication_type` (`publication_type`),
  ADD KEY `idx_source_status` (`source`,`status`),
  ADD KEY `index_status_source` (`status`,`source`);

--
-- Indexes for table `article_countries`
--
ALTER TABLE `article_countries`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `article_keywords`
--
ALTER TABLE `article_keywords`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `article_logs`
--
ALTER TABLE `article_logs`
  ADD PRIMARY KEY (`id`),
  ADD KEY `index_article` (`article_id`);

--
-- Indexes for table `article_read`
--
ALTER TABLE `article_read`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `categories`
--
ALTER TABLE `categories`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `cities`
--
ALTER TABLE `cities`
  ADD PRIMARY KEY (`id`),
  ADD KEY `country_id` (`country_id`);

--
-- Indexes for table `contact_us`
--
ALTER TABLE `contact_us`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `controls`
--
ALTER TABLE `controls`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `countries`
--
ALTER TABLE `countries`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `emails`
--
ALTER TABLE `emails`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `email_articles`
--
ALTER TABLE `email_articles`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `email_researchers`
--
ALTER TABLE `email_researchers`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `email_shortlists`
--
ALTER TABLE `email_shortlists`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `email_templates`
--
ALTER TABLE `email_templates`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `experts`
--
ALTER TABLE `experts`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `institutions`
--
ALTER TABLE `institutions`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `institution_experts`
--
ALTER TABLE `institution_experts`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `keywords`
--
ALTER TABLE `keywords`
  ADD PRIMARY KEY (`id`),
  ADD KEY `parent_id` (`parent_id`);

--
-- Indexes for table `knowledge_base_articles`
--
ALTER TABLE `knowledge_base_articles`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `knowledge_base_categories`
--
ALTER TABLE `knowledge_base_categories`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `migrations`
--
ALTER TABLE `migrations`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `notifications`
--
ALTER TABLE `notifications`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `pages`
--
ALTER TABLE `pages`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `page_tests`
--
ALTER TABLE `page_tests`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `password_resets`
--
ALTER TABLE `password_resets`
  ADD KEY `password_resets_email_index` (`email`(191));

--
-- Indexes for table `permissions`
--
ALTER TABLE `permissions`
  ADD PRIMARY KEY (`id`),
  ADD KEY `page_id` (`page_id`),
  ADD KEY `role_id` (`role_id`);

--
-- Indexes for table `promoted_messages`
--
ALTER TABLE `promoted_messages`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `publication_types`
--
ALTER TABLE `publication_types`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `qualifiers`
--
ALTER TABLE `qualifiers`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `keyword_en` (`name`);

--
-- Indexes for table `resource_types`
--
ALTER TABLE `resource_types`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `roles`
--
ALTER TABLE `roles`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `rss`
--
ALTER TABLE `rss`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `rss_articles`
--
ALTER TABLE `rss_articles`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `sent_emails`
--
ALTER TABLE `sent_emails`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `sent_emails_hash_unique` (`hash`);

--
-- Indexes for table `sent_emails_url_clicked`
--
ALTER TABLE `sent_emails_url_clicked`
  ADD PRIMARY KEY (`id`),
  ADD KEY `sent_emails_url_clicked_sent_email_id_foreign` (`sent_email_id`);

--
-- Indexes for table `settings`
--
ALTER TABLE `settings`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `sources`
--
ALTER TABLE `sources`
  ADD PRIMARY KEY (`id`),
  ADD KEY `category_id` (`category_id`),
  ADD KEY `name` (`name`);

--
-- Indexes for table `sources_order`
--
ALTER TABLE `sources_order`
  ADD PRIMARY KEY (`id`),
  ADD KEY `source_id` (`source_id`);

--
-- Indexes for table `specialities`
--
ALTER TABLE `specialities`
  ADD PRIMARY KEY (`id`),
  ADD KEY `parent_id` (`parent_id`);

--
-- Indexes for table `topics_of_interests`
--
ALTER TABLE `topics_of_interests`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `users`
--
ALTER TABLE `users`
  ADD PRIMARY KEY (`id`),
  ADD KEY `role_id` (`role_id`);

--
-- Indexes for table `users_groups`
--
ALTER TABLE `users_groups`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `user_favourites`
--
ALTER TABLE `user_favourites`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `user_saves`
--
ALTER TABLE `user_saves`
  ADD PRIMARY KEY (`id`);

--
-- AUTO_INCREMENT for dumped tables
--

--
-- AUTO_INCREMENT for table `activity_logs`
--
ALTER TABLE `activity_logs`
  MODIFY `id` bigint(20) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=126;

--
-- AUTO_INCREMENT for table `articles`
--
ALTER TABLE `articles`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=61098;

--
-- AUTO_INCREMENT for table `article_countries`
--
ALTER TABLE `article_countries`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=90572;

--
-- AUTO_INCREMENT for table `article_keywords`
--
ALTER TABLE `article_keywords`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=156854;

--
-- AUTO_INCREMENT for table `article_logs`
--
ALTER TABLE `article_logs`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=17;

--
-- AUTO_INCREMENT for table `article_read`
--
ALTER TABLE `article_read`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=12;

--
-- AUTO_INCREMENT for table `categories`
--
ALTER TABLE `categories`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=17;

--
-- AUTO_INCREMENT for table `cities`
--
ALTER TABLE `cities`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `contact_us`
--
ALTER TABLE `contact_us`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=12;

--
-- AUTO_INCREMENT for table `controls`
--
ALTER TABLE `controls`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `countries`
--
ALTER TABLE `countries`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=23;

--
-- AUTO_INCREMENT for table `emails`
--
ALTER TABLE `emails`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=44;

--
-- AUTO_INCREMENT for table `email_articles`
--
ALTER TABLE `email_articles`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=243;

--
-- AUTO_INCREMENT for table `email_researchers`
--
ALTER TABLE `email_researchers`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=148;

--
-- AUTO_INCREMENT for table `email_shortlists`
--
ALTER TABLE `email_shortlists`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=108;

--
-- AUTO_INCREMENT for table `email_templates`
--
ALTER TABLE `email_templates`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=13;

--
-- AUTO_INCREMENT for table `experts`
--
ALTER TABLE `experts`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=32;

--
-- AUTO_INCREMENT for table `institutions`
--
ALTER TABLE `institutions`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=24;

--
-- AUTO_INCREMENT for table `institution_experts`
--
ALTER TABLE `institution_experts`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=45;

--
-- AUTO_INCREMENT for table `keywords`
--
ALTER TABLE `keywords`
  MODIFY `id` int(11) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=151;

--
-- AUTO_INCREMENT for table `knowledge_base_articles`
--
ALTER TABLE `knowledge_base_articles`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=10;

--
-- AUTO_INCREMENT for table `knowledge_base_categories`
--
ALTER TABLE `knowledge_base_categories`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=12;

--
-- AUTO_INCREMENT for table `migrations`
--
ALTER TABLE `migrations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `notifications`
--
ALTER TABLE `notifications`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=121;

--
-- AUTO_INCREMENT for table `pages`
--
ALTER TABLE `pages`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=48;

--
-- AUTO_INCREMENT for table `page_tests`
--
ALTER TABLE `page_tests`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `permissions`
--
ALTER TABLE `permissions`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=1738;

--
-- AUTO_INCREMENT for table `promoted_messages`
--
ALTER TABLE `promoted_messages`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=6;

--
-- AUTO_INCREMENT for table `publication_types`
--
ALTER TABLE `publication_types`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=171;

--
-- AUTO_INCREMENT for table `qualifiers`
--
ALTER TABLE `qualifiers`
  MODIFY `id` int(11) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=236;

--
-- AUTO_INCREMENT for table `resource_types`
--
ALTER TABLE `resource_types`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=24;

--
-- AUTO_INCREMENT for table `roles`
--
ALTER TABLE `roles`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=21;

--
-- AUTO_INCREMENT for table `rss`
--
ALTER TABLE `rss`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=28;

--
-- AUTO_INCREMENT for table `rss_articles`
--
ALTER TABLE `rss_articles`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=657;

--
-- AUTO_INCREMENT for table `sent_emails`
--
ALTER TABLE `sent_emails`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=36;

--
-- AUTO_INCREMENT for table `sent_emails_url_clicked`
--
ALTER TABLE `sent_emails_url_clicked`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=6;

--
-- AUTO_INCREMENT for table `settings`
--
ALTER TABLE `settings`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `sources`
--
ALTER TABLE `sources`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=28;

--
-- AUTO_INCREMENT for table `sources_order`
--
ALTER TABLE `sources_order`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=1956;

--
-- AUTO_INCREMENT for table `specialities`
--
ALTER TABLE `specialities`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=9;

--
-- AUTO_INCREMENT for table `topics_of_interests`
--
ALTER TABLE `topics_of_interests`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=329;

--
-- AUTO_INCREMENT for table `users`
--
ALTER TABLE `users`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=106;

--
-- AUTO_INCREMENT for table `users_groups`
--
ALTER TABLE `users_groups`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=3;

--
-- AUTO_INCREMENT for table `user_favourites`
--
ALTER TABLE `user_favourites`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=121;

--
-- AUTO_INCREMENT for table `user_saves`
--
ALTER TABLE `user_saves`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=5;

--
-- Constraints for dumped tables
--

--
-- Constraints for table `cities`
--
ALTER TABLE `cities`
  ADD CONSTRAINT `cities_ibfk_1` FOREIGN KEY (`country_id`) REFERENCES `countries` (`id`) ON DELETE NO ACTION ON UPDATE NO ACTION;

--
-- Constraints for table `keywords`
--
ALTER TABLE `keywords`
  ADD CONSTRAINT `keywords_ibfk_1` FOREIGN KEY (`parent_id`) REFERENCES `keywords` (`id`) ON DELETE CASCADE ON UPDATE NO ACTION;

--
-- Constraints for table `permissions`
--
ALTER TABLE `permissions`
  ADD CONSTRAINT `permissions_ibfk_1` FOREIGN KEY (`page_id`) REFERENCES `pages` (`id`) ON DELETE CASCADE ON UPDATE NO ACTION,
  ADD CONSTRAINT `permissions_ibfk_2` FOREIGN KEY (`role_id`) REFERENCES `roles` (`id`) ON DELETE CASCADE ON UPDATE NO ACTION;

--
-- Constraints for table `sent_emails_url_clicked`
--
ALTER TABLE `sent_emails_url_clicked`
  ADD CONSTRAINT `sent_emails_url_clicked_sent_email_id_foreign` FOREIGN KEY (`sent_email_id`) REFERENCES `sent_emails` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `sources`
--
ALTER TABLE `sources`
  ADD CONSTRAINT `sources_ibfk_1` FOREIGN KEY (`category_id`) REFERENCES `resource_types` (`id`) ON UPDATE NO ACTION;

--
-- Constraints for table `specialities`
--
ALTER TABLE `specialities`
  ADD CONSTRAINT `specialities_ibfk_1` FOREIGN KEY (`parent_id`) REFERENCES `specialities` (`id`) ON DELETE NO ACTION ON UPDATE NO ACTION;

--
-- Constraints for table `users`
--
ALTER TABLE `users`
  ADD CONSTRAINT `users_ibfk_1` FOREIGN KEY (`role_id`) REFERENCES `roles` (`id`) ON DELETE CASCADE ON UPDATE NO ACTION;
COMMIT;

